primaryid,caseid,drug_seq,role_cod,drugname,prod_ai,val_vbm,route,dose_vbm,cum_dose_chr,cum_dose_unit,dechal,rechal,lot_num,exp_dt,nda_num,dose_amt,dose_unit,dose_form,dose_freq,year_x,quarter_x,pt,drug_rec_act,year_y,quarter_y,caseversion,i_f_code,event_dt,mfr_dt,init_fda_dt,fda_dt,rept_cod,auth_num,mfr_num,mfr_sndr,lit_ref,age,age_cod,age_grp,sex,e_sub,wt,wt_cod,rept_dt,to_mfr,occp_cod,reporter_country,occr_country,year,quarter,age_group
127597973,12759797,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q1,Conjunctivitis allergic,,2018,Q1,3,F,20160312.0,20180308.0,20160919,20180316,EXP,,JP-JNJFOC-20160618215,JANSSEN,,65.0,YR,A,F,Y,66.0,KG,20180316.0,,OT,JP,JP,2018,Q1,Elderly
127597973,12759797,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q1,Diabetic retinopathy,,2018,Q1,3,F,20160312.0,20180308.0,20160919,20180316,EXP,,JP-JNJFOC-20160618215,JANSSEN,,65.0,YR,A,F,Y,66.0,KG,20180316.0,,OT,JP,JP,2018,Q1,Elderly
127597973,12759797,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q1,Migraine,,2018,Q1,3,F,20160312.0,20180308.0,20160919,20180316,EXP,,JP-JNJFOC-20160618215,JANSSEN,,65.0,YR,A,F,Y,66.0,KG,20180316.0,,OT,JP,JP,2018,Q1,Elderly
130741522,13074152,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,,2018,Q1,Influenza like illness,,2018,Q1,2,F,20161024.0,20180215.0,20161230,20180228,EXP,,US-ROCHE-1870521,ROCHE,,50.0,YR,,F,Y,111.7,KG,20180228.0,,MD,US,US,2018,Q1,Adult
132790432,13279043,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 TABLET BEFORE BREAKFAST, QD",,,,,,,,100.0,MG,TABLET,QD,2018,Q1,Agitation,,2018,Q1,2,F,20150228.0,20170223.0,20170228,20180131,PER,,US-ALLERGAN-1700923US,ALLERGAN,,63.0,YR,,M,Y,131.7,KG,20180131.0,,MD,US,US,2018,Q1,Adult
132790432,13279043,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 TABLET BEFORE BREAKFAST, QD",,,,,,,,100.0,MG,TABLET,QD,2018,Q1,Hypersensitivity,,2018,Q1,2,F,20150228.0,20170223.0,20170228,20180131,PER,,US-ALLERGAN-1700923US,ALLERGAN,,63.0,YR,,M,Y,131.7,KG,20180131.0,,MD,US,US,2018,Q1,Adult
136287203,13628720,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,300.0,MG,UNSPECIFIED,QD,2018,Q1,Arthralgia,,2018,Q1,3,F,2017.0,20180110.0,20170607,20180112,EXP,,GB-JNJFOC-20170402335,JANSSEN,,42.0,YR,A,F,Y,,,20180112.0,,MD,GB,GB,2018,Q1,Adult
136287203,13628720,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,300.0,MG,UNSPECIFIED,QD,2018,Q1,Arthropathy,,2018,Q1,3,F,2017.0,20180110.0,20170607,20180112,EXP,,GB-JNJFOC-20170402335,JANSSEN,,42.0,YR,A,F,Y,,,20180112.0,,MD,GB,GB,2018,Q1,Adult
136287203,13628720,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,300.0,MG,UNSPECIFIED,QD,2018,Q1,Cholecystitis infective,,2018,Q1,3,F,2017.0,20180110.0,20170607,20180112,EXP,,GB-JNJFOC-20170402335,JANSSEN,,42.0,YR,A,F,Y,,,20180112.0,,MD,GB,GB,2018,Q1,Adult
136287203,13628720,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,300.0,MG,UNSPECIFIED,QD,2018,Q1,Ill-defined disorder,,2018,Q1,3,F,2017.0,20180110.0,20170607,20180112,EXP,,GB-JNJFOC-20170402335,JANSSEN,,42.0,YR,A,F,Y,,,20180112.0,,MD,GB,GB,2018,Q1,Adult
136287203,13628720,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,300.0,MG,UNSPECIFIED,QD,2018,Q1,Pustular psoriasis,,2018,Q1,3,F,2017.0,20180110.0,20170607,20180112,EXP,,GB-JNJFOC-20170402335,JANSSEN,,42.0,YR,A,F,Y,,,20180112.0,,MD,GB,GB,2018,Q1,Adult
136287203,13628720,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,300.0,MG,UNSPECIFIED,QD,2018,Q1,Subcutaneous abscess,,2018,Q1,3,F,2017.0,20180110.0,20170607,20180112,EXP,,GB-JNJFOC-20170402335,JANSSEN,,42.0,YR,A,F,Y,,,20180112.0,,MD,GB,GB,2018,Q1,Adult
136287203,13628720,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,300.0,MG,UNSPECIFIED,QD,2018,Q1,Urticaria,,2018,Q1,3,F,2017.0,20180110.0,20170607,20180112,EXP,,GB-JNJFOC-20170402335,JANSSEN,,42.0,YR,A,F,Y,,,20180112.0,,MD,GB,GB,2018,Q1,Adult
139860052,13986005,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q1,Acute kidney injury,,2018,Q1,2,F,,20180201.0,20170919,20180214,EXP,,AT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-083317,BRISTOL MYERS SQUIBB,,71.0,YR,,M,Y,,,20180214.0,,OT,AT,AT,2018,Q1,Elderly
139860052,13986005,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q1,Diabetic ketoacidosis,,2018,Q1,2,F,,20180201.0,20170919,20180214,EXP,,AT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-083317,BRISTOL MYERS SQUIBB,,71.0,YR,,M,Y,,,20180214.0,,OT,AT,AT,2018,Q1,Elderly
139860052,13986005,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q1,Lactic acidosis,,2018,Q1,2,F,,20180201.0,20170919,20180214,EXP,,AT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-083317,BRISTOL MYERS SQUIBB,,71.0,YR,,M,Y,,,20180214.0,,OT,AT,AT,2018,Q1,Elderly
142930274,14293027,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,,,2018,Q1,Cardiac operation,,2018,Q1,4,F,201710.0,20180112.0,20171215,20180122,EXP,,US-ALLERGAN-1771821US,ALLERGAN,,70.0,YR,,F,Y,88.44,KG,20180122.0,,CN,US,US,2018,Q1,Elderly
142930274,14293027,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,,,2018,Q1,Chest pain,,2018,Q1,4,F,201710.0,20180112.0,20171215,20180122,EXP,,US-ALLERGAN-1771821US,ALLERGAN,,70.0,YR,,F,Y,88.44,KG,20180122.0,,CN,US,US,2018,Q1,Elderly
142930274,14293027,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,,,2018,Q1,Diarrhoea,,2018,Q1,4,F,201710.0,20180112.0,20171215,20180122,EXP,,US-ALLERGAN-1771821US,ALLERGAN,,70.0,YR,,F,Y,88.44,KG,20180122.0,,CN,US,US,2018,Q1,Elderly
142930274,14293027,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,,,2018,Q1,Fall,,2018,Q1,4,F,201710.0,20180112.0,20171215,20180122,EXP,,US-ALLERGAN-1771821US,ALLERGAN,,70.0,YR,,F,Y,88.44,KG,20180122.0,,CN,US,US,2018,Q1,Elderly
142930274,14293027,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,,,2018,Q1,Off label use,,2018,Q1,4,F,201710.0,20180112.0,20171215,20180122,EXP,,US-ALLERGAN-1771821US,ALLERGAN,,70.0,YR,,F,Y,88.44,KG,20180122.0,,CN,US,US,2018,Q1,Elderly
142930274,14293027,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,,,2018,Q1,Pain in extremity,,2018,Q1,4,F,201710.0,20180112.0,20171215,20180122,EXP,,US-ALLERGAN-1771821US,ALLERGAN,,70.0,YR,,F,Y,88.44,KG,20180122.0,,CN,US,US,2018,Q1,Elderly
142930274,14293027,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,,,2018,Q1,Spinal operation,,2018,Q1,4,F,201710.0,20180112.0,20171215,20180122,EXP,,US-ALLERGAN-1771821US,ALLERGAN,,70.0,YR,,F,Y,88.44,KG,20180122.0,,CN,US,US,2018,Q1,Elderly
142930274,14293027,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,,,2018,Q1,Upper limb fracture,,2018,Q1,4,F,201710.0,20180112.0,20171215,20180122,EXP,,US-ALLERGAN-1771821US,ALLERGAN,,70.0,YR,,F,Y,88.44,KG,20180122.0,,CN,US,US,2018,Q1,Elderly
143430231,14343023,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q1,Peripheral artery occlusion,,2018,Q1,1,I,20171212.0,20171225.0,20180102,20180102,EXP,,JP-JNJFOC-20171236913,JANSSEN,,62.0,YR,A,M,Y,73.0,KG,20180102.0,,OT,JP,JP,2018,Q1,Adult
143505372,14350537,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNK,,,300.0,MG,,QD,2018,Q1,Blood glucose increased,,2018,Q1,2,F,,20180118.0,20180103,20180125,EXP,,CA-SA-2017SA269393,AVENTIS,"NADEAU-FORTIER K, JANECEK SS, TRUDEL J-F, BRETON V, JANECEK SS. KETOACIDOSIS ASSOCIATED WITH SODIUM GLUCOSE COTRANSPORTER 2 INHIBITORS: SHOULD WE BE CAUTIOUS. QUEBEC PHARMACIE; 2017 DEC-2018 JAN;64(8).",58.0,YR,A,M,Y,,,20180125.0,,OT,CA,CA,2018,Q1,Adult
143505372,14350537,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNK,,,300.0,MG,,QD,2018,Q1,Decreased appetite,,2018,Q1,2,F,,20180118.0,20180103,20180125,EXP,,CA-SA-2017SA269393,AVENTIS,"NADEAU-FORTIER K, JANECEK SS, TRUDEL J-F, BRETON V, JANECEK SS. KETOACIDOSIS ASSOCIATED WITH SODIUM GLUCOSE COTRANSPORTER 2 INHIBITORS: SHOULD WE BE CAUTIOUS. QUEBEC PHARMACIE; 2017 DEC-2018 JAN;64(8).",58.0,YR,A,M,Y,,,20180125.0,,OT,CA,CA,2018,Q1,Adult
143505372,14350537,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNK,,,300.0,MG,,QD,2018,Q1,Diabetic ketoacidosis,,2018,Q1,2,F,,20180118.0,20180103,20180125,EXP,,CA-SA-2017SA269393,AVENTIS,"NADEAU-FORTIER K, JANECEK SS, TRUDEL J-F, BRETON V, JANECEK SS. KETOACIDOSIS ASSOCIATED WITH SODIUM GLUCOSE COTRANSPORTER 2 INHIBITORS: SHOULD WE BE CAUTIOUS. QUEBEC PHARMACIE; 2017 DEC-2018 JAN;64(8).",58.0,YR,A,M,Y,,,20180125.0,,OT,CA,CA,2018,Q1,Adult
143505372,14350537,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNK,,,300.0,MG,,QD,2018,Q1,Fatigue,,2018,Q1,2,F,,20180118.0,20180103,20180125,EXP,,CA-SA-2017SA269393,AVENTIS,"NADEAU-FORTIER K, JANECEK SS, TRUDEL J-F, BRETON V, JANECEK SS. KETOACIDOSIS ASSOCIATED WITH SODIUM GLUCOSE COTRANSPORTER 2 INHIBITORS: SHOULD WE BE CAUTIOUS. QUEBEC PHARMACIE; 2017 DEC-2018 JAN;64(8).",58.0,YR,A,M,Y,,,20180125.0,,OT,CA,CA,2018,Q1,Adult
143505372,14350537,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNK,,,300.0,MG,,QD,2018,Q1,Heart rate increased,,2018,Q1,2,F,,20180118.0,20180103,20180125,EXP,,CA-SA-2017SA269393,AVENTIS,"NADEAU-FORTIER K, JANECEK SS, TRUDEL J-F, BRETON V, JANECEK SS. KETOACIDOSIS ASSOCIATED WITH SODIUM GLUCOSE COTRANSPORTER 2 INHIBITORS: SHOULD WE BE CAUTIOUS. QUEBEC PHARMACIE; 2017 DEC-2018 JAN;64(8).",58.0,YR,A,M,Y,,,20180125.0,,OT,CA,CA,2018,Q1,Adult
143505372,14350537,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNK,,,300.0,MG,,QD,2018,Q1,Nausea,,2018,Q1,2,F,,20180118.0,20180103,20180125,EXP,,CA-SA-2017SA269393,AVENTIS,"NADEAU-FORTIER K, JANECEK SS, TRUDEL J-F, BRETON V, JANECEK SS. KETOACIDOSIS ASSOCIATED WITH SODIUM GLUCOSE COTRANSPORTER 2 INHIBITORS: SHOULD WE BE CAUTIOUS. QUEBEC PHARMACIE; 2017 DEC-2018 JAN;64(8).",58.0,YR,A,M,Y,,,20180125.0,,OT,CA,CA,2018,Q1,Adult
143505372,14350537,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,, UNK,,,300.0,MG,,QD,2018,Q1,Vomiting,,2018,Q1,2,F,,20180118.0,20180103,20180125,EXP,,CA-SA-2017SA269393,AVENTIS,"NADEAU-FORTIER K, JANECEK SS, TRUDEL J-F, BRETON V, JANECEK SS. KETOACIDOSIS ASSOCIATED WITH SODIUM GLUCOSE COTRANSPORTER 2 INHIBITORS: SHOULD WE BE CAUTIOUS. QUEBEC PHARMACIE; 2017 DEC-2018 JAN;64(8).",58.0,YR,A,M,Y,,,20180125.0,,OT,CA,CA,2018,Q1,Adult
143626021,14362602,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q1,Palpitations,,2018,Q1,1,I,,20171226.0,20180108,20180108,EXP,,GB-JNJFOC-20171233209,JANSSEN,,59.0,YR,A,F,Y,,,20180108.0,,PH,GB,GB,2018,Q1,Adult
143626021,14362602,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q1,Thirst,,2018,Q1,1,I,,20171226.0,20180108,20180108,EXP,,GB-JNJFOC-20171233209,JANSSEN,,59.0,YR,A,F,Y,,,20180108.0,,PH,GB,GB,2018,Q1,Adult
143744221,14374422,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,QD,2018,Q1,Hyperkalaemia,,2018,Q1,1,I,,20171229.0,20180111,20180111,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-120595,BRISTOL MYERS SQUIBB,,67.0,YR,,,Y,,,20180111.0,,PH,GB,GB,2018,Q1,Elderly
143744221,14374422,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,U,,,,,100.0,MG,,QD,2018,Q1,Lactic acidosis,,2018,Q1,1,I,,20171229.0,20180111,20180111,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-120595,BRISTOL MYERS SQUIBB,,67.0,YR,,,Y,,,20180111.0,,PH,GB,GB,2018,Q1,Elderly
143800061,14380006,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,PREFERABLY BEFORE BREAKFAST,,,,U,,,,100.0,MG,,,2018,Q1,Hyperkalaemia,,2018,Q1,1,I,,20171229.0,20180112,20180112,EXP,,GB-AUROBINDO-AUR-APL-2018-001456,AUROBINDO,,67.0,YR,,,Y,,,20180112.0,,PH,GB,GB,2018,Q1,Elderly
143800061,14380006,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,PREFERABLY BEFORE BREAKFAST,,,,U,,,,100.0,MG,,,2018,Q1,Lactic acidosis,,2018,Q1,1,I,,20171229.0,20180112,20180112,EXP,,GB-AUROBINDO-AUR-APL-2018-001456,AUROBINDO,,67.0,YR,,,Y,,,20180112.0,,PH,GB,GB,2018,Q1,Elderly
143918331,14391833,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,TABLET,QD,2018,Q1,Hypokalaemia,,2018,Q1,1,I,20170719.0,20180105.0,20180116,20180116,EXP,,JP-JNJFOC-20180117331,JANSSEN,,89.0,YR,E,F,Y,45.0,KG,20180116.0,,OT,JP,JP,2018,Q1,Elderly
144019351,14401935,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,,,TABLET,,2018,Q1,Diabetic ketoacidosis,,2018,Q1,1,I,,20180109.0,20180117,20180117,EXP,,US-JNJFOC-20180112616,JANSSEN,"AHMED A, KAUR J, LEVINE D. CANAGLIFLOZIN: MASKING HYPERGLYCEMIA IN DKA. DIAGNOSIS (BERLIN) 2017;4(4):EA80.",32.0,YR,A,M,Y,,,20180117.0,,MD,US,US,2018,Q1,Young Adult
144019382,14401938,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q1,Blood ketone body increased,,2018,Q1,2,F,20170308.0,20180129.0,20180117,20180319,EXP,,JP-JNJFOC-20180118995,JANSSEN,,7.0,DEC,E,M,Y,,,20180319.0,,OT,JP,JP,2018,Q1,Child
144068391,14406839,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,PREFERABLY BEFORE BREAKFAST,,,,,,,,100.0,MG,,QD,2018,Q1,Hyperkalaemia,,2018,Q1,1,I,,20180106.0,20180118,20180118,EXP,GB-MHRA-ADR 24271807,GB-BAUSCH-BL-2018-001023,BAUSCH AND LOMB,,67.0,YR,,,Y,,,20180118.0,,PH,GB,GB,2018,Q1,Elderly
144068391,14406839,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,PREFERABLY BEFORE BREAKFAST,,,,,,,,100.0,MG,,QD,2018,Q1,Lactic acidosis,,2018,Q1,1,I,,20180106.0,20180118,20180118,EXP,GB-MHRA-ADR 24271807,GB-BAUSCH-BL-2018-001023,BAUSCH AND LOMB,,67.0,YR,,,Y,,,20180118.0,,PH,GB,GB,2018,Q1,Elderly
144180281,14418028,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q1,Heart rate increased,,2018,Q1,1,I,20180116.0,20180117.0,20180122,20180122,EXP,,US-TAKEDA-2018TUS001541,TAKEDA,,57.0,YR,,M,Y,68.03,KG,20180122.0,,MD,US,US,2018,Q1,Adult
144180281,14418028,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q1,Impulsive behaviour,,2018,Q1,1,I,20180116.0,20180117.0,20180122,20180122,EXP,,US-TAKEDA-2018TUS001541,TAKEDA,,57.0,YR,,M,Y,68.03,KG,20180122.0,,MD,US,US,2018,Q1,Adult
144180281,14418028,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q1,Memory impairment,,2018,Q1,1,I,20180116.0,20180117.0,20180122,20180122,EXP,,US-TAKEDA-2018TUS001541,TAKEDA,,57.0,YR,,M,Y,68.03,KG,20180122.0,,MD,US,US,2018,Q1,Adult
144180281,14418028,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,,,,,,,,,,2018,Q1,Suicidal ideation,,2018,Q1,1,I,20180116.0,20180117.0,20180122,20180122,EXP,,US-TAKEDA-2018TUS001541,TAKEDA,,57.0,YR,,M,Y,68.03,KG,20180122.0,,MD,US,US,2018,Q1,Adult
144200702,14420070,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q1,Diabetic ketoacidosis,,2018,Q1,2,F,,20180123.0,20180122,20180130,EXP,,"ES-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-003765",BOEHRINGER INGELHEIM,,7.0,DEC,,F,Y,,,20180130.0,,MD,ES,ES,2018,Q1,Child
144407281,14440728,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, QD",,,,,,,,300.0,MG,,QD,2018,Q1,Balance disorder,,2018,Q1,1,I,2017.0,20171109.0,20180125,20180125,PER,,US-AMGEN-USASP2017169628,AMGEN,,60.0,YR,A,M,Y,,,20180125.0,,MD,US,US,2018,Q1,Adult
144407281,14440728,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, QD",,,,,,,,300.0,MG,,QD,2018,Q1,Disorganised speech,,2018,Q1,1,I,2017.0,20171109.0,20180125,20180125,PER,,US-AMGEN-USASP2017169628,AMGEN,,60.0,YR,A,M,Y,,,20180125.0,,MD,US,US,2018,Q1,Adult
144407281,14440728,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, QD",,,,,,,,300.0,MG,,QD,2018,Q1,Dizziness,,2018,Q1,1,I,2017.0,20171109.0,20180125,20180125,PER,,US-AMGEN-USASP2017169628,AMGEN,,60.0,YR,A,M,Y,,,20180125.0,,MD,US,US,2018,Q1,Adult
144407281,14440728,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, QD",,,,,,,,300.0,MG,,QD,2018,Q1,Fatigue,,2018,Q1,1,I,2017.0,20171109.0,20180125,20180125,PER,,US-AMGEN-USASP2017169628,AMGEN,,60.0,YR,A,M,Y,,,20180125.0,,MD,US,US,2018,Q1,Adult
144529081,14452908,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 DOSAGE FORMS DAILY;,154.958333,DF,,,,,,1.0,DF,,QD,2018,Q1,Hypersensitivity,,2018,Q1,1,I,20170824.0,20170905.0,20180129,20180129,EXP,GB-MHRA-TPP16637C1449561YC1503568791379,GB-TEVA-804819ACC,TEVA,,47.0,YR,,F,Y,74.0,KG,20180129.0,,OT,GB,GB,2018,Q1,Adult
144529081,14452908,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 DOSAGE FORMS DAILY;,154.958333,DF,,,,,,1.0,DF,,QD,2018,Q1,Lip swelling,,2018,Q1,1,I,20170824.0,20170905.0,20180129,20180129,EXP,GB-MHRA-TPP16637C1449561YC1503568791379,GB-TEVA-804819ACC,TEVA,,47.0,YR,,F,Y,74.0,KG,20180129.0,,OT,GB,GB,2018,Q1,Adult
144529081,14452908,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 DOSAGE FORMS DAILY;,154.958333,DF,,,,,,1.0,DF,,QD,2018,Q1,Pharyngeal oedema,,2018,Q1,1,I,20170824.0,20170905.0,20180129,20180129,EXP,GB-MHRA-TPP16637C1449561YC1503568791379,GB-TEVA-804819ACC,TEVA,,47.0,YR,,F,Y,74.0,KG,20180129.0,,OT,GB,GB,2018,Q1,Adult
144529081,14452908,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 DOSAGE FORMS DAILY;,154.958333,DF,,,,,,1.0,DF,,QD,2018,Q1,Swelling face,,2018,Q1,1,I,20170824.0,20170905.0,20180129,20180129,EXP,GB-MHRA-TPP16637C1449561YC1503568791379,GB-TEVA-804819ACC,TEVA,,47.0,YR,,F,Y,74.0,KG,20180129.0,,OT,GB,GB,2018,Q1,Adult
144570801,14457080,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,,,TABLET,,2018,Q1,Diabetic ketoacidosis,,2018,Q1,1,I,,20180122.0,20180130,20180130,EXP,,IE-JNJFOC-20180132389,JANSSEN,,5.0,DEC,A,F,Y,,,20180130.0,,MD,IE,IE,2018,Q1,Child
144570801,14457080,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,,,TABLET,,2018,Q1,Lower respiratory tract infection,,2018,Q1,1,I,,20180122.0,20180130,20180130,EXP,,IE-JNJFOC-20180132389,JANSSEN,,5.0,DEC,A,F,Y,,,20180130.0,,MD,IE,IE,2018,Q1,Child
144673142,14467314,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q1,Henoch-Schonlein purpura,,2018,Q1,2,F,20170418.0,20180222.0,20180131,20180305,EXP,,JP-JNJFOC-20180137865,JANSSEN,,54.0,YR,A,F,Y,115.0,KG,20180305.0,,OT,JP,JP,2018,Q1,Adult
144983751,14498375,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,,,TABLET,,2018,Q1,Peripheral coldness,,2018,Q1,1,I,,20180130.0,20180207,20180207,EXP,,GB-JNJFOC-20180137433,JANSSEN,,48.0,YR,A,F,Y,67.0,KG,20180207.0,,PH,GB,GB,2018,Q1,Adult
145036791,14503679,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"1 DF, UNK (PREFERABLY BEFORE BREAKFAST)",,,U,,,,,1.0,DF,,,2018,Q1,Hyperkalaemia,,2018,Q1,1,I,,20180130.0,20180208,20180208,EXP,GB-MHRA-MIDB-C57B9B12-0FAF-460B-BA1D-CA0A0A5EFAE4,PHHY2018GB020255,SANDOZ,,67.0,YR,,,Y,,,20180208.0,,OT,GB,GB,2018,Q1,Elderly
145036791,14503679,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"1 DF, UNK (PREFERABLY BEFORE BREAKFAST)",,,U,,,,,1.0,DF,,,2018,Q1,Lactic acidosis,,2018,Q1,1,I,,20180130.0,20180208,20180208,EXP,GB-MHRA-MIDB-C57B9B12-0FAF-460B-BA1D-CA0A0A5EFAE4,PHHY2018GB020255,SANDOZ,,67.0,YR,,,Y,,,20180208.0,,OT,GB,GB,2018,Q1,Elderly
145088311,14508831,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,,,,,,,,,2018,Q1,Hypersensitivity vasculitis,,2018,Q1,1,I,,20180202.0,20180209,20180209,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-010725,BRISTOL MYERS SQUIBB,,60.0,YR,,M,Y,,,20180209.0,,MD,US,US,2018,Q1,Adult
145168731,14516873,7,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q1,Dizziness,,2018,Q1,1,I,,20180205.0,20180212,20180212,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-006781",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,,,20180212.0,,MD,CA,CA,2018,Q1,Elderly
145168731,14516873,7,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q1,Drug ineffective,,2018,Q1,1,I,,20180205.0,20180212,20180212,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-006781",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,,,20180212.0,,MD,CA,CA,2018,Q1,Elderly
145168731,14516873,7,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q1,Dyspnoea,,2018,Q1,1,I,,20180205.0,20180212,20180212,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-006781",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,,,20180212.0,,MD,CA,CA,2018,Q1,Elderly
145168731,14516873,7,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q1,Fatigue,,2018,Q1,1,I,,20180205.0,20180212,20180212,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-006781",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,,,20180212.0,,MD,CA,CA,2018,Q1,Elderly
145168731,14516873,7,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q1,Flushing,,2018,Q1,1,I,,20180205.0,20180212,20180212,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-006781",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,,,20180212.0,,MD,CA,CA,2018,Q1,Elderly
145168731,14516873,7,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q1,Headache,,2018,Q1,1,I,,20180205.0,20180212,20180212,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-006781",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,,,20180212.0,,MD,CA,CA,2018,Q1,Elderly
145168731,14516873,7,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q1,Hypoxia,,2018,Q1,1,I,,20180205.0,20180212,20180212,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-006781",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,,,20180212.0,,MD,CA,CA,2018,Q1,Elderly
145168731,14516873,7,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q1,Muscular weakness,,2018,Q1,1,I,,20180205.0,20180212,20180212,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-006781",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,,,20180212.0,,MD,CA,CA,2018,Q1,Elderly
145168731,14516873,7,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q1,Nausea,,2018,Q1,1,I,,20180205.0,20180212,20180212,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-006781",BOEHRINGER INGELHEIM,,66.0,YR,,M,Y,,,20180212.0,,MD,CA,CA,2018,Q1,Elderly
145268731,14526873,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"1 DF, 1X/DAY",221.0,DF,,,,,,1.0,DF,,QD,2018,Q1,Lip swelling,,2018,Q1,1,I,20180122.0,20180209.0,20180213,20180213,EXP,GB-MHRA-TPP36059351C2438106YC1516624192539,GB-PFIZER INC-2018060611,PFIZER,,65.0,YR,,M,Y,92.0,KG,20180213.0,,MD,GB,GB,2018,Q1,Elderly
145366141,14536614,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,PREFERABLY BEFORE BREAKFAST,,,,,,,,100.0,MG,,,2018,Q1,Hyperkalaemia,,2018,Q1,1,I,,20180201.0,20180215,20180215,EXP,GB-MHRA-MIDB-C57B9B12-0FAF-460B-BA1D-CA0A0A5EFAE4,GB-TEVA-2018-GB-857024,TEVA,,67.0,YR,,,Y,,,20180215.0,,PH,GB,GB,2018,Q1,Elderly
145366141,14536614,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,PREFERABLY BEFORE BREAKFAST,,,,,,,,100.0,MG,,,2018,Q1,Lactic acidosis,,2018,Q1,1,I,,20180201.0,20180215,20180215,EXP,GB-MHRA-MIDB-C57B9B12-0FAF-460B-BA1D-CA0A0A5EFAE4,GB-TEVA-2018-GB-857024,TEVA,,67.0,YR,,,Y,,,20180215.0,,PH,GB,GB,2018,Q1,Elderly
145373091,14537309,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,28.0,DF,TABLET,,2018,Q1,Intentional overdose,,2018,Q1,1,I,,20180209.0,20180215,20180215,EXP,,GB-BAUSCH-BL-2018-004140,BAUSCH AND LOMB,,29.0,YR,,F,Y,,,20180215.0,,OT,GB,GB,2018,Q1,Young Adult
145373091,14537309,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,28.0,DF,TABLET,,2018,Q1,Ovarian cancer,,2018,Q1,1,I,,20180209.0,20180215,20180215,EXP,,GB-BAUSCH-BL-2018-004140,BAUSCH AND LOMB,,29.0,YR,,F,Y,,,20180215.0,,OT,GB,GB,2018,Q1,Young Adult
145373091,14537309,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,100.0,MG,TABLET,QD,2018,Q1,Intentional overdose,,2018,Q1,1,I,,20180209.0,20180215,20180215,EXP,,GB-BAUSCH-BL-2018-004140,BAUSCH AND LOMB,,29.0,YR,,F,Y,,,20180215.0,,OT,GB,GB,2018,Q1,Young Adult
145373091,14537309,5,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,100.0,MG,TABLET,QD,2018,Q1,Ovarian cancer,,2018,Q1,1,I,,20180209.0,20180215,20180215,EXP,,GB-BAUSCH-BL-2018-004140,BAUSCH AND LOMB,,29.0,YR,,F,Y,,,20180215.0,,OT,GB,GB,2018,Q1,Young Adult
145394951,14539495,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q1,Urine ketone body present,,2018,Q1,1,I,20170327.0,20180205.0,20180216,20180216,EXP,,JP-JNJFOC-20180221160,JANSSEN,,49.0,YR,A,F,Y,87.0,KG,20180216.0,,OT,JP,JP,2018,Q1,Adult
145428951,14542895,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q1,Diabetic ketoacidosis,,2018,Q1,1,I,20180121.0,20180206.0,20180216,20180216,EXP,,GB-JNJFOC-20180208238,JANSSEN,,57.0,YR,A,M,Y,64.1,KG,20180216.0,,MD,GB,GB,2018,Q1,Adult
145527001,14552700,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q1,Eczema,,2018,Q1,1,I,20171102.0,20180209.0,20180220,20180220,EXP,,JP-JNJFOC-20180224611,JANSSEN,,50.0,YR,A,F,Y,62.0,KG,20180220.0,,OT,JP,JP,2018,Q1,Adult
145527001,14552700,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q1,Swelling face,,2018,Q1,1,I,20171102.0,20180209.0,20180220,20180220,EXP,,JP-JNJFOC-20180224611,JANSSEN,,50.0,YR,A,F,Y,62.0,KG,20180220.0,,OT,JP,JP,2018,Q1,Adult
145527071,14552707,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,,28.0,DF,TABLET,,2018,Q1,Intentional overdose,,2018,Q1,1,I,,20180213.0,20180220,20180220,EXP,,GB-JNJFOC-20180219384,JANSSEN,,29.0,YR,A,F,Y,,,20180220.0,,MD,GB,GB,2018,Q1,Young Adult
145527071,14552707,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,,28.0,DF,TABLET,,2018,Q1,Ovarian cancer,,2018,Q1,1,I,,20180213.0,20180220,20180220,EXP,,GB-JNJFOC-20180219384,JANSSEN,,29.0,YR,A,F,Y,,,20180220.0,,MD,GB,GB,2018,Q1,Young Adult
145527071,14552707,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,TABLET,,2018,Q1,Intentional overdose,,2018,Q1,1,I,,20180213.0,20180220,20180220,EXP,,GB-JNJFOC-20180219384,JANSSEN,,29.0,YR,A,F,Y,,,20180220.0,,MD,GB,GB,2018,Q1,Young Adult
145527071,14552707,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,TABLET,,2018,Q1,Ovarian cancer,,2018,Q1,1,I,,20180213.0,20180220,20180220,EXP,,GB-JNJFOC-20180219384,JANSSEN,,29.0,YR,A,F,Y,,,20180220.0,,MD,GB,GB,2018,Q1,Young Adult
145541971,14554197,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 15EG261X,20170228,,100.0,MG,,QD,2018,Q1,Blood glucose increased,,2018,Q1,1,I,20150729.0,,20180208,20180208,DIR,,,FDA-CTU,,77.0,YR,,M,N,204.8,KG,20151016.0,N,PH,US,US,2018,Q1,Elderly
145541971,14554197,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 15EG261X,20170228,,100.0,MG,,QD,2018,Q1,Blood potassium increased,,2018,Q1,1,I,20150729.0,,20180208,20180208,DIR,,,FDA-CTU,,77.0,YR,,M,N,204.8,KG,20151016.0,N,PH,US,US,2018,Q1,Elderly
145541971,14554197,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 15EG261X,20170228,,100.0,MG,,QD,2018,Q1,Blood urea increased,,2018,Q1,1,I,20150729.0,,20180208,20180208,DIR,,,FDA-CTU,,77.0,YR,,M,N,204.8,KG,20151016.0,N,PH,US,US,2018,Q1,Elderly
145541971,14554197,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 15EG261X,20170228,,100.0,MG,,QD,2018,Q1,Dry mouth,,2018,Q1,1,I,20150729.0,,20180208,20180208,DIR,,,FDA-CTU,,77.0,YR,,M,N,204.8,KG,20151016.0,N,PH,US,US,2018,Q1,Elderly
145541971,14554197,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 15EG261X,20170228,,100.0,MG,,QD,2018,Q1,Lactic acidosis,,2018,Q1,1,I,20150729.0,,20180208,20180208,DIR,,,FDA-CTU,,77.0,YR,,M,N,204.8,KG,20151016.0,N,PH,US,US,2018,Q1,Elderly
145541971,14554197,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 15EG261X,20170228,,100.0,MG,,QD,2018,Q1,Nausea,,2018,Q1,1,I,20150729.0,,20180208,20180208,DIR,,,FDA-CTU,,77.0,YR,,M,N,204.8,KG,20151016.0,N,PH,US,US,2018,Q1,Elderly
145541971,14554197,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, 15EG261X,20170228,,100.0,MG,,QD,2018,Q1,Polyuria,,2018,Q1,1,I,20150729.0,,20180208,20180208,DIR,,,FDA-CTU,,77.0,YR,,M,N,204.8,KG,20151016.0,N,PH,US,US,2018,Q1,Elderly
145575781,14557578,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,100.0,MG,TABLET,QD,2018,Q1,Hypokalaemia,,2018,Q1,1,I,,20180213.0,20180221,20180221,EXP,,US-JNJFOC-20180219677,JANSSEN,"SCHAEFFER SE, DESLAURIERS C, SPILLER HA, ALEGUAS A, BAEZA S, RYAN ML. RETROSPECTIVE REVIEW OF SGLT2 INHIBITOR EXPOSURES REPORTED TO 13 POISON CENTERS. CLINICAL TOXICOLOGY 2018;56/3:204-208.",65.0,YR,A,M,Y,,,20180221.0,,MD,US,US,2018,Q1,Elderly
145575781,14557578,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,100.0,MG,TABLET,QD,2018,Q1,Metabolic acidosis,,2018,Q1,1,I,,20180213.0,20180221,20180221,EXP,,US-JNJFOC-20180219677,JANSSEN,"SCHAEFFER SE, DESLAURIERS C, SPILLER HA, ALEGUAS A, BAEZA S, RYAN ML. RETROSPECTIVE REVIEW OF SGLT2 INHIBITOR EXPOSURES REPORTED TO 13 POISON CENTERS. CLINICAL TOXICOLOGY 2018;56/3:204-208.",65.0,YR,A,M,Y,,,20180221.0,,MD,US,US,2018,Q1,Elderly
145619411,14561941,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,,,,TABLET,,2018,Q1,Hypertension,,2018,Q1,1,I,,20180213.0,20180222,20180222,EXP,,US-JNJFOC-20180226570,JANSSEN,"SCHAEFFER SE, DESLAURIERS C, SPILLER HA, ALEGUAS A, BAEZA S, RYAN ML. RETROSPECTIVE REVIEW OF SGLT2 INHIBITOR EXPOSURES REPORTED TO 13 POISON CENTERS. CLINICAL TOXICOLOGY 2018;56(3):204-208.",43.0,YR,A,F,Y,,,20180222.0,,MD,US,US,2018,Q1,Adult
145619411,14561941,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,,,,TABLET,,2018,Q1,Suicide attempt,,2018,Q1,1,I,,20180213.0,20180222,20180222,EXP,,US-JNJFOC-20180226570,JANSSEN,"SCHAEFFER SE, DESLAURIERS C, SPILLER HA, ALEGUAS A, BAEZA S, RYAN ML. RETROSPECTIVE REVIEW OF SGLT2 INHIBITOR EXPOSURES REPORTED TO 13 POISON CENTERS. CLINICAL TOXICOLOGY 2018;56(3):204-208.",43.0,YR,A,F,Y,,,20180222.0,,MD,US,US,2018,Q1,Adult
145619411,14561941,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,,,,TABLET,,2018,Q1,Tachycardia,,2018,Q1,1,I,,20180213.0,20180222,20180222,EXP,,US-JNJFOC-20180226570,JANSSEN,"SCHAEFFER SE, DESLAURIERS C, SPILLER HA, ALEGUAS A, BAEZA S, RYAN ML. RETROSPECTIVE REVIEW OF SGLT2 INHIBITOR EXPOSURES REPORTED TO 13 POISON CENTERS. CLINICAL TOXICOLOGY 2018;56(3):204-208.",43.0,YR,A,F,Y,,,20180222.0,,MD,US,US,2018,Q1,Adult
145619411,14561941,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,,,,TABLET,,2018,Q1,Toxicity to various agents,,2018,Q1,1,I,,20180213.0,20180222,20180222,EXP,,US-JNJFOC-20180226570,JANSSEN,"SCHAEFFER SE, DESLAURIERS C, SPILLER HA, ALEGUAS A, BAEZA S, RYAN ML. RETROSPECTIVE REVIEW OF SGLT2 INHIBITOR EXPOSURES REPORTED TO 13 POISON CENTERS. CLINICAL TOXICOLOGY 2018;56(3):204-208.",43.0,YR,A,F,Y,,,20180222.0,,MD,US,US,2018,Q1,Adult
145619411,14561941,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,,,,TABLET,,2018,Q1,Vomiting,,2018,Q1,1,I,,20180213.0,20180222,20180222,EXP,,US-JNJFOC-20180226570,JANSSEN,"SCHAEFFER SE, DESLAURIERS C, SPILLER HA, ALEGUAS A, BAEZA S, RYAN ML. RETROSPECTIVE REVIEW OF SGLT2 INHIBITOR EXPOSURES REPORTED TO 13 POISON CENTERS. CLINICAL TOXICOLOGY 2018;56(3):204-208.",43.0,YR,A,F,Y,,,20180222.0,,MD,US,US,2018,Q1,Adult
145619411,14561941,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,6000.0,MG,TABLET,,2018,Q1,Hypertension,,2018,Q1,1,I,,20180213.0,20180222,20180222,EXP,,US-JNJFOC-20180226570,JANSSEN,"SCHAEFFER SE, DESLAURIERS C, SPILLER HA, ALEGUAS A, BAEZA S, RYAN ML. RETROSPECTIVE REVIEW OF SGLT2 INHIBITOR EXPOSURES REPORTED TO 13 POISON CENTERS. CLINICAL TOXICOLOGY 2018;56(3):204-208.",43.0,YR,A,F,Y,,,20180222.0,,MD,US,US,2018,Q1,Adult
145619411,14561941,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,6000.0,MG,TABLET,,2018,Q1,Suicide attempt,,2018,Q1,1,I,,20180213.0,20180222,20180222,EXP,,US-JNJFOC-20180226570,JANSSEN,"SCHAEFFER SE, DESLAURIERS C, SPILLER HA, ALEGUAS A, BAEZA S, RYAN ML. RETROSPECTIVE REVIEW OF SGLT2 INHIBITOR EXPOSURES REPORTED TO 13 POISON CENTERS. CLINICAL TOXICOLOGY 2018;56(3):204-208.",43.0,YR,A,F,Y,,,20180222.0,,MD,US,US,2018,Q1,Adult
145619411,14561941,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,6000.0,MG,TABLET,,2018,Q1,Tachycardia,,2018,Q1,1,I,,20180213.0,20180222,20180222,EXP,,US-JNJFOC-20180226570,JANSSEN,"SCHAEFFER SE, DESLAURIERS C, SPILLER HA, ALEGUAS A, BAEZA S, RYAN ML. RETROSPECTIVE REVIEW OF SGLT2 INHIBITOR EXPOSURES REPORTED TO 13 POISON CENTERS. CLINICAL TOXICOLOGY 2018;56(3):204-208.",43.0,YR,A,F,Y,,,20180222.0,,MD,US,US,2018,Q1,Adult
145619411,14561941,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,6000.0,MG,TABLET,,2018,Q1,Toxicity to various agents,,2018,Q1,1,I,,20180213.0,20180222,20180222,EXP,,US-JNJFOC-20180226570,JANSSEN,"SCHAEFFER SE, DESLAURIERS C, SPILLER HA, ALEGUAS A, BAEZA S, RYAN ML. RETROSPECTIVE REVIEW OF SGLT2 INHIBITOR EXPOSURES REPORTED TO 13 POISON CENTERS. CLINICAL TOXICOLOGY 2018;56(3):204-208.",43.0,YR,A,F,Y,,,20180222.0,,MD,US,US,2018,Q1,Adult
145619411,14561941,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,6000.0,MG,TABLET,,2018,Q1,Vomiting,,2018,Q1,1,I,,20180213.0,20180222,20180222,EXP,,US-JNJFOC-20180226570,JANSSEN,"SCHAEFFER SE, DESLAURIERS C, SPILLER HA, ALEGUAS A, BAEZA S, RYAN ML. RETROSPECTIVE REVIEW OF SGLT2 INHIBITOR EXPOSURES REPORTED TO 13 POISON CENTERS. CLINICAL TOXICOLOGY 2018;56(3):204-208.",43.0,YR,A,F,Y,,,20180222.0,,MD,US,US,2018,Q1,Adult
145663001,14566300,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"28 DF, UNK",,,U,, UNKNOWN,,,28.0,DF,TABLET,,2018,Q1,Intentional overdose,,2018,Q1,1,I,,20180209.0,20180223,20180223,EXP,GB-MYLANLABS-2018M1007776,GB-LUPIN PHARMACEUTICALS INC.-2018-01087,LUPIN,,29.0,YR,,F,Y,,,20180223.0,,CN,GB,GB,2018,Q1,Young Adult
145663001,14566300,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"28 DF, UNK",,,U,, UNKNOWN,,,28.0,DF,TABLET,,2018,Q1,Ovarian cancer,,2018,Q1,1,I,,20180209.0,20180223,20180223,EXP,GB-MYLANLABS-2018M1007776,GB-LUPIN PHARMACEUTICALS INC.-2018-01087,LUPIN,,29.0,YR,,F,Y,,,20180223.0,,CN,GB,GB,2018,Q1,Young Adult
145663001,14566300,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",,,U,, UNKNOWN,,,100.0,MG,TABLET,,2018,Q1,Intentional overdose,,2018,Q1,1,I,,20180209.0,20180223,20180223,EXP,GB-MYLANLABS-2018M1007776,GB-LUPIN PHARMACEUTICALS INC.-2018-01087,LUPIN,,29.0,YR,,F,Y,,,20180223.0,,CN,GB,GB,2018,Q1,Young Adult
145663001,14566300,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",,,U,, UNKNOWN,,,100.0,MG,TABLET,,2018,Q1,Ovarian cancer,,2018,Q1,1,I,,20180209.0,20180223,20180223,EXP,GB-MYLANLABS-2018M1007776,GB-LUPIN PHARMACEUTICALS INC.-2018-01087,LUPIN,,29.0,YR,,F,Y,,,20180223.0,,CN,GB,GB,2018,Q1,Young Adult
145670821,14567082,2,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q1,Toe amputation,,2018,Q1,1,I,,20180216.0,20180223,20180223,EXP,,"FR-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-009944",BOEHRINGER INGELHEIM,"ROUSTIT M, KHOURI C, CRACOWSKI J. SGLT-2 INHIBITORS AND THE RISK OF LOWER-LIMB AMPUTATION: IS THIS A CLASS EFFECT?. DIABETES OBESITY AND METABOLISM. 2018;.",56.0,YR,,F,Y,,,20180223.0,,MD,FR,US,2018,Q1,Adult
145987492,14598749,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,300.0,MG,TABLET,,2018,Q1,Accident at work,,2018,Q1,2,F,,20180305.0,20180305,20180309,EXP,,CA-JNJFOC-20180303560,JANSSEN,,63.0,YR,A,M,Y,,,20180309.0,,OT,CA,CA,2018,Q1,Adult
145987492,14598749,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,300.0,MG,TABLET,,2018,Q1,Osteomyelitis,,2018,Q1,2,F,,20180305.0,20180305,20180309,EXP,,CA-JNJFOC-20180303560,JANSSEN,,63.0,YR,A,M,Y,,,20180309.0,,OT,CA,CA,2018,Q1,Adult
146172551,14617255,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,N,,,204042.0,,,TABLET,,2018,Q1,Skin necrosis,,2018,Q1,1,I,,20180302.0,20180309,20180309,EXP,,GB-JNJFOC-20180304519,JANSSEN,,49.0,YR,A,M,Y,,,20180309.0,,MD,GB,GB,2018,Q1,Adult
146380551,14638055,2,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Unknown,"100 MG, UNK",,,U,,,,,100.0,MG,,,2018,Q1,Euglycaemic diabetic ketoacidosis,,2018,Q1,1,I,,20180301.0,20180314,20180314,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-022466,BRISTOL MYERS SQUIBB,KATO. A CASE OF EUGLYCAUMIC DIABETIC KETOACIDOSIS CAUSED BY SODIUM-GLUCOSE LINKED TRANSPORTER 2 (SGLT2) INHIBITOR THAT WAS USED DURING CARBOHYDRATE-RESTRICTED DIET THERAPY.. PROGRAMME AND ABSTRACTS OF THE PAPERS FOR THE 55TH LOCAL MEETING OF THE KANTO KO. 2018;82,44.0,YR,,M,Y,,,20180314.0,,OT,JP,JP,2018,Q1,Adult
146412431,14641243,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,100.0,MG,TABLET,,2018,Q1,Suicidal ideation,,2018,Q1,1,I,,20180308.0,20180315,20180315,EXP,,GB-JNJFOC-20180312264,JANSSEN,,68.0,YR,E,M,Y,96.8,KG,20180315.0,,OT,GB,GB,2018,Q1,Elderly
146482841,14648284,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q1,Diabetic ketoacidosis,,2018,Q1,1,I,20180212.0,20180314.0,20180316,20180316,EXP,,GB-JNJFOC-20180320278,JANSSEN,,68.0,YR,E,M,Y,90.0,KG,20180316.0,,OT,GB,GB,2018,Q1,Elderly
146532581,14653258,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N,,,204042.0,100.0,MG,TABLET,,2018,Q1,Ketoacidosis,,2018,Q1,1,I,20171021.0,20180118.0,20180319,20180319,EXP,,GB-JNJFOC-20180125399,JANSSEN,,34.0,YR,A,M,Y,78.0,KG,20180319.0,,CN,GB,GB,2018,Q1,Young Adult
146550162,14655016,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,100.0,MG,TABLET,,2018,Q1,Cellulitis,,2018,Q1,2,F,,20180315.0,20180319,20180323,EXP,,GB-JNJFOC-20180322010,JANSSEN,,62.0,YR,A,M,Y,,,20180323.0,,OT,GB,GB,2018,Q1,Adult
146662181,14666218,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 DOSAGE FORMS DAILY;,221.04167,DF,,,,,,1.0,DF,,,2018,Q1,Lip swelling,,2018,Q1,1,I,,20180309.0,20180321,20180321,EXP,GB-MHRA-TPP36059351C2438106YC1516624192539,GB-TEVA-2018-GB-870140,TEVA,,65.0,YR,,M,Y,92.0,KG,20180322.0,,MD,GB,GB,2018,Q1,Elderly
146747661,14674766,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,,2018,Q1,Dyspnoea,,2018,Q1,1,I,20180303.0,20180322.0,20180323,20180323,EXP,,GB-JNJFOC-20180329972,JANSSEN,,62.0,YR,A,F,Y,71.0,KG,20180323.0,,PH,GB,GB,2018,Q1,Adult
146747661,14674766,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,,2018,Q1,Euglycaemic diabetic ketoacidosis,,2018,Q1,1,I,20180303.0,20180322.0,20180323,20180323,EXP,,GB-JNJFOC-20180329972,JANSSEN,,62.0,YR,A,F,Y,71.0,KG,20180323.0,,PH,GB,GB,2018,Q1,Adult
146747661,14674766,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,,2018,Q1,Metabolic acidosis,,2018,Q1,1,I,20180303.0,20180322.0,20180323,20180323,EXP,,GB-JNJFOC-20180329972,JANSSEN,,62.0,YR,A,F,Y,71.0,KG,20180323.0,,PH,GB,GB,2018,Q1,Adult
146858991,14685899,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,D,D,,,,300.0,MG,,QD,2018,Q1,Diabetic ketoacidosis,,2018,Q1,1,I,20180305.0,,20180326,20180326,DIR,,,FDA-CTU,,51.0,YR,,M,N,87.1,KG,20180326.0,N,PH,US,US,2018,Q1,Adult
146858991,14685899,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,D,D,,,,300.0,MG,,QD,2018,Q1,Metabolic acidosis,,2018,Q1,1,I,20180305.0,,20180326,20180326,DIR,,,FDA-CTU,,51.0,YR,,M,N,87.1,KG,20180326.0,N,PH,US,US,2018,Q1,Adult
146858991,14685899,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,D,D,,,,300.0,MG,,QD,2018,Q1,Shock,,2018,Q1,1,I,20180305.0,,20180326,20180326,DIR,,,FDA-CTU,,51.0,YR,,M,N,87.1,KG,20180326.0,N,PH,US,US,2018,Q1,Adult
146884981,14688498,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q1,Acute kidney injury,,2018,Q1,1,I,20180223.0,20180319.0,20180328,20180328,EXP,,JP-JNJFOC-20180336637,JANSSEN,,77.0,YR,E,M,Y,,,20180328.0,,OT,JP,JP,2018,Q1,Elderly
146884981,14688498,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q1,Septic shock,,2018,Q1,1,I,20180223.0,20180319.0,20180328,20180328,EXP,,JP-JNJFOC-20180336637,JANSSEN,,77.0,YR,E,M,Y,,,20180328.0,,OT,JP,JP,2018,Q1,Elderly
130741523,13074152,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,,2018,Q2,Influenza like illness,,2018,Q2,3,F,20161024.0,20180606.0,20161230,20180614,EXP,,US-ROCHE-1870521,ROCHE,,50.0,YR,,F,Y,111.7,KG,20180614.0,,MD,US,US,2018,Q2,Adult
132043782,13204378,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,DOSE: 300 (UNITS UNSPECIFIED).,,,N,N,,,204042.0,300.0,MG,TABLET,QD,2018,Q2,Impaired healing,,2018,Q2,2,F,20160404.0,20180529.0,20170209,20180606,EXP,,GB-JNJFOC-20170207785,JANSSEN,,55.0,YR,A,M,Y,122.0,KG,20180606.0,,MD,GB,GB,2018,Q2,Adult
132043782,13204378,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,DOSE: 300 (UNITS UNSPECIFIED).,,,N,N,,,204042.0,300.0,MG,TABLET,QD,2018,Q2,Toe amputation,,2018,Q2,2,F,20160404.0,20180529.0,20170209,20180606,EXP,,GB-JNJFOC-20170207785,JANSSEN,,55.0,YR,A,M,Y,122.0,KG,20180606.0,,MD,GB,GB,2018,Q2,Adult
134236433,13423643,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,BEFORE BREAKFAST,,,Y,N,,,,100.0,MG,TABLET,QD,2018,Q2,Diabetic ketoacidosis,,2018,Q2,3,F,20170323.0,20180426.0,20170410,20180430,EXP,,GB-JNJFOC-20170407792,JANSSEN,,46.0,YR,A,F,Y,70.0,KG,20180430.0,,MD,GB,GB,2018,Q2,Adult
134236433,13423643,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,BEFORE BREAKFAST,,,Y,N,,,,100.0,MG,TABLET,QD,2018,Q2,Diarrhoea,,2018,Q2,3,F,20170323.0,20180426.0,20170410,20180430,EXP,,GB-JNJFOC-20170407792,JANSSEN,,46.0,YR,A,F,Y,70.0,KG,20180430.0,,MD,GB,GB,2018,Q2,Adult
134236433,13423643,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,BEFORE BREAKFAST,,,Y,N,,,,100.0,MG,TABLET,QD,2018,Q2,Hypothermia,,2018,Q2,3,F,20170323.0,20180426.0,20170410,20180430,EXP,,GB-JNJFOC-20170407792,JANSSEN,,46.0,YR,A,F,Y,70.0,KG,20180430.0,,MD,GB,GB,2018,Q2,Adult
134236433,13423643,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,BEFORE BREAKFAST,,,Y,N,,,,100.0,MG,TABLET,QD,2018,Q2,Pancreatitis,,2018,Q2,3,F,20170323.0,20180426.0,20170410,20180430,EXP,,GB-JNJFOC-20170407792,JANSSEN,,46.0,YR,A,F,Y,70.0,KG,20180430.0,,MD,GB,GB,2018,Q2,Adult
134236433,13423643,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,BEFORE BREAKFAST,,,Y,N,,,,100.0,MG,TABLET,QD,2018,Q2,Vomiting,,2018,Q2,3,F,20170323.0,20180426.0,20170410,20180430,EXP,,GB-JNJFOC-20170407792,JANSSEN,,46.0,YR,A,F,Y,70.0,KG,20180430.0,,MD,GB,GB,2018,Q2,Adult
134236433,13423643,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,,2018,Q2,Diabetic ketoacidosis,,2018,Q2,3,F,20170323.0,20180426.0,20170410,20180430,EXP,,GB-JNJFOC-20170407792,JANSSEN,,46.0,YR,A,F,Y,70.0,KG,20180430.0,,MD,GB,GB,2018,Q2,Adult
134236433,13423643,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,,2018,Q2,Diarrhoea,,2018,Q2,3,F,20170323.0,20180426.0,20170410,20180430,EXP,,GB-JNJFOC-20170407792,JANSSEN,,46.0,YR,A,F,Y,70.0,KG,20180430.0,,MD,GB,GB,2018,Q2,Adult
134236433,13423643,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,,2018,Q2,Hypothermia,,2018,Q2,3,F,20170323.0,20180426.0,20170410,20180430,EXP,,GB-JNJFOC-20170407792,JANSSEN,,46.0,YR,A,F,Y,70.0,KG,20180430.0,,MD,GB,GB,2018,Q2,Adult
134236433,13423643,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,,2018,Q2,Pancreatitis,,2018,Q2,3,F,20170323.0,20180426.0,20170410,20180430,EXP,,GB-JNJFOC-20170407792,JANSSEN,,46.0,YR,A,F,Y,70.0,KG,20180430.0,,MD,GB,GB,2018,Q2,Adult
134236433,13423643,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,,2018,Q2,Vomiting,,2018,Q2,3,F,20170323.0,20180426.0,20170410,20180430,EXP,,GB-JNJFOC-20170407792,JANSSEN,,46.0,YR,A,F,Y,70.0,KG,20180430.0,,MD,GB,GB,2018,Q2,Adult
134964882,13496488,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,,,TABLET,,2018,Q2,Acute kidney injury,,2018,Q2,2,F,,20180418.0,20170428,20180420,EXP,,GB-JNJFOC-20170426253,JANSSEN,,47.0,YR,A,F,Y,,,20180420.0,,MD,GB,GB,2018,Q2,Adult
134964882,13496488,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,,,TABLET,,2018,Q2,Arrhythmia,,2018,Q2,2,F,,20180418.0,20170428,20180420,EXP,,GB-JNJFOC-20170426253,JANSSEN,,47.0,YR,A,F,Y,,,20180420.0,,MD,GB,GB,2018,Q2,Adult
134964882,13496488,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,,,TABLET,,2018,Q2,Euglycaemic diabetic ketoacidosis,,2018,Q2,2,F,,20180418.0,20170428,20180420,EXP,,GB-JNJFOC-20170426253,JANSSEN,,47.0,YR,A,F,Y,,,20180420.0,,MD,GB,GB,2018,Q2,Adult
135677502,13567750,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,DOSE 100 (UNITS UNSPECIFIED),,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q2,Diabetic foot,,2018,Q2,2,F,20170428.0,20180529.0,20170522,20180606,EXP,,GB-JNJFOC-20170516204,JANSSEN,,59.0,YR,A,M,Y,103.0,KG,20180606.0,,PH,GB,GB,2018,Q2,Adult
135677502,13567750,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,DOSE 100 (UNITS UNSPECIFIED),,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q2,Peripheral ischaemia,,2018,Q2,2,F,20170428.0,20180529.0,20170522,20180606,EXP,,GB-JNJFOC-20170516204,JANSSEN,,59.0,YR,A,M,Y,103.0,KG,20180606.0,,PH,GB,GB,2018,Q2,Adult
135677502,13567750,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,DOSE 100 (UNITS UNSPECIFIED),,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q2,Toe amputation,,2018,Q2,2,F,20170428.0,20180529.0,20170522,20180606,EXP,,GB-JNJFOC-20170516204,JANSSEN,,59.0,YR,A,M,Y,103.0,KG,20180606.0,,PH,GB,GB,2018,Q2,Adult
137931292,13793129,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,,,TABLET,,2018,Q2,Toe amputation,,2018,Q2,2,F,20170714.0,20180529.0,20170726,20180606,EXP,,GB-JNJFOC-20170717505,JANSSEN,,36.0,YR,A,M,Y,124.0,KG,20180606.0,,OT,GB,GB,2018,Q2,Adult
138557952,13855795,16,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q2,Angina unstable,,2018,Q2,2,F,20160313.0,20180404.0,20170810,20180404,EXP,,US-EISAI MEDICAL RESEARCH-EC-2016-015280,EISAI,,67.0,YR,,M,Y,95.8,KG,20180404.0,,MD,US,US,2018,Q2,Elderly
138557952,13855795,16,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q2,Coronary artery disease,,2018,Q2,2,F,20160313.0,20180404.0,20170810,20180404,EXP,,US-EISAI MEDICAL RESEARCH-EC-2016-015280,EISAI,,67.0,YR,,M,Y,95.8,KG,20180404.0,,MD,US,US,2018,Q2,Elderly
139845606,13984560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,, UNK,,,,,,,2018,Q2,Acute kidney injury,,2018,Q2,6,F,,20180614.0,20170918,20180627,EXP,,PHHY2017AT137108,SANDOZ,,71.0,YR,,M,Y,,,20180627.0,,OT,AT,AT,2018,Q2,Elderly
139845606,13984560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,, UNK,,,,,,,2018,Q2,Anion gap increased,,2018,Q2,6,F,,20180614.0,20170918,20180627,EXP,,PHHY2017AT137108,SANDOZ,,71.0,YR,,M,Y,,,20180627.0,,OT,AT,AT,2018,Q2,Elderly
139845606,13984560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,, UNK,,,,,,,2018,Q2,Base excess decreased,,2018,Q2,6,F,,20180614.0,20170918,20180627,EXP,,PHHY2017AT137108,SANDOZ,,71.0,YR,,M,Y,,,20180627.0,,OT,AT,AT,2018,Q2,Elderly
139845606,13984560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,, UNK,,,,,,,2018,Q2,Blood bicarbonate decreased,,2018,Q2,6,F,,20180614.0,20170918,20180627,EXP,,PHHY2017AT137108,SANDOZ,,71.0,YR,,M,Y,,,20180627.0,,OT,AT,AT,2018,Q2,Elderly
139845606,13984560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,, UNK,,,,,,,2018,Q2,Blood lactic acid increased,,2018,Q2,6,F,,20180614.0,20170918,20180627,EXP,,PHHY2017AT137108,SANDOZ,,71.0,YR,,M,Y,,,20180627.0,,OT,AT,AT,2018,Q2,Elderly
139845606,13984560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,, UNK,,,,,,,2018,Q2,Blood pH decreased,,2018,Q2,6,F,,20180614.0,20170918,20180627,EXP,,PHHY2017AT137108,SANDOZ,,71.0,YR,,M,Y,,,20180627.0,,OT,AT,AT,2018,Q2,Elderly
139845606,13984560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,, UNK,,,,,,,2018,Q2,Body temperature decreased,,2018,Q2,6,F,,20180614.0,20170918,20180627,EXP,,PHHY2017AT137108,SANDOZ,,71.0,YR,,M,Y,,,20180627.0,,OT,AT,AT,2018,Q2,Elderly
139845606,13984560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,, UNK,,,,,,,2018,Q2,Diabetic ketoacidosis,,2018,Q2,6,F,,20180614.0,20170918,20180627,EXP,,PHHY2017AT137108,SANDOZ,,71.0,YR,,M,Y,,,20180627.0,,OT,AT,AT,2018,Q2,Elderly
139845606,13984560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,, UNK,,,,,,,2018,Q2,Hyperventilation,,2018,Q2,6,F,,20180614.0,20170918,20180627,EXP,,PHHY2017AT137108,SANDOZ,,71.0,YR,,M,Y,,,20180627.0,,OT,AT,AT,2018,Q2,Elderly
139845606,13984560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,, UNK,,,,,,,2018,Q2,Hypotension,,2018,Q2,6,F,,20180614.0,20170918,20180627,EXP,,PHHY2017AT137108,SANDOZ,,71.0,YR,,M,Y,,,20180627.0,,OT,AT,AT,2018,Q2,Elderly
139845606,13984560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,, UNK,,,,,,,2018,Q2,Kussmaul respiration,,2018,Q2,6,F,,20180614.0,20170918,20180627,EXP,,PHHY2017AT137108,SANDOZ,,71.0,YR,,M,Y,,,20180627.0,,OT,AT,AT,2018,Q2,Elderly
139845606,13984560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,, UNK,,,,,,,2018,Q2,Lactic acidosis,,2018,Q2,6,F,,20180614.0,20170918,20180627,EXP,,PHHY2017AT137108,SANDOZ,,71.0,YR,,M,Y,,,20180627.0,,OT,AT,AT,2018,Q2,Elderly
139845606,13984560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,, UNK,,,,,,,2018,Q2,Nausea,,2018,Q2,6,F,,20180614.0,20170918,20180627,EXP,,PHHY2017AT137108,SANDOZ,,71.0,YR,,M,Y,,,20180627.0,,OT,AT,AT,2018,Q2,Elderly
139845606,13984560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,, UNK,,,,,,,2018,Q2,PCO2 decreased,,2018,Q2,6,F,,20180614.0,20170918,20180627,EXP,,PHHY2017AT137108,SANDOZ,,71.0,YR,,M,Y,,,20180627.0,,OT,AT,AT,2018,Q2,Elderly
139845606,13984560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,, UNK,,,,,,,2018,Q2,Pneumonia,,2018,Q2,6,F,,20180614.0,20170918,20180627,EXP,,PHHY2017AT137108,SANDOZ,,71.0,YR,,M,Y,,,20180627.0,,OT,AT,AT,2018,Q2,Elderly
139845606,13984560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,, UNK,,,,,,,2018,Q2,Somnolence,,2018,Q2,6,F,,20180614.0,20170918,20180627,EXP,,PHHY2017AT137108,SANDOZ,,71.0,YR,,M,Y,,,20180627.0,,OT,AT,AT,2018,Q2,Elderly
139845606,13984560,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,, UNK,,,,,,,2018,Q2,Vomiting,,2018,Q2,6,F,,20180614.0,20170918,20180627,EXP,,PHHY2017AT137108,SANDOZ,,71.0,YR,,M,Y,,,20180627.0,,OT,AT,AT,2018,Q2,Elderly
140098314,14009831,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q2,Diabetic ketoacidosis,,2018,Q2,4,F,,20180402.0,20170925,20180416,EXP,,AT-BAUSCH-BL-2017-027759,BAUSCH AND LOMB,"SCHWETZ V, EISNER F, SCHILCHER G, ELLER K, PLANK J, LIND A. COMBINED METFORMIN-ASSOCIATED LACTIC ACIDOSIS AND EUGLYCEMIC KETOACIDOSIS. WIENER KLINISCHE WOCHENSCHRIFT. 2017;129(17):646-649.",71.0,YR,,M,Y,,,20180416.0,,MD,AT,AT,2018,Q2,Elderly
140098314,14009831,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q2,Lactic acidosis,,2018,Q2,4,F,,20180402.0,20170925,20180416,EXP,,AT-BAUSCH-BL-2017-027759,BAUSCH AND LOMB,"SCHWETZ V, EISNER F, SCHILCHER G, ELLER K, PLANK J, LIND A. COMBINED METFORMIN-ASSOCIATED LACTIC ACIDOSIS AND EUGLYCEMIC KETOACIDOSIS. WIENER KLINISCHE WOCHENSCHRIFT. 2017;129(17):646-649.",71.0,YR,,M,Y,,,20180416.0,,MD,AT,AT,2018,Q2,Elderly
140118453,14011845,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,,,TABLET,,2018,Q2,Ketoacidosis,,2018,Q2,3,F,,20180330.0,20170926,20180403,EXP,,AT-JNJFOC-20170924766,JANSSEN,"SCHWETZ V, EISNER F, SCHILCHER G, ELLER K, PLANK J, LIND A, ET AL. COMBINED METFORMIN-ASSOCIATED LACTIC ACIDOSIS AND EUGLYCEMIC KETOACIDOSIS. WEINER KLINISCHE WOCHENSCHRIFT 01-SEP-2017;129 (17-18):646-649.",71.0,YR,E,M,Y,,,20180403.0,,MD,AT,AT,2018,Q2,Elderly
140337837,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,(),,,U,U,,,,,,,,2018,Q2,Acute kidney injury,,2018,Q2,7,F,,20180412.0,20171003,20180426,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20180426.0,,OT,AT,AT,2018,Q2,Elderly
140337837,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,(),,,U,U,,,,,,,,2018,Q2,Anion gap increased,,2018,Q2,7,F,,20180412.0,20171003,20180426,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20180426.0,,OT,AT,AT,2018,Q2,Elderly
140337837,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,(),,,U,U,,,,,,,,2018,Q2,Base excess decreased,,2018,Q2,7,F,,20180412.0,20171003,20180426,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20180426.0,,OT,AT,AT,2018,Q2,Elderly
140337837,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,(),,,U,U,,,,,,,,2018,Q2,Blood bicarbonate decreased,,2018,Q2,7,F,,20180412.0,20171003,20180426,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20180426.0,,OT,AT,AT,2018,Q2,Elderly
140337837,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,(),,,U,U,,,,,,,,2018,Q2,Blood lactic acid increased,,2018,Q2,7,F,,20180412.0,20171003,20180426,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20180426.0,,OT,AT,AT,2018,Q2,Elderly
140337837,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,(),,,U,U,,,,,,,,2018,Q2,Blood pH decreased,,2018,Q2,7,F,,20180412.0,20171003,20180426,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20180426.0,,OT,AT,AT,2018,Q2,Elderly
140337837,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,(),,,U,U,,,,,,,,2018,Q2,Body temperature decreased,,2018,Q2,7,F,,20180412.0,20171003,20180426,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20180426.0,,OT,AT,AT,2018,Q2,Elderly
140337837,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,(),,,U,U,,,,,,,,2018,Q2,Diabetic ketoacidosis,,2018,Q2,7,F,,20180412.0,20171003,20180426,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20180426.0,,OT,AT,AT,2018,Q2,Elderly
140337837,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,(),,,U,U,,,,,,,,2018,Q2,Hyperventilation,,2018,Q2,7,F,,20180412.0,20171003,20180426,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20180426.0,,OT,AT,AT,2018,Q2,Elderly
140337837,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,(),,,U,U,,,,,,,,2018,Q2,Hypotension,,2018,Q2,7,F,,20180412.0,20171003,20180426,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20180426.0,,OT,AT,AT,2018,Q2,Elderly
140337837,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,(),,,U,U,,,,,,,,2018,Q2,Ketoacidosis,,2018,Q2,7,F,,20180412.0,20171003,20180426,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20180426.0,,OT,AT,AT,2018,Q2,Elderly
140337837,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,(),,,U,U,,,,,,,,2018,Q2,Lactic acidosis,,2018,Q2,7,F,,20180412.0,20171003,20180426,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20180426.0,,OT,AT,AT,2018,Q2,Elderly
140337837,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,(),,,U,U,,,,,,,,2018,Q2,PCO2 decreased,,2018,Q2,7,F,,20180412.0,20171003,20180426,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20180426.0,,OT,AT,AT,2018,Q2,Elderly
140369183,14036918,11,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,TABLET,,2018,Q2,Arthralgia,,2018,Q2,3,F,201605.0,20180514.0,20171004,20180524,EXP,,US-UCBSA-2016020304,UCB,,65.0,YR,,F,Y,,,20180525.0,,PH,US,US,2018,Q2,Elderly
140369183,14036918,11,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,TABLET,,2018,Q2,Arthritis,,2018,Q2,3,F,201605.0,20180514.0,20171004,20180524,EXP,,US-UCBSA-2016020304,UCB,,65.0,YR,,F,Y,,,20180525.0,,PH,US,US,2018,Q2,Elderly
140369183,14036918,11,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,TABLET,,2018,Q2,Bronchitis,,2018,Q2,3,F,201605.0,20180514.0,20171004,20180524,EXP,,US-UCBSA-2016020304,UCB,,65.0,YR,,F,Y,,,20180525.0,,PH,US,US,2018,Q2,Elderly
140369183,14036918,11,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,TABLET,,2018,Q2,Pneumonia,,2018,Q2,3,F,201605.0,20180514.0,20171004,20180524,EXP,,US-UCBSA-2016020304,UCB,,65.0,YR,,F,Y,,,20180525.0,,PH,US,US,2018,Q2,Elderly
140369183,14036918,11,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,TABLET,,2018,Q2,Rheumatoid arthritis,,2018,Q2,3,F,201605.0,20180514.0,20171004,20180524,EXP,,US-UCBSA-2016020304,UCB,,65.0,YR,,F,Y,,,20180525.0,,PH,US,US,2018,Q2,Elderly
140369183,14036918,11,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,TABLET,,2018,Q2,Sinusitis,,2018,Q2,3,F,201605.0,20180514.0,20171004,20180524,EXP,,US-UCBSA-2016020304,UCB,,65.0,YR,,F,Y,,,20180525.0,,PH,US,US,2018,Q2,Elderly
142924635,14292463,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q2,Hypoacusis,,2018,Q2,5,F,20171016.0,20180406.0,20171215,20180411,EXP,,US-ROCHE-2035495,ROCHE,,64.0,YR,,F,Y,73.1,KG,20180411.0,,MD,US,US,2018,Q2,Adult
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Abscess bacterial,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Anaemia,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Atrial fibrillation,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Beta haemolytic streptococcal infection,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Chronic kidney disease,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Cytomegalovirus infection,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Depressed level of consciousness,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Effusion,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Embolic stroke,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Erythema,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Faeces discoloured,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Fungal paronychia,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Gastric ulcer,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Gastrointestinal haemorrhage,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Laryngeal ulceration,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Lung abscess,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Melaena,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Multiple-drug resistance,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Occult blood positive,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Platelet count decreased,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Pneumonia,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Pseudomonal sepsis,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Pulmonary cavitation,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Pulmonary congestion,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Rectal lesion,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Rectal ulcer,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Retinopathy,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Stenotrophomonas infection,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
143059244,14305924,5,C,CANAGLIFLOZIN HYDRATE,,2,,,,,,,,,,,,,,2018,Q2,Stomatitis,,2018,Q2,4,F,2017.0,20180328.0,20171219,20180403,EXP,,JP-ABBVIE-17K-087-2090189-00,ABBVIE,,78.0,YR,,M,Y,68.0,KG,20180403.0,,MD,JP,JP,2018,Q2,Elderly
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Asthenia,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Bladder stenosis,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Blood glucose increased,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Chills,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Diabetes mellitus,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Dizziness,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Dry throat,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Erythema,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Fatigue,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Gait disturbance,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Genitourinary operation,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Headache,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Hot flush,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Hypersomnia,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Hypophagia,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Myalgia,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Nasal dryness,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Nausea,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Pain,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Pain in extremity,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Penile pain,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Pruritus,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Radical prostatectomy,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Rash erythematous,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Skin plaque,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Thrombosis in device,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145150483,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q2,Urinary incontinence,,2018,Q2,3,F,201711.0,20180428.0,20180209,20180507,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180507.0,,MD,CA,CA,2018,Q2,Adult
145698742,14569874,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q2,Infusion site extravasation,,2018,Q2,2,F,20180212.0,20180330.0,20180224,20180413,PER,,US-JNJFOC-20180217076,JANSSEN,,51.0,YR,A,M,Y,78.8,KG,20180413.0,,PH,US,US,2018,Q2,Adult
145698742,14569874,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q2,Peripheral swelling,,2018,Q2,2,F,20180212.0,20180330.0,20180224,20180413,PER,,US-JNJFOC-20180217076,JANSSEN,,51.0,YR,A,M,Y,78.8,KG,20180413.0,,PH,US,US,2018,Q2,Adult
145698742,14569874,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q2,Underdose,,2018,Q2,2,F,20180212.0,20180330.0,20180224,20180413,PER,,US-JNJFOC-20180217076,JANSSEN,,51.0,YR,A,M,Y,78.8,KG,20180413.0,,PH,US,US,2018,Q2,Adult
145779342,14577934,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q2,Osteomyelitis,,2018,Q2,2,F,20170630.0,20180426.0,20180227,20180503,EXP,,GB-JNJFOC-20180232588,JANSSEN,,63.0,YR,A,F,Y,88.0,KG,20180503.0,,MD,GB,GB,2018,Q2,Adult
145779342,14577934,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q2,Skin ulcer,,2018,Q2,2,F,20170630.0,20180426.0,20180227,20180503,EXP,,GB-JNJFOC-20180232588,JANSSEN,,63.0,YR,A,F,Y,88.0,KG,20180503.0,,MD,GB,GB,2018,Q2,Adult
145779342,14577934,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q2,Toe amputation,,2018,Q2,2,F,20170630.0,20180426.0,20180227,20180503,EXP,,GB-JNJFOC-20180232588,JANSSEN,,63.0,YR,A,F,Y,88.0,KG,20180503.0,,MD,GB,GB,2018,Q2,Adult
146662182,14666218,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,1 DOSAGE FORMS DAILY;,221.04167,DF,U,,,,,1.0,DF,,,2018,Q2,Lip swelling,,2018,Q2,2,F,,20180531.0,20180321,20180608,EXP,GB-MHRA-TPP36059351C2438106YC1516624192539,GB-TEVA-2018-GB-870140,TEVA,,65.0,YR,,M,Y,92.0,KG,20180608.0,,MD,GB,GB,2018,Q2,Elderly
146733052,14673305,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,1.0,DF,TABLET,QD,2018,Q2,Tongue neoplasm malignant stage unspecified,,2018,Q2,2,F,20180219.0,20180514.0,20180323,20180521,EXP,,US-ROCHE-2093456,ROCHE,,66.0,YR,,M,Y,151.0,KG,20180521.0,,MD,US,US,2018,Q2,Elderly
146835902,14683590,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q2,Acute kidney injury,,2018,Q2,2,F,,20180405.0,20180327,20180418,EXP,,PHHY2017AT137115,SANDOZ,,71.0,YR,,M,Y,,,20180418.0,,OT,AT,AT,2018,Q2,Elderly
146835902,14683590,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q2,Diabetic ketoacidosis,,2018,Q2,2,F,,20180405.0,20180327,20180418,EXP,,PHHY2017AT137115,SANDOZ,,71.0,YR,,M,Y,,,20180418.0,,OT,AT,AT,2018,Q2,Elderly
146835902,14683590,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q2,Hyperventilation,,2018,Q2,2,F,,20180405.0,20180327,20180418,EXP,,PHHY2017AT137115,SANDOZ,,71.0,YR,,M,Y,,,20180418.0,,OT,AT,AT,2018,Q2,Elderly
146835902,14683590,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q2,Ketoacidosis,,2018,Q2,2,F,,20180405.0,20180327,20180418,EXP,,PHHY2017AT137115,SANDOZ,,71.0,YR,,M,Y,,,20180418.0,,OT,AT,AT,2018,Q2,Elderly
146835902,14683590,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q2,Lactic acidosis,,2018,Q2,2,F,,20180405.0,20180327,20180418,EXP,,PHHY2017AT137115,SANDOZ,,71.0,YR,,M,Y,,,20180418.0,,OT,AT,AT,2018,Q2,Elderly
146884982,14688498,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q2,Acute kidney injury,,2018,Q2,2,F,20180220.0,20180530.0,20180328,20180611,EXP,,JP-JNJFOC-20180336637,JANSSEN,,77.0,YR,E,M,Y,,,20180611.0,,OT,JP,JP,2018,Q2,Elderly
146884982,14688498,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q2,Dehydration,,2018,Q2,2,F,20180220.0,20180530.0,20180328,20180611,EXP,,JP-JNJFOC-20180336637,JANSSEN,,77.0,YR,E,M,Y,,,20180611.0,,OT,JP,JP,2018,Q2,Elderly
146884982,14688498,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q2,Pneumonia aspiration,,2018,Q2,2,F,20180220.0,20180530.0,20180328,20180611,EXP,,JP-JNJFOC-20180336637,JANSSEN,,77.0,YR,E,M,Y,,,20180611.0,,OT,JP,JP,2018,Q2,Elderly
146884982,14688498,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q2,Renal impairment,,2018,Q2,2,F,20180220.0,20180530.0,20180328,20180611,EXP,,JP-JNJFOC-20180336637,JANSSEN,,77.0,YR,E,M,Y,,,20180611.0,,OT,JP,JP,2018,Q2,Elderly
146884982,14688498,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q2,Septic shock,,2018,Q2,2,F,20180220.0,20180530.0,20180328,20180611,EXP,,JP-JNJFOC-20180336637,JANSSEN,,77.0,YR,E,M,Y,,,20180611.0,,OT,JP,JP,2018,Q2,Elderly
147049251,14704925,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q2,Urine ketone body present,,2018,Q2,1,I,20160803.0,20180305.0,20180402,20180402,EXP,,JP-JNJFOC-20180329196,JANSSEN,,55.0,YR,A,M,Y,91.0,KG,20180402.0,,OT,JP,JP,2018,Q2,Adult
147092531,14709253,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MG, QD",,,Y,,,,,100.0,MG,,,2018,Q2,Acute kidney injury,,2018,Q2,1,I,,20180323.0,20180403,20180403,EXP,,"US-ARBOR PHARMACEUTICALS, LLC-US-2018ARB000402",ARBOR,"AL-SOFIANI M, STEPHEN J. ACUTE RENAL FAILURE ASSOCIATED WITH THE CONCURRENT USE OF SGLT-2 INHIBITOR AND CHLORTHALIDONE. ENDOCRINE SOCIETY. 2016",44.0,YR,,M,Y,,,20180403.0,,OT,US,US,2018,Q2,Adult
147092531,14709253,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"100 MG, QD",,,Y,,,,,100.0,MG,,,2018,Q2,Hypovolaemia,,2018,Q2,1,I,,20180323.0,20180403,20180403,EXP,,"US-ARBOR PHARMACEUTICALS, LLC-US-2018ARB000402",ARBOR,"AL-SOFIANI M, STEPHEN J. ACUTE RENAL FAILURE ASSOCIATED WITH THE CONCURRENT USE OF SGLT-2 INHIBITOR AND CHLORTHALIDONE. ENDOCRINE SOCIETY. 2016",44.0,YR,,M,Y,,,20180403.0,,OT,US,US,2018,Q2,Adult
147263001,14726300,5,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2018,Q2,Knee arthroplasty,,2018,Q2,1,I,20180312.0,20180328.0,20180406,20180406,EXP,,US-UCBSA-2018014296,UCB,,46.0,YR,,M,Y,,,20180406.0,,PH,US,US,2018,Q2,Adult
147263001,14726300,5,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,U,,,,,,,,2018,Q2,Rheumatoid arthritis,,2018,Q2,1,I,20180312.0,20180328.0,20180406,20180406,EXP,,US-UCBSA-2018014296,UCB,,46.0,YR,,M,Y,,,20180406.0,,PH,US,US,2018,Q2,Adult
147308401,14730840,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2018,Q2,Dehydration,,2018,Q2,1,I,201711.0,20180326.0,20180406,20180406,EXP,,US-VALIDUS PHARMACEUTICALS LLC-US-2018VAL000582,VALIDUS,,64.0,YR,,F,Y,,,20180406.0,,MD,US,US,2018,Q2,Adult
147308401,14730840,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,D,,,,,,,,,2018,Q2,Renal impairment,,2018,Q2,1,I,201711.0,20180326.0,20180406,20180406,EXP,,US-VALIDUS PHARMACEUTICALS LLC-US-2018VAL000582,VALIDUS,,64.0,YR,,F,Y,,,20180406.0,,MD,US,US,2018,Q2,Adult
147413522,14741352,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,,100.0,MG,TABLET,,2018,Q2,Caesarean section,,2018,Q2,2,F,20180404.0,20180411.0,20180410,20180418,EXP,,KZ-JNJFOC-20171001412,JANSSEN,,27.0,YR,A,F,Y,40.0,KG,20180418.0,,OT,KZ,KZ,2018,Q2,Young Adult
147413522,14741352,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,D,,,,,100.0,MG,TABLET,,2018,Q2,Exposure during pregnancy,,2018,Q2,2,F,20180404.0,20180411.0,20180410,20180418,EXP,,KZ-JNJFOC-20171001412,JANSSEN,,27.0,YR,A,F,Y,40.0,KG,20180418.0,,OT,KZ,KZ,2018,Q2,Young Adult
147589281,14758928,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2018,Q2,Euglycaemic diabetic ketoacidosis,,2018,Q2,1,I,,20180404.0,20180413,20180413,EXP,,"GB-IMPAX LABORATORIES, INC-2018-IPXL-01152",IMPAX,"CHONG ZM, STIRLING A, SANDEEP T. SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT-2): CAUSE OF PROLONGED EUGLYCAEMIC KETOACIDOSIS AND KETONAEMIA FOLLOWING GENERAL ANAESTHESIA?. DIABET MED. 2018;35(SUPPL 1):100",52.0,YR,,F,Y,,,20180413.0,,OT,GB,GB,2018,Q2,Adult
147589281,14758928,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,,,,,2018,Q2,Ileus paralytic,,2018,Q2,1,I,,20180404.0,20180413,20180413,EXP,,"GB-IMPAX LABORATORIES, INC-2018-IPXL-01152",IMPAX,"CHONG ZM, STIRLING A, SANDEEP T. SODIUM-GLUCOSE COTRANSPORTER 2 (SGLT-2): CAUSE OF PROLONGED EUGLYCAEMIC KETOACIDOSIS AND KETONAEMIA FOLLOWING GENERAL ANAESTHESIA?. DIABET MED. 2018;35(SUPPL 1):100",52.0,YR,,F,Y,,,20180413.0,,OT,GB,GB,2018,Q2,Adult
147744011,14774401,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,N,,,204042.0,300.0,MG,TABLET,QD,2018,Q2,Ketoacidosis,,2018,Q2,1,I,,20180410.0,20180418,20180418,EXP,,US-JNJFOC-20180415278,JANSSEN,"KOHLI J, GOLDFARB S. QUIZ: METABOLIC ACIDOSIS IN A PATIENT WITH TYPE 2 DIABETES. AMERICAN JOURNAL OF KIDNEY DISEASES 2017.",65.0,YR,A,M,Y,,,20180418.0,,MD,US,US,2018,Q2,Elderly
147770741,14777074,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q2,Acute kidney injury,,2018,Q2,1,I,20180228.0,20180301.0,20180419,20180419,EXP,,CA-ORION CORPORATION ORION PHARMA-TREX2018-0651,ORION,,63.0,YR,,M,Y,103.4,KG,20180419.0,,MD,CA,US,2018,Q2,Adult
147770741,14777074,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q2,Cellulitis,,2018,Q2,1,I,20180228.0,20180301.0,20180419,20180419,EXP,,CA-ORION CORPORATION ORION PHARMA-TREX2018-0651,ORION,,63.0,YR,,M,Y,103.4,KG,20180419.0,,MD,CA,US,2018,Q2,Adult
147770741,14777074,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q2,Device related infection,,2018,Q2,1,I,20180228.0,20180301.0,20180419,20180419,EXP,,CA-ORION CORPORATION ORION PHARMA-TREX2018-0651,ORION,,63.0,YR,,M,Y,103.4,KG,20180419.0,,MD,CA,US,2018,Q2,Adult
147770741,14777074,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q2,Diabetes mellitus,,2018,Q2,1,I,20180228.0,20180301.0,20180419,20180419,EXP,,CA-ORION CORPORATION ORION PHARMA-TREX2018-0651,ORION,,63.0,YR,,M,Y,103.4,KG,20180419.0,,MD,CA,US,2018,Q2,Adult
147770741,14777074,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q2,Staphylococcal sepsis,,2018,Q2,1,I,20180228.0,20180301.0,20180419,20180419,EXP,,CA-ORION CORPORATION ORION PHARMA-TREX2018-0651,ORION,,63.0,YR,,M,Y,103.4,KG,20180419.0,,MD,CA,US,2018,Q2,Adult
147770741,14777074,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q2,Tachycardia,,2018,Q2,1,I,20180228.0,20180301.0,20180419,20180419,EXP,,CA-ORION CORPORATION ORION PHARMA-TREX2018-0651,ORION,,63.0,YR,,M,Y,103.4,KG,20180419.0,,MD,CA,US,2018,Q2,Adult
147784561,14778456,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q2,Neuropathic arthropathy,,2018,Q2,1,I,20171118.0,20180416.0,20180419,20180419,EXP,,GB-JNJFOC-20180420105,JANSSEN,,53.0,YR,A,M,Y,145.0,KG,20180419.0,,PH,GB,GB,2018,Q2,Adult
147908051,14790805,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,101100.0,MG,Y,,,,,300.0,MG,,QD,2018,Q2,Ketoacidosis,,2018,Q2,1,I,20150710.0,20180412.0,20180423,20180423,EXP,,AU-ASTRAZENECA-2018SE48850,ASTRAZENECA,,44.0,YR,,F,Y,,,20180423.0,,PH,AU,AU,2018,Q2,Adult
148053661,14805366,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q2,Diabetic ketoacidosis,,2018,Q2,1,I,20180403.0,20180424.0,20180425,20180425,EXP,,GB-JNJFOC-20180430860,JANSSEN,,68.0,YR,E,M,Y,102.0,KG,20180425.0,,MD,GB,GB,2018,Q2,Elderly
148148061,14814806,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q2,Diabetic ketoacidosis,,2018,Q2,1,I,20180329.0,20180418.0,20180426,20180426,EXP,,GB-JNJFOC-20180424019,JANSSEN,,60.0,YR,A,M,Y,,,20180426.0,,OT,GB,GB,2018,Q2,Adult
148148061,14814806,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q2,Fluid intake reduced,,2018,Q2,1,I,20180329.0,20180418.0,20180426,20180426,EXP,,GB-JNJFOC-20180424019,JANSSEN,,60.0,YR,A,M,Y,,,20180426.0,,OT,GB,GB,2018,Q2,Adult
148148061,14814806,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q2,Hypophagia,,2018,Q2,1,I,20180329.0,20180418.0,20180426,20180426,EXP,,GB-JNJFOC-20180424019,JANSSEN,,60.0,YR,A,M,Y,,,20180426.0,,OT,GB,GB,2018,Q2,Adult
148148061,14814806,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q2,Malaise,,2018,Q2,1,I,20180329.0,20180418.0,20180426,20180426,EXP,,GB-JNJFOC-20180424019,JANSSEN,,60.0,YR,A,M,Y,,,20180426.0,,OT,GB,GB,2018,Q2,Adult
148148061,14814806,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q2,Subcutaneous abscess,,2018,Q2,1,I,20180329.0,20180418.0,20180426,20180426,EXP,,GB-JNJFOC-20180424019,JANSSEN,,60.0,YR,A,M,Y,,,20180426.0,,OT,GB,GB,2018,Q2,Adult
148148061,14814806,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q2,Vomiting,,2018,Q2,1,I,20180329.0,20180418.0,20180426,20180426,EXP,,GB-JNJFOC-20180424019,JANSSEN,,60.0,YR,A,M,Y,,,20180426.0,,OT,GB,GB,2018,Q2,Adult
148184271,14818427,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q2,Diabetic ketoacidosis,,2018,Q2,1,I,,20180412.0,20180427,20180427,EXP,,IE-AUROBINDO-AUR-APL-2018-021909,AUROBINDO,,44.0,YR,,M,Y,,,20180427.0,,OT,IE,IE,2018,Q2,Adult
148419571,14841957,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q2,Otosclerosis,,2018,Q2,1,I,20170115.0,20180425.0,20180503,20180503,EXP,,JP-JNJFOC-20180502898,JANSSEN,,63.0,YR,A,F,Y,68.0,KG,20180503.0,,OT,JP,JP,2018,Q2,Adult
148473451,14847345,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q2,Ketonuria,,2018,Q2,1,I,,20180502.0,20180504,20180504,EXP,,GB-JNJFOC-20180503411,JANSSEN,,44.0,YR,A,M,Y,100.4,KG,20180504.0,,OT,GB,GB,2018,Q2,Adult
148600201,14860020,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q2,Myalgia,,2018,Q2,1,I,20180419.0,20180503.0,20180508,20180508,EXP,,GB-JNJFOC-20180504524,JANSSEN,,75.0,YR,E,F,Y,88.0,KG,20180508.0,,MD,GB,GB,2018,Q2,Elderly
148677792,14867779,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2018,Q2,Adverse drug reaction,,2018,Q2,2,F,201703.0,20180525.0,20180509,20180531,EXP,,CA-ABBVIE-18K-028-2346381-00,ABBVIE,,47.0,YR,,F,Y,,,20180531.0,,MD,CA,CA,2018,Q2,Adult
148677792,14867779,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2018,Q2,Arthralgia,,2018,Q2,2,F,201703.0,20180525.0,20180509,20180531,EXP,,CA-ABBVIE-18K-028-2346381-00,ABBVIE,,47.0,YR,,F,Y,,,20180531.0,,MD,CA,CA,2018,Q2,Adult
148677792,14867779,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2018,Q2,Arthritis,,2018,Q2,2,F,201703.0,20180525.0,20180509,20180531,EXP,,CA-ABBVIE-18K-028-2346381-00,ABBVIE,,47.0,YR,,F,Y,,,20180531.0,,MD,CA,CA,2018,Q2,Adult
148677792,14867779,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2018,Q2,Blood creatinine decreased,,2018,Q2,2,F,201703.0,20180525.0,20180509,20180531,EXP,,CA-ABBVIE-18K-028-2346381-00,ABBVIE,,47.0,YR,,F,Y,,,20180531.0,,MD,CA,CA,2018,Q2,Adult
148677792,14867779,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2018,Q2,Blood uric acid decreased,,2018,Q2,2,F,201703.0,20180525.0,20180509,20180531,EXP,,CA-ABBVIE-18K-028-2346381-00,ABBVIE,,47.0,YR,,F,Y,,,20180531.0,,MD,CA,CA,2018,Q2,Adult
148677792,14867779,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2018,Q2,Drug effect decreased,,2018,Q2,2,F,201703.0,20180525.0,20180509,20180531,EXP,,CA-ABBVIE-18K-028-2346381-00,ABBVIE,,47.0,YR,,F,Y,,,20180531.0,,MD,CA,CA,2018,Q2,Adult
148677792,14867779,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2018,Q2,Drug effect incomplete,,2018,Q2,2,F,201703.0,20180525.0,20180509,20180531,EXP,,CA-ABBVIE-18K-028-2346381-00,ABBVIE,,47.0,YR,,F,Y,,,20180531.0,,MD,CA,CA,2018,Q2,Adult
148677792,14867779,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2018,Q2,Drug ineffective,,2018,Q2,2,F,201703.0,20180525.0,20180509,20180531,EXP,,CA-ABBVIE-18K-028-2346381-00,ABBVIE,,47.0,YR,,F,Y,,,20180531.0,,MD,CA,CA,2018,Q2,Adult
148677792,14867779,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2018,Q2,Gastrointestinal haemorrhage,,2018,Q2,2,F,201703.0,20180525.0,20180509,20180531,EXP,,CA-ABBVIE-18K-028-2346381-00,ABBVIE,,47.0,YR,,F,Y,,,20180531.0,,MD,CA,CA,2018,Q2,Adult
148677792,14867779,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2018,Q2,Glycosylated haemoglobin increased,,2018,Q2,2,F,201703.0,20180525.0,20180509,20180531,EXP,,CA-ABBVIE-18K-028-2346381-00,ABBVIE,,47.0,YR,,F,Y,,,20180531.0,,MD,CA,CA,2018,Q2,Adult
148677792,14867779,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2018,Q2,Haemoglobin decreased,,2018,Q2,2,F,201703.0,20180525.0,20180509,20180531,EXP,,CA-ABBVIE-18K-028-2346381-00,ABBVIE,,47.0,YR,,F,Y,,,20180531.0,,MD,CA,CA,2018,Q2,Adult
148677792,14867779,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2018,Q2,Hepatic cirrhosis,,2018,Q2,2,F,201703.0,20180525.0,20180509,20180531,EXP,,CA-ABBVIE-18K-028-2346381-00,ABBVIE,,47.0,YR,,F,Y,,,20180531.0,,MD,CA,CA,2018,Q2,Adult
148677792,14867779,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2018,Q2,Hepatosplenomegaly,,2018,Q2,2,F,201703.0,20180525.0,20180509,20180531,EXP,,CA-ABBVIE-18K-028-2346381-00,ABBVIE,,47.0,YR,,F,Y,,,20180531.0,,MD,CA,CA,2018,Q2,Adult
148677792,14867779,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2018,Q2,Hypertrophy,,2018,Q2,2,F,201703.0,20180525.0,20180509,20180531,EXP,,CA-ABBVIE-18K-028-2346381-00,ABBVIE,,47.0,YR,,F,Y,,,20180531.0,,MD,CA,CA,2018,Q2,Adult
148677792,14867779,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2018,Q2,Inflammatory marker increased,,2018,Q2,2,F,201703.0,20180525.0,20180509,20180531,EXP,,CA-ABBVIE-18K-028-2346381-00,ABBVIE,,47.0,YR,,F,Y,,,20180531.0,,MD,CA,CA,2018,Q2,Adult
148677792,14867779,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2018,Q2,Joint effusion,,2018,Q2,2,F,201703.0,20180525.0,20180509,20180531,EXP,,CA-ABBVIE-18K-028-2346381-00,ABBVIE,,47.0,YR,,F,Y,,,20180531.0,,MD,CA,CA,2018,Q2,Adult
148677792,14867779,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2018,Q2,Joint swelling,,2018,Q2,2,F,201703.0,20180525.0,20180509,20180531,EXP,,CA-ABBVIE-18K-028-2346381-00,ABBVIE,,47.0,YR,,F,Y,,,20180531.0,,MD,CA,CA,2018,Q2,Adult
148677792,14867779,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2018,Q2,Liver disorder,,2018,Q2,2,F,201703.0,20180525.0,20180509,20180531,EXP,,CA-ABBVIE-18K-028-2346381-00,ABBVIE,,47.0,YR,,F,Y,,,20180531.0,,MD,CA,CA,2018,Q2,Adult
148677792,14867779,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2018,Q2,Low density lipoprotein increased,,2018,Q2,2,F,201703.0,20180525.0,20180509,20180531,EXP,,CA-ABBVIE-18K-028-2346381-00,ABBVIE,,47.0,YR,,F,Y,,,20180531.0,,MD,CA,CA,2018,Q2,Adult
148677792,14867779,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2018,Q2,Nausea,,2018,Q2,2,F,201703.0,20180525.0,20180509,20180531,EXP,,CA-ABBVIE-18K-028-2346381-00,ABBVIE,,47.0,YR,,F,Y,,,20180531.0,,MD,CA,CA,2018,Q2,Adult
148677792,14867779,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2018,Q2,Non-alcoholic fatty liver,,2018,Q2,2,F,201703.0,20180525.0,20180509,20180531,EXP,,CA-ABBVIE-18K-028-2346381-00,ABBVIE,,47.0,YR,,F,Y,,,20180531.0,,MD,CA,CA,2018,Q2,Adult
148677792,14867779,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2018,Q2,Pain in extremity,,2018,Q2,2,F,201703.0,20180525.0,20180509,20180531,EXP,,CA-ABBVIE-18K-028-2346381-00,ABBVIE,,47.0,YR,,F,Y,,,20180531.0,,MD,CA,CA,2018,Q2,Adult
148677792,14867779,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2018,Q2,Psoriasis,,2018,Q2,2,F,201703.0,20180525.0,20180509,20180531,EXP,,CA-ABBVIE-18K-028-2346381-00,ABBVIE,,47.0,YR,,F,Y,,,20180531.0,,MD,CA,CA,2018,Q2,Adult
148677792,14867779,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2018,Q2,Red blood cell sedimentation rate increased,,2018,Q2,2,F,201703.0,20180525.0,20180509,20180531,EXP,,CA-ABBVIE-18K-028-2346381-00,ABBVIE,,47.0,YR,,F,Y,,,20180531.0,,MD,CA,CA,2018,Q2,Adult
148677792,14867779,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,,2018,Q2,Varices oesophageal,,2018,Q2,2,F,201703.0,20180525.0,20180509,20180531,EXP,,CA-ABBVIE-18K-028-2346381-00,ABBVIE,,47.0,YR,,F,Y,,,20180531.0,,MD,CA,CA,2018,Q2,Adult
148727571,14872757,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q2,Blood creatinine decreased,,2018,Q2,1,I,2007.0,20180430.0,20180510,20180510,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20180510.0,,CN,CA,CA,2018,Q2,Adult
148727571,14872757,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q2,Blood uric acid decreased,,2018,Q2,1,I,2007.0,20180430.0,20180510,20180510,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20180510.0,,CN,CA,CA,2018,Q2,Adult
148727571,14872757,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q2,Drug ineffective,,2018,Q2,1,I,2007.0,20180430.0,20180510,20180510,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20180510.0,,CN,CA,CA,2018,Q2,Adult
148727571,14872757,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q2,Gastrointestinal haemorrhage,,2018,Q2,1,I,2007.0,20180430.0,20180510,20180510,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20180510.0,,CN,CA,CA,2018,Q2,Adult
148727571,14872757,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q2,Hepatic cirrhosis,,2018,Q2,1,I,2007.0,20180430.0,20180510,20180510,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20180510.0,,CN,CA,CA,2018,Q2,Adult
148727571,14872757,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q2,Hepatosplenomegaly,,2018,Q2,1,I,2007.0,20180430.0,20180510,20180510,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20180510.0,,CN,CA,CA,2018,Q2,Adult
148727571,14872757,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q2,Liver disorder,,2018,Q2,1,I,2007.0,20180430.0,20180510,20180510,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20180510.0,,CN,CA,CA,2018,Q2,Adult
148727571,14872757,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q2,Low density lipoprotein increased,,2018,Q2,1,I,2007.0,20180430.0,20180510,20180510,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20180510.0,,CN,CA,CA,2018,Q2,Adult
148727571,14872757,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q2,Non-alcoholic fatty liver,,2018,Q2,1,I,2007.0,20180430.0,20180510,20180510,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20180510.0,,CN,CA,CA,2018,Q2,Adult
148727571,14872757,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q2,Psoriasis,,2018,Q2,1,I,2007.0,20180430.0,20180510,20180510,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20180510.0,,CN,CA,CA,2018,Q2,Adult
148727571,14872757,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q2,Psoriatic arthropathy,,2018,Q2,1,I,2007.0,20180430.0,20180510,20180510,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20180510.0,,CN,CA,CA,2018,Q2,Adult
148727571,14872757,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q2,Rheumatoid arthritis,,2018,Q2,1,I,2007.0,20180430.0,20180510,20180510,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20180510.0,,CN,CA,CA,2018,Q2,Adult
148727571,14872757,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q2,Type 2 diabetes mellitus,,2018,Q2,1,I,2007.0,20180430.0,20180510,20180510,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20180510.0,,CN,CA,CA,2018,Q2,Adult
148727571,14872757,10,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q2,Varices oesophageal,,2018,Q2,1,I,2007.0,20180430.0,20180510,20180510,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20180510.0,,CN,CA,CA,2018,Q2,Adult
148995351,14899535,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,PREFERABLY BEFORE BREAKFAST,,,U,U,,,,300.0,MG,,,2018,Q2,Constipation,,2018,Q2,1,I,,20180504.0,20180516,20180516,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-172891,RANBAXY,,56.0,YR,,M,Y,,,20180516.0,,OT,GB,GB,2018,Q2,Adult
148995351,14899535,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,PREFERABLY BEFORE BREAKFAST,,,U,U,,,,300.0,MG,,,2018,Q2,Epistaxis,,2018,Q2,1,I,,20180504.0,20180516,20180516,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2018RR-172891,RANBAXY,,56.0,YR,,M,Y,,,20180516.0,,OT,GB,GB,2018,Q2,Adult
148998884,14899888,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"150/1000 MG, BID",,,Y,,,,,,,,,2018,Q2,Syncope,,2018,Q2,4,F,20180210.0,20180620.0,20180516,20180620,EXP,,PHHO2018US005666,SANDOZ,,55.0,YR,,F,Y,96.0,KG,20180620.0,,OT,US,US,2018,Q2,Adult
149011401,14901140,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,Y,,,,,,,,,2018,Q2,Pancreatitis acute,,2018,Q2,1,I,,20180511.0,20180516,20180516,EXP,,US-009507513-1805USA005277,MERCK,"DAFALLA M, GANTA V, HAGAHMED N, ODONKOR W, NUNLEE-BLAND G. CANAGLIFLOZIN AND SITAGLIPTIN INDUCED ACUTE PANCREATITIS. ENDOCRINE PRACT. 2018;24 (S1):30",54.0,YR,,F,Y,,,20180516.0,,MD,US,US,2018,Q2,Adult
149135191,14913519,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q2,Diabetic ketoacidosis,,2018,Q2,1,I,,20180516.0,20180518,20180518,EXP,,GB-JNJFOC-20180522031,JANSSEN,,56.0,YR,A,F,Y,,,20180518.0,,OT,GB,GB,2018,Q2,Adult
149135191,14913519,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q2,Diarrhoea,,2018,Q2,1,I,,20180516.0,20180518,20180518,EXP,,GB-JNJFOC-20180522031,JANSSEN,,56.0,YR,A,F,Y,,,20180518.0,,OT,GB,GB,2018,Q2,Adult
149135191,14913519,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q2,Influenza,,2018,Q2,1,I,,20180516.0,20180518,20180518,EXP,,GB-JNJFOC-20180522031,JANSSEN,,56.0,YR,A,F,Y,,,20180518.0,,OT,GB,GB,2018,Q2,Adult
149341062,14934106,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,300.0,MG,TABLET,,2018,Q2,Diabetic foot infection,,2018,Q2,2,F,20171030.0,20180613.0,20180524,20180621,EXP,,GB-JNJFOC-20180524350,JANSSEN,,58.0,YR,A,M,Y,,,20180621.0,,PH,GB,GB,2018,Q2,Adult
149341062,14934106,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,300.0,MG,TABLET,,2018,Q2,Infection,,2018,Q2,2,F,20171030.0,20180613.0,20180524,20180621,EXP,,GB-JNJFOC-20180524350,JANSSEN,,58.0,YR,A,M,Y,,,20180621.0,,PH,GB,GB,2018,Q2,Adult
149341062,14934106,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,300.0,MG,TABLET,,2018,Q2,Osteomyelitis,,2018,Q2,2,F,20171030.0,20180613.0,20180524,20180621,EXP,,GB-JNJFOC-20180524350,JANSSEN,,58.0,YR,A,M,Y,,,20180621.0,,PH,GB,GB,2018,Q2,Adult
149341062,14934106,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,300.0,MG,TABLET,,2018,Q2,Skin ulcer,,2018,Q2,2,F,20171030.0,20180613.0,20180524,20180621,EXP,,GB-JNJFOC-20180524350,JANSSEN,,58.0,YR,A,M,Y,,,20180621.0,,PH,GB,GB,2018,Q2,Adult
149341062,14934106,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,U,,,204042.0,300.0,MG,TABLET,,2018,Q2,Toe amputation,,2018,Q2,2,F,20171030.0,20180613.0,20180524,20180621,EXP,,GB-JNJFOC-20180524350,JANSSEN,,58.0,YR,A,M,Y,,,20180621.0,,PH,GB,GB,2018,Q2,Adult
149385421,14938542,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,QD,2018,Q2,Diabetic ketoacidosis,,2018,Q2,1,I,,20180523.0,20180525,20180525,EXP,,GB-JNJFOC-20180532609,JANSSEN,,45.0,YR,A,F,Y,,,20180525.0,,PH,GB,GB,2018,Q2,Adult
149452471,14945247,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,QD,2018,Q2,Product physical consistency issue,,2018,Q2,1,I,201707.0,20170729.0,20180529,20180529,PER,,US-BIODELIVERY SCIENCES INTERNATIONAL-2017BDSI0145,BIODELIVERY SCIENCES INTERNATIONAL,,47.0,YR,,F,Y,95.34,KG,20180525.0,,CN,US,US,2018,Q2,Adult
149452471,14945247,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,QD,2018,Q2,Product solubility abnormal,,2018,Q2,1,I,201707.0,20170729.0,20180529,20180529,PER,,US-BIODELIVERY SCIENCES INTERNATIONAL-2017BDSI0145,BIODELIVERY SCIENCES INTERNATIONAL,,47.0,YR,,F,Y,95.34,KG,20180525.0,,CN,US,US,2018,Q2,Adult
149452471,14945247,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,,,,QD,2018,Q2,Wrong technique in product usage process,,2018,Q2,1,I,201707.0,20170729.0,20180529,20180529,PER,,US-BIODELIVERY SCIENCES INTERNATIONAL-2017BDSI0145,BIODELIVERY SCIENCES INTERNATIONAL,,47.0,YR,,F,Y,95.34,KG,20180525.0,,CN,US,US,2018,Q2,Adult
149472801,14947280,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,,,TABLET,,2018,Q2,Candida sepsis,,2018,Q2,1,I,,20180522.0,20180529,20180529,EXP,,US-JNJFOC-20180530601,JANSSEN,"BLLOSHMI K, SHEPPELL A. A MYCOTIC RENAL STONE: A CASE OF CANDIDA SEPTICEMIA WITH CANAGLIFLOZIN. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY 2018;66 (SUPPLEMENT 2):S176-S177.",77.0,YR,E,M,Y,,,20180529.0,,MD,US,US,2018,Q2,Elderly
149472812,14947281,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,300.0,MG,TABLET,,2018,Q2,Fanconi syndrome acquired,,2018,Q2,2,F,,20180625.0,20180529,20180627,EXP,,US-JNJFOC-20180531517,JANSSEN,"ESPRIT DH, KORATALA A. FANCONI SYNDROME ASSOCIATED WITH SGLT2 INHIBITOR, CANAGLIFLOZIN. NEPHROLOGY 2018;23(5):493.",54.0,YR,A,F,Y,,,20180627.0,,OT,US,US,2018,Q2,Adult
149532601,14953260,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2018,Q2,Acute kidney injury,,2018,Q2,1,I,,20180521.0,20180530,20180530,EXP,,"US-IMPAX LABORATORIES, INC-2018-IPXL-01819",IMPAX,"BLLOSHMI K, SHEPPELL A.. A MYCOTIC RENAL STONE: A CASE OF CANDIDA SEPTICEMIA WITH CANAGLIFLOZIN. J AM GERIATR SOC. 2018;66(SUPPL 2):S176-S177",77.0,YR,,M,Y,,,20180530.0,,OT,US,US,2018,Q2,Elderly
149532601,14953260,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2018,Q2,Atrial fibrillation,,2018,Q2,1,I,,20180521.0,20180530,20180530,EXP,,"US-IMPAX LABORATORIES, INC-2018-IPXL-01819",IMPAX,"BLLOSHMI K, SHEPPELL A.. A MYCOTIC RENAL STONE: A CASE OF CANDIDA SEPTICEMIA WITH CANAGLIFLOZIN. J AM GERIATR SOC. 2018;66(SUPPL 2):S176-S177",77.0,YR,,M,Y,,,20180530.0,,OT,US,US,2018,Q2,Elderly
149532601,14953260,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2018,Q2,Bladder outlet obstruction,,2018,Q2,1,I,,20180521.0,20180530,20180530,EXP,,"US-IMPAX LABORATORIES, INC-2018-IPXL-01819",IMPAX,"BLLOSHMI K, SHEPPELL A.. A MYCOTIC RENAL STONE: A CASE OF CANDIDA SEPTICEMIA WITH CANAGLIFLOZIN. J AM GERIATR SOC. 2018;66(SUPPL 2):S176-S177",77.0,YR,,M,Y,,,20180530.0,,OT,US,US,2018,Q2,Elderly
149532601,14953260,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2018,Q2,Candida infection,,2018,Q2,1,I,,20180521.0,20180530,20180530,EXP,,"US-IMPAX LABORATORIES, INC-2018-IPXL-01819",IMPAX,"BLLOSHMI K, SHEPPELL A.. A MYCOTIC RENAL STONE: A CASE OF CANDIDA SEPTICEMIA WITH CANAGLIFLOZIN. J AM GERIATR SOC. 2018;66(SUPPL 2):S176-S177",77.0,YR,,M,Y,,,20180530.0,,OT,US,US,2018,Q2,Elderly
149532601,14953260,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2018,Q2,Candida sepsis,,2018,Q2,1,I,,20180521.0,20180530,20180530,EXP,,"US-IMPAX LABORATORIES, INC-2018-IPXL-01819",IMPAX,"BLLOSHMI K, SHEPPELL A.. A MYCOTIC RENAL STONE: A CASE OF CANDIDA SEPTICEMIA WITH CANAGLIFLOZIN. J AM GERIATR SOC. 2018;66(SUPPL 2):S176-S177",77.0,YR,,M,Y,,,20180530.0,,OT,US,US,2018,Q2,Elderly
149532601,14953260,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2018,Q2,Hydronephrosis,,2018,Q2,1,I,,20180521.0,20180530,20180530,EXP,,"US-IMPAX LABORATORIES, INC-2018-IPXL-01819",IMPAX,"BLLOSHMI K, SHEPPELL A.. A MYCOTIC RENAL STONE: A CASE OF CANDIDA SEPTICEMIA WITH CANAGLIFLOZIN. J AM GERIATR SOC. 2018;66(SUPPL 2):S176-S177",77.0,YR,,M,Y,,,20180530.0,,OT,US,US,2018,Q2,Elderly
149532601,14953260,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2018,Q2,Nephrolithiasis,,2018,Q2,1,I,,20180521.0,20180530,20180530,EXP,,"US-IMPAX LABORATORIES, INC-2018-IPXL-01819",IMPAX,"BLLOSHMI K, SHEPPELL A.. A MYCOTIC RENAL STONE: A CASE OF CANDIDA SEPTICEMIA WITH CANAGLIFLOZIN. J AM GERIATR SOC. 2018;66(SUPPL 2):S176-S177",77.0,YR,,M,Y,,,20180530.0,,OT,US,US,2018,Q2,Elderly
149532601,14953260,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2018,Q2,Urinary tract infection fungal,,2018,Q2,1,I,,20180521.0,20180530,20180530,EXP,,"US-IMPAX LABORATORIES, INC-2018-IPXL-01819",IMPAX,"BLLOSHMI K, SHEPPELL A.. A MYCOTIC RENAL STONE: A CASE OF CANDIDA SEPTICEMIA WITH CANAGLIFLOZIN. J AM GERIATR SOC. 2018;66(SUPPL 2):S176-S177",77.0,YR,,M,Y,,,20180530.0,,OT,US,US,2018,Q2,Elderly
149588681,14958868,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Oral,300 MG DAILLY,,,U,U,,,,,,,,2018,Q2,Ketoacidosis,,2018,Q2,1,I,20180424.0,20180524.0,20180531,20180531,EXP,LU-AFSSAPS-NY20180867,LU-UCBSA-2018023378,UCB,,51.0,YR,,M,Y,78.0,KG,20180531.0,,MD,LU,LU,2018,Q2,Adult
149660231,14966023,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q2,Back pain,,2018,Q2,1,I,201701.0,20180522.0,20180603,20180603,PER,,US-JNJFOC-20180530875,JANSSEN,,82.0,YR,E,F,Y,,,20180603.0,,MD,US,US,2018,Q2,Elderly
149660231,14966023,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q2,Hyponatraemia,,2018,Q2,1,I,201701.0,20180522.0,20180603,20180603,PER,,US-JNJFOC-20180530875,JANSSEN,,82.0,YR,E,F,Y,,,20180603.0,,MD,US,US,2018,Q2,Elderly
149660231,14966023,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q2,Rash,,2018,Q2,1,I,201701.0,20180522.0,20180603,20180603,PER,,US-JNJFOC-20180530875,JANSSEN,,82.0,YR,E,F,Y,,,20180603.0,,MD,US,US,2018,Q2,Elderly
149740081,14974008,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, 1X/DAY (PREFERABLY BEFORE BREAKFAST)",,,,,,,,300.0,MG,TABLET,QD,2018,Q2,Constipation,,2018,Q2,1,I,,20180529.0,20180605,20180605,EXP,GB-MHRA-MIDB-64B279B2-8181-411B-A153-70B5E2234649,GB-PFIZER INC-2018220142,PFIZER,,56.0,YR,,M,Y,,,20180605.0,,PH,GB,GB,2018,Q2,Adult
149740081,14974008,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, 1X/DAY (PREFERABLY BEFORE BREAKFAST)",,,,,,,,300.0,MG,TABLET,QD,2018,Q2,Epistaxis,,2018,Q2,1,I,,20180529.0,20180605,20180605,EXP,GB-MHRA-MIDB-64B279B2-8181-411B-A153-70B5E2234649,GB-PFIZER INC-2018220142,PFIZER,,56.0,YR,,M,Y,,,20180605.0,,PH,GB,GB,2018,Q2,Adult
149908311,14990831,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"UNK UNK, QD",4.0,DF,,, UNKNOWN,,,,,,QD,2018,Q2,Dizziness,,2018,Q2,1,I,20180521.0,20180607.0,20180608,20180608,EXP,GB-MHRA-TPP11196432C1459473YC1526910887638,GB-TAKEDA-2018TEU003719,TAKEDA,,60.0,YR,,F,Y,99.0,KG,20180608.0,,OT,GB,GB,2018,Q2,Adult
149908311,14990831,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"UNK UNK, QD",4.0,DF,,, UNKNOWN,,,,,,QD,2018,Q2,Malaise,,2018,Q2,1,I,20180521.0,20180607.0,20180608,20180608,EXP,GB-MHRA-TPP11196432C1459473YC1526910887638,GB-TAKEDA-2018TEU003719,TAKEDA,,60.0,YR,,F,Y,99.0,KG,20180608.0,,OT,GB,GB,2018,Q2,Adult
149958501,14995850,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q2,Diabetic ketoacidosis,,2018,Q2,1,I,20180521.0,20180607.0,20180611,20180611,EXP,,GB-JNJFOC-20180610970,JANSSEN,,61.0,YR,A,M,Y,90.0,KG,20180611.0,,OT,GB,GB,2018,Q2,Adult
149958511,14995851,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q2,Hepatic function abnormal,,2018,Q2,1,I,20170116.0,20170912.0,20180611,20180611,EXP,,JP-JNJFOC-20170924905,JANSSEN,,75.0,YR,E,M,Y,62.0,KG,20180611.0,,OT,JP,JP,2018,Q2,Elderly
149958511,14995851,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q2,Silent myocardial infarction,,2018,Q2,1,I,20170116.0,20170912.0,20180611,20180611,EXP,,JP-JNJFOC-20170924905,JANSSEN,,75.0,YR,E,M,Y,62.0,KG,20180611.0,,OT,JP,JP,2018,Q2,Elderly
150072001,15007200,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,,,TABLET,,2018,Q2,Diabetic ketoacidosis,,2018,Q2,1,I,,20180605.0,20180613,20180613,EXP,,US-JNJFOC-20180608259,JANSSEN,"MELNICK S, BASNET S, SHARMA P, NAZIR S. SODIUM GLUCOSE CO-TRANSPORTER 2 INHIBITORS AND THE POTENTIAL FOR DIABETIC KETOACIDOSIS. JOURNAL OF GENERAL INTERNAL MEDICINE 2018;33 (2 SUPPLEMENT 1):622-623.",46.0,YR,A,M,Y,,,20180613.0,,OT,US,US,2018,Q2,Adult
150094671,15009467,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,300 MILLIGRAM DAILY; PREFERABLY BEFORE BREAKFAST,,,,,,,,300.0,MG,TABLET,,2018,Q2,Constipation,,2018,Q2,1,I,,20180610.0,20180614,20180614,EXP,GB-MHRA-MIDB-64B279B2-8181-411B-A153-70B5E2234649,GB-TEVA-2018-GB-906192,TEVA,,56.0,YR,,M,Y,,,20180614.0,,PH,GB,GB,2018,Q2,Adult
150094671,15009467,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,300 MILLIGRAM DAILY; PREFERABLY BEFORE BREAKFAST,,,,,,,,300.0,MG,TABLET,,2018,Q2,Epistaxis,,2018,Q2,1,I,,20180610.0,20180614,20180614,EXP,GB-MHRA-MIDB-64B279B2-8181-411B-A153-70B5E2234649,GB-TEVA-2018-GB-906192,TEVA,,56.0,YR,,M,Y,,,20180614.0,,PH,GB,GB,2018,Q2,Adult
150109721,15010972,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,,U,,,,100.0,MG,,,2018,Q2,Diabetes mellitus inadequate control,,2018,Q2,1,I,,20170822.0,20180614,20180614,EXP,,ES-APOTEX-2017AP017719,APOTEX,"MARTINEZ D.B, PONCE M.H, ROMERO A.C, VILLAMARIN X.D, MEDINA M.D.C.G, HIDALGO I.C, DELGADO A.R, RAYA P.M.. RISK ASSESSMENT OF DIABETES KETOACIDOSIS IN TYPE 2 DIABETES MELLITUS PATIENTS TREATED WITH SODIUM-GLUCOSE COTRANSPORTER TYPE 2 INHIBITORS. EUROPEAN JOURNAL OF HOSPITAL PHARMACY. 2017;24:A4-A5",58.0,YR,,M,Y,,,20180614.0,,OT,ES,ES,2018,Q2,Adult
150109721,15010972,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, QD",,,,U,,,,100.0,MG,,,2018,Q2,Drug ineffective,,2018,Q2,1,I,,20170822.0,20180614,20180614,EXP,,ES-APOTEX-2017AP017719,APOTEX,"MARTINEZ D.B, PONCE M.H, ROMERO A.C, VILLAMARIN X.D, MEDINA M.D.C.G, HIDALGO I.C, DELGADO A.R, RAYA P.M.. RISK ASSESSMENT OF DIABETES KETOACIDOSIS IN TYPE 2 DIABETES MELLITUS PATIENTS TREATED WITH SODIUM-GLUCOSE COTRANSPORTER TYPE 2 INHIBITORS. EUROPEAN JOURNAL OF HOSPITAL PHARMACY. 2017;24:A4-A5",58.0,YR,,M,Y,,,20180614.0,,OT,ES,ES,2018,Q2,Adult
150109721,15010972,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, QD",,,,U,,,,300.0,MG,,,2018,Q2,Diabetes mellitus inadequate control,,2018,Q2,1,I,,20170822.0,20180614,20180614,EXP,,ES-APOTEX-2017AP017719,APOTEX,"MARTINEZ D.B, PONCE M.H, ROMERO A.C, VILLAMARIN X.D, MEDINA M.D.C.G, HIDALGO I.C, DELGADO A.R, RAYA P.M.. RISK ASSESSMENT OF DIABETES KETOACIDOSIS IN TYPE 2 DIABETES MELLITUS PATIENTS TREATED WITH SODIUM-GLUCOSE COTRANSPORTER TYPE 2 INHIBITORS. EUROPEAN JOURNAL OF HOSPITAL PHARMACY. 2017;24:A4-A5",58.0,YR,,M,Y,,,20180614.0,,OT,ES,ES,2018,Q2,Adult
150109721,15010972,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, QD",,,,U,,,,300.0,MG,,,2018,Q2,Drug ineffective,,2018,Q2,1,I,,20170822.0,20180614,20180614,EXP,,ES-APOTEX-2017AP017719,APOTEX,"MARTINEZ D.B, PONCE M.H, ROMERO A.C, VILLAMARIN X.D, MEDINA M.D.C.G, HIDALGO I.C, DELGADO A.R, RAYA P.M.. RISK ASSESSMENT OF DIABETES KETOACIDOSIS IN TYPE 2 DIABETES MELLITUS PATIENTS TREATED WITH SODIUM-GLUCOSE COTRANSPORTER TYPE 2 INHIBITORS. EUROPEAN JOURNAL OF HOSPITAL PHARMACY. 2017;24:A4-A5",58.0,YR,,M,Y,,,20180614.0,,OT,ES,ES,2018,Q2,Adult
150701061,15070106,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q2,Diarrhoea,,2018,Q2,1,I,20180601.0,20180619.0,20180626,20180626,EXP,,GB-JNJFOC-20180627173,JANSSEN,,57.0,YR,A,F,Y,60.0,KG,20180626.0,,MD,GB,GB,2018,Q2,Adult
150701061,15070106,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q2,Hyperglycaemia,,2018,Q2,1,I,20180601.0,20180619.0,20180626,20180626,EXP,,GB-JNJFOC-20180627173,JANSSEN,,57.0,YR,A,F,Y,60.0,KG,20180626.0,,MD,GB,GB,2018,Q2,Adult
150701061,15070106,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q2,Ketosis,,2018,Q2,1,I,20180601.0,20180619.0,20180626,20180626,EXP,,GB-JNJFOC-20180627173,JANSSEN,,57.0,YR,A,F,Y,60.0,KG,20180626.0,,MD,GB,GB,2018,Q2,Adult
150701061,15070106,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q2,Malaise,,2018,Q2,1,I,20180601.0,20180619.0,20180626,20180626,EXP,,GB-JNJFOC-20180627173,JANSSEN,,57.0,YR,A,F,Y,60.0,KG,20180626.0,,MD,GB,GB,2018,Q2,Adult
150701061,15070106,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q2,Vomiting,,2018,Q2,1,I,20180601.0,20180619.0,20180626,20180626,EXP,,GB-JNJFOC-20180627173,JANSSEN,,57.0,YR,A,F,Y,60.0,KG,20180626.0,,MD,GB,GB,2018,Q2,Adult
150701071,15070107,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,TABLET,QD,2018,Q2,Diabetic ketoacidosis,,2018,Q2,1,I,,20180613.0,20180626,20180626,EXP,,JP-JNJFOC-20180630663,JANSSEN,ANDO R. A PATIENT WITH TYPE 2 DIABETES MELLITUS WHO WAS TRANSPORTED BY AMBULANCE FOR DIABETIC KETOACIDOSIS 4 DAYS AFTER START OF A SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITOR (IN JAPANESE)..,37.0,YR,A,M,Y,,,20180626.0,,OT,JP,JP,2018,Q2,Adult
150845891,15084589,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,D,D,,,,,,,QD,2018,Q2,Euglycaemic diabetic ketoacidosis,,2018,Q2,1,I,20180607.0,,20180608,20180608,DIR,,,FDA-CTU,,46.0,YR,,M,N,115.7,KG,20180608.0,N,PH,US,US,2018,Q2,Adult
150845891,15084589,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,D,D,,,,,,,QD,2018,Q2,Hypophagia,,2018,Q2,1,I,20180607.0,,20180608,20180608,DIR,,,FDA-CTU,,46.0,YR,,M,N,115.7,KG,20180608.0,N,PH,US,US,2018,Q2,Adult
112291683,11229168,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, UNKNOWN,,204042.0,100.0,MG,TABLET,,2018,Q3,Diabetic ketoacidosis,,2018,Q3,3,F,20130925.0,20180723.0,20150630,20180727,EXP,,US-JNJFOC-20150620478,JANSSEN,,37.0,YR,A,F,Y,74.39,KG,20180727.0,,CN,US,US,2018,Q3,Adult
112291683,11229168,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, UNKNOWN,,204042.0,100.0,MG,TABLET,,2018,Q3,Off label use,,2018,Q3,3,F,20130925.0,20180723.0,20150630,20180727,EXP,,US-JNJFOC-20150620478,JANSSEN,,37.0,YR,A,F,Y,74.39,KG,20180727.0,,CN,US,US,2018,Q3,Adult
112291683,11229168,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, UNKNOWN,,204042.0,100.0,MG,TABLET,,2018,Q3,Product use in unapproved indication,,2018,Q3,3,F,20130925.0,20180723.0,20150630,20180727,EXP,,US-JNJFOC-20150620478,JANSSEN,,37.0,YR,A,F,Y,74.39,KG,20180727.0,,CN,US,US,2018,Q3,Adult
135280742,13528074,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,300.0,MG,TABLET,QD,2018,Q3,Euglycaemic diabetic ketoacidosis,,2018,Q3,2,F,,20180911.0,20170509,20180919,EXP,,US-JNJFOC-20170502771,JANSSEN,"VAN NIEKERK CJ, WALLACE JD, TAKATA MC, YU RC. EUGLYCEMIC DIABETIC KETOACIDOSIS IN BARIATRIC SURGERY PATIENTS TAKING CANAGLIFLOZIN. SURG ENDOSC 2017?31 (S180):S137?S334. VAN NIEKERK C, WALLACE J, TAKATA M, YU R. EUGLYCAEMIC DIABETIC KETOACIDOSIS IN BARIATRIC SURGERY PATIENTS WITH TYPE 2 DIABETES TAKING CANAGLIFLOZIN. BMJ CASE REPORTS 221527 2018.",52.0,YR,A,M,Y,,,20180919.0,,MD,US,US,2018,Q3,Adult
135280742,13528074,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,300.0,MG,TABLET,QD,2018,Q3,Leukocytosis,,2018,Q3,2,F,,20180911.0,20170509,20180919,EXP,,US-JNJFOC-20170502771,JANSSEN,"VAN NIEKERK CJ, WALLACE JD, TAKATA MC, YU RC. EUGLYCEMIC DIABETIC KETOACIDOSIS IN BARIATRIC SURGERY PATIENTS TAKING CANAGLIFLOZIN. SURG ENDOSC 2017?31 (S180):S137?S334. VAN NIEKERK C, WALLACE J, TAKATA M, YU R. EUGLYCAEMIC DIABETIC KETOACIDOSIS IN BARIATRIC SURGERY PATIENTS WITH TYPE 2 DIABETES TAKING CANAGLIFLOZIN. BMJ CASE REPORTS 221527 2018.",52.0,YR,A,M,Y,,,20180919.0,,MD,US,US,2018,Q3,Adult
139571295,13957129,74,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,INVOKANALINVOKAMET,,,,,,,,,,,,2018,Q3,Acute kidney injury,,2018,Q3,5,F,20140522.0,20180906.0,20170912,20180914,EXP,,US-ASTRAZENECA-2017SE91706,ASTRAZENECA,,19883.0,DY,,F,Y,63.5,KG,20180914.0,,,US,US,2018,Q3,Elderly
139571295,13957129,74,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,INVOKANALINVOKAMET,,,,,,,,,,,,2018,Q3,Diabetic ketoacidosis,,2018,Q3,5,F,20140522.0,20180906.0,20170912,20180914,EXP,,US-ASTRAZENECA-2017SE91706,ASTRAZENECA,,19883.0,DY,,F,Y,63.5,KG,20180914.0,,,US,US,2018,Q3,Elderly
139571295,13957129,74,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,INVOKANALINVOKAMET,,,,,,,,,,,,2018,Q3,Diabetic neuropathy,,2018,Q3,5,F,20140522.0,20180906.0,20170912,20180914,EXP,,US-ASTRAZENECA-2017SE91706,ASTRAZENECA,,19883.0,DY,,F,Y,63.5,KG,20180914.0,,,US,US,2018,Q3,Elderly
140797652,14079765,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,100 (UNITS UNSPECIFIED),,,Y,N,,,,,,TABLET,,2018,Q3,Diabetic ketoacidosis,,2018,Q3,2,F,,20180913.0,20171012,20180919,EXP,,GB-JNJFOC-20171010008,JANSSEN,,60.0,YR,A,F,Y,,,20180919.0,,PH,GB,GB,2018,Q3,Adult
140797652,14079765,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,QD,2018,Q3,Diabetic ketoacidosis,,2018,Q3,2,F,,20180913.0,20171012,20180919,EXP,,GB-JNJFOC-20171010008,JANSSEN,,60.0,YR,A,F,Y,,,20180919.0,,PH,GB,GB,2018,Q3,Adult
143218103,14321810,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,LAST DOSE: 04/02/17 20:00,,,,,,,,300.0,MG,TABLET,QD,2018,Q3,Lower gastrointestinal haemorrhage,,2018,Q3,3,F,20170403.0,20180821.0,20171224,20180828,PER,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-BI-068336",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,100.3,KG,20180828.0,,CN,US,US,2018,Q3,Elderly
143918332,14391833,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,U,,,204042.0,100.0,MG,TABLET,QD,2018,Q3,Hypokalaemia,,2018,Q3,2,F,20170719.0,20180903.0,20180116,20180920,EXP,,JP-JNJFOC-20180117331,JANSSEN,,89.0,YR,E,F,Y,45.0,KG,20180914.0,,OT,JP,JP,2018,Q3,Elderly
143924413,14392441,150,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2018,Q3,Chronic kidney disease,,2018,Q3,3,F,2015.0,20180618.0,20180116,20180904,EXP,,US-PFIZER INC-2018017588,PFIZER,,59.0,YR,,F,Y,82.0,KG,20180904.0,,CN,US,US,2018,Q3,Adult
143924413,14392441,150,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2018,Q3,Gastric ulcer,,2018,Q3,3,F,2015.0,20180618.0,20180116,20180904,EXP,,US-PFIZER INC-2018017588,PFIZER,,59.0,YR,,F,Y,82.0,KG,20180904.0,,CN,US,US,2018,Q3,Adult
143924413,14392441,150,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2018,Q3,Renal failure,,2018,Q3,3,F,2015.0,20180618.0,20180116,20180904,EXP,,US-PFIZER INC-2018017588,PFIZER,,59.0,YR,,F,Y,82.0,KG,20180904.0,,CN,US,US,2018,Q3,Adult
143924413,14392441,150,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2018,Q3,Renal injury,,2018,Q3,3,F,2015.0,20180618.0,20180116,20180904,EXP,,US-PFIZER INC-2018017588,PFIZER,,59.0,YR,,F,Y,82.0,KG,20180904.0,,CN,US,US,2018,Q3,Adult
143924413,14392441,150,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2018,Q3,Suicidal ideation,,2018,Q3,3,F,2015.0,20180618.0,20180116,20180904,EXP,,US-PFIZER INC-2018017588,PFIZER,,59.0,YR,,F,Y,82.0,KG,20180904.0,,CN,US,US,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Asthenia,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Bladder stenosis,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Blood glucose increased,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Chills,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Deafness unilateral,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Diabetes mellitus,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Dizziness,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Dry throat,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Erythema,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Fatigue,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Gait disturbance,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Genitourinary operation,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Headache,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Hot flush,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Hypersomnia,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Hypophagia,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Muscle spasms,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Myalgia,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Nasal dryness,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Nausea,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Pain,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Pain in extremity,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Penile pain,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Plantar fasciitis,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Pruritus,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Radical prostatectomy,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Rash erythematous,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Skin plaque,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Thrombosis in device,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
145150484,14515048,10,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q3,Urinary incontinence,,2018,Q3,4,F,201711.0,20180721.0,20180209,20180725,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20180725.0,,MD,CA,CA,2018,Q3,Adult
147902574,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2018,Q3,Diarrhoea,,2018,Q3,4,F,2011.0,20180802.0,20180423,20180810,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20180810.0,,CN,US,US,2018,Q3,Adult
147902574,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2018,Q3,Fall,,2018,Q3,4,F,2011.0,20180802.0,20180423,20180810,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20180810.0,,CN,US,US,2018,Q3,Adult
147902574,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2018,Q3,Fatigue,,2018,Q3,4,F,2011.0,20180802.0,20180423,20180810,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20180810.0,,CN,US,US,2018,Q3,Adult
147902574,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2018,Q3,Limb injury,,2018,Q3,4,F,2011.0,20180802.0,20180423,20180810,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20180810.0,,CN,US,US,2018,Q3,Adult
147902574,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2018,Q3,Off label use,,2018,Q3,4,F,2011.0,20180802.0,20180423,20180810,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20180810.0,,CN,US,US,2018,Q3,Adult
147902574,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2018,Q3,Root canal infection,,2018,Q3,4,F,2011.0,20180802.0,20180423,20180810,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20180810.0,,CN,US,US,2018,Q3,Adult
147902574,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2018,Q3,Sepsis,,2018,Q3,4,F,2011.0,20180802.0,20180423,20180810,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20180810.0,,CN,US,US,2018,Q3,Adult
147902574,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2018,Q3,Tooth abscess,,2018,Q3,4,F,2011.0,20180802.0,20180423,20180810,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20180810.0,,CN,US,US,2018,Q3,Adult
147902574,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2018,Q3,Tooth infection,,2018,Q3,4,F,2011.0,20180802.0,20180423,20180810,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20180810.0,,CN,US,US,2018,Q3,Adult
148998886,14899888,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"150/1000 MG, BID",,,Y,,,,,,,,,2018,Q3,Syncope,,2018,Q3,6,F,20180210.0,20180813.0,20180516,20180817,EXP,,PHHO2018US005666,SANDOZ,,55.0,YR,,F,Y,96.0,KG,20180817.0,,OT,US,US,2018,Q3,Adult
149660232,14966023,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q3,Back pain,,2018,Q3,2,F,201701.0,20180703.0,20180603,20180720,PER,,US-JNJFOC-20180530875,JANSSEN,,82.0,YR,E,F,Y,,,20180720.0,,MD,US,US,2018,Q3,Elderly
149660232,14966023,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q3,Hyponatraemia,,2018,Q3,2,F,201701.0,20180703.0,20180603,20180720,PER,,US-JNJFOC-20180530875,JANSSEN,,82.0,YR,E,F,Y,,,20180720.0,,MD,US,US,2018,Q3,Elderly
149660232,14966023,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,D,,,,,,,UNSPECIFIED,,2018,Q3,Rash pruritic,,2018,Q3,2,F,201701.0,20180703.0,20180603,20180720,PER,,US-JNJFOC-20180530875,JANSSEN,,82.0,YR,E,F,Y,,,20180720.0,,MD,US,US,2018,Q3,Elderly
150986161,15098616,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q3,Diabetic ketoacidosis,,2018,Q3,1,I,20180611.0,20180628.0,20180702,20180702,EXP,,GB-JNJFOC-20180639278,JANSSEN,,57.0,YR,A,F,Y,80.0,KG,20180702.0,,MD,GB,GB,2018,Q3,Adult
151036491,15103649,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,N,,,204042.0,,,TABLET,,2018,Q3,Acetonaemia,,2018,Q3,1,I,201806.0,20180628.0,20180703,20180703,EXP,,GB-JNJFOC-20180638965,JANSSEN,,27.0,YR,A,M,Y,,,20180703.0,,MD,GB,GB,2018,Q3,Young Adult
151036491,15103649,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,N,,,204042.0,,,TABLET,,2018,Q3,Diabetic foot,,2018,Q3,1,I,201806.0,20180628.0,20180703,20180703,EXP,,GB-JNJFOC-20180638965,JANSSEN,,27.0,YR,A,M,Y,,,20180703.0,,MD,GB,GB,2018,Q3,Young Adult
151036531,15103653,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,U,,,204042.0,100.0,MG,TABLET,,2018,Q3,Cough,,2018,Q3,1,I,20180614.0,20180629.0,20180703,20180703,EXP,,GB-JNJFOC-20180639663,JANSSEN,,72.0,YR,E,M,Y,104.0,KG,20180703.0,,PH,GB,GB,2018,Q3,Elderly
151036531,15103653,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,U,,,204042.0,100.0,MG,TABLET,,2018,Q3,Dyspnoea,,2018,Q3,1,I,20180614.0,20180629.0,20180703,20180703,EXP,,GB-JNJFOC-20180639663,JANSSEN,,72.0,YR,E,M,Y,104.0,KG,20180703.0,,PH,GB,GB,2018,Q3,Elderly
151036531,15103653,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,U,,,204042.0,100.0,MG,TABLET,,2018,Q3,Erythema multiforme,,2018,Q3,1,I,20180614.0,20180629.0,20180703,20180703,EXP,,GB-JNJFOC-20180639663,JANSSEN,,72.0,YR,E,M,Y,104.0,KG,20180703.0,,PH,GB,GB,2018,Q3,Elderly
151215891,15121589,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,EVERY MORNING,,,,N,,,204042.0,200.0,MG,TABLET,,2018,Q3,Gastroenteritis,,2018,Q3,1,I,201709.0,20180705.0,20180709,20180709,EXP,,GB-JNJFOC-20180706894,JANSSEN,,65.0,YR,A,M,Y,,,20180709.0,,PH,GB,GB,2018,Q3,Elderly
151215891,15121589,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,EVERY MORNING,,,,N,,,204042.0,200.0,MG,TABLET,,2018,Q3,Incorrect dose administered,,2018,Q3,1,I,201709.0,20180705.0,20180709,20180709,EXP,,GB-JNJFOC-20180706894,JANSSEN,,65.0,YR,A,M,Y,,,20180709.0,,PH,GB,GB,2018,Q3,Elderly
151215891,15121589,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,EVERY MORNING,,,,N,,,204042.0,200.0,MG,TABLET,,2018,Q3,Ketoacidosis,,2018,Q3,1,I,201709.0,20180705.0,20180709,20180709,EXP,,GB-JNJFOC-20180706894,JANSSEN,,65.0,YR,A,M,Y,,,20180709.0,,PH,GB,GB,2018,Q3,Elderly
151215891,15121589,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,EVERY MORNING,,,,N,,,204042.0,200.0,MG,TABLET,,2018,Q3,Off label use,,2018,Q3,1,I,201709.0,20180705.0,20180709,20180709,EXP,,GB-JNJFOC-20180706894,JANSSEN,,65.0,YR,A,M,Y,,,20180709.0,,PH,GB,GB,2018,Q3,Elderly
151215891,15121589,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,EVERY MORNING,,,,N,,,204042.0,200.0,MG,TABLET,,2018,Q3,Vomiting,,2018,Q3,1,I,201709.0,20180705.0,20180709,20180709,EXP,,GB-JNJFOC-20180706894,JANSSEN,,65.0,YR,A,M,Y,,,20180709.0,,PH,GB,GB,2018,Q3,Elderly
151277131,15127713,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,,,,,2018,Q3,Pneumonitis,,2018,Q3,1,I,,20180703.0,20180710,20180710,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-062644,BRISTOL MYERS SQUIBB,,64.0,YR,,F,Y,,,20180710.0,,OT,US,US,2018,Q3,Adult
151549151,15154915,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,N,D,,,,300.0,MG,,QD,2018,Q3,Localised infection,,2018,Q3,1,I,20180301.0,,20180620,20180620,DIR,,,FDA-CTU,,72.0,YR,,M,N,106.65,KG,20180620.0,N,OT,US,US,2018,Q3,Elderly
151549151,15154915,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,N,D,,,,300.0,MG,,QD,2018,Q3,Toe amputation,,2018,Q3,1,I,20180301.0,,20180620,20180620,DIR,,,FDA-CTU,,72.0,YR,,M,N,106.65,KG,20180620.0,N,OT,US,US,2018,Q3,Elderly
151549151,15154915,2,C,canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q3,Localised infection,,2018,Q3,1,I,20180301.0,,20180620,20180620,DIR,,,FDA-CTU,,72.0,YR,,M,N,106.65,KG,20180620.0,N,OT,US,US,2018,Q3,Elderly
151549151,15154915,2,C,canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q3,Toe amputation,,2018,Q3,1,I,20180301.0,,20180620,20180620,DIR,,,FDA-CTU,,72.0,YR,,M,N,106.65,KG,20180620.0,N,OT,US,US,2018,Q3,Elderly
151708491,15170849,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,N,N,,,204042.0,100.0,MG,TABLET,,2018,Q3,Skin ulcer,,2018,Q3,1,I,20180628.0,20180718.0,20180720,20180720,EXP,,GB-JNJFOC-20180724238,JANSSEN,,7.0,DEC,,M,Y,98.0,KG,20180720.0,,PH,GB,GB,2018,Q3,Child
151810562,15181056,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,UNK,,,,,,,,,,,,2018,Q3,Product use in unapproved indication,,2018,Q3,2,F,,20180807.0,20180723,20180906,PER,,US-009507513-1807USA008355,MERCK,"IWAMAYE A, AYE SM, VAZ C. LATENT AUTOIMMUNE DIABETES IN THE OBESE PATIENT: A CASE SERIES. ENDOCRINE PRACTICE. 2018?24(S1):55?6",34.0,YR,,M,Y,,,20180906.0,,MD,US,US,2018,Q3,Young Adult
151970671,15197067,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,300.0,MG,TABLET,,2018,Q3,Cellulitis,,2018,Q3,1,I,,20180717.0,20180725,20180725,EXP,,US-JNJFOC-20180722329,JANSSEN,"SHARMA PV, JOBANPUTRA YB, LEWIN K, BAGATELL S, LICHTSTEIN DM. DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES ON SODIUM?GLUCOSE COTRANSPORTER?2 INHIBITORS ? A CASE SERIES. REVIEWS ON RECENT CLINICAL TRIALS 2018?13 (2):156?160.",56.0,YR,A,F,Y,,,20180725.0,,OT,US,US,2018,Q3,Adult
151970671,15197067,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,300.0,MG,TABLET,,2018,Q3,Diabetic ketoacidosis,,2018,Q3,1,I,,20180717.0,20180725,20180725,EXP,,US-JNJFOC-20180722329,JANSSEN,"SHARMA PV, JOBANPUTRA YB, LEWIN K, BAGATELL S, LICHTSTEIN DM. DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES ON SODIUM?GLUCOSE COTRANSPORTER?2 INHIBITORS ? A CASE SERIES. REVIEWS ON RECENT CLINICAL TRIALS 2018?13 (2):156?160.",56.0,YR,A,F,Y,,,20180725.0,,OT,US,US,2018,Q3,Adult
151970671,15197067,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,300.0,MG,TABLET,,2018,Q3,Urinary tract infection,,2018,Q3,1,I,,20180717.0,20180725,20180725,EXP,,US-JNJFOC-20180722329,JANSSEN,"SHARMA PV, JOBANPUTRA YB, LEWIN K, BAGATELL S, LICHTSTEIN DM. DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES ON SODIUM?GLUCOSE COTRANSPORTER?2 INHIBITORS ? A CASE SERIES. REVIEWS ON RECENT CLINICAL TRIALS 2018?13 (2):156?160.",56.0,YR,A,F,Y,,,20180725.0,,OT,US,US,2018,Q3,Adult
152329161,15232916,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,TABLET,,2018,Q3,Acute myocardial infarction,,2018,Q3,1,I,,20180726.0,20180802,20180802,EXP,,CA-FRESENIUS KABI-FK201808314,FRESENIUS KABI,,73.0,YR,,M,Y,107.0,KG,20180802.0,,OT,CA,CA,2018,Q3,Elderly
152329161,15232916,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,TABLET,,2018,Q3,Endotracheal intubation,,2018,Q3,1,I,,20180726.0,20180802,20180802,EXP,,CA-FRESENIUS KABI-FK201808314,FRESENIUS KABI,,73.0,YR,,M,Y,107.0,KG,20180802.0,,OT,CA,CA,2018,Q3,Elderly
152329161,15232916,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,TABLET,,2018,Q3,Heart rate increased,,2018,Q3,1,I,,20180726.0,20180802,20180802,EXP,,CA-FRESENIUS KABI-FK201808314,FRESENIUS KABI,,73.0,YR,,M,Y,107.0,KG,20180802.0,,OT,CA,CA,2018,Q3,Elderly
152329161,15232916,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,TABLET,,2018,Q3,Hypersensitivity,,2018,Q3,1,I,,20180726.0,20180802,20180802,EXP,,CA-FRESENIUS KABI-FK201808314,FRESENIUS KABI,,73.0,YR,,M,Y,107.0,KG,20180802.0,,OT,CA,CA,2018,Q3,Elderly
152329161,15232916,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,TABLET,,2018,Q3,Hypertension,,2018,Q3,1,I,,20180726.0,20180802,20180802,EXP,,CA-FRESENIUS KABI-FK201808314,FRESENIUS KABI,,73.0,YR,,M,Y,107.0,KG,20180802.0,,OT,CA,CA,2018,Q3,Elderly
152329161,15232916,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,TABLET,,2018,Q3,Oxygen saturation decreased,,2018,Q3,1,I,,20180726.0,20180802,20180802,EXP,,CA-FRESENIUS KABI-FK201808314,FRESENIUS KABI,,73.0,YR,,M,Y,107.0,KG,20180802.0,,OT,CA,CA,2018,Q3,Elderly
152329161,15232916,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,TABLET,,2018,Q3,Respiratory failure,,2018,Q3,1,I,,20180726.0,20180802,20180802,EXP,,CA-FRESENIUS KABI-FK201808314,FRESENIUS KABI,,73.0,YR,,M,Y,107.0,KG,20180802.0,,OT,CA,CA,2018,Q3,Elderly
152329161,15232916,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,TABLET,,2018,Q3,Speech disorder,,2018,Q3,1,I,,20180726.0,20180802,20180802,EXP,,CA-FRESENIUS KABI-FK201808314,FRESENIUS KABI,,73.0,YR,,M,Y,107.0,KG,20180802.0,,OT,CA,CA,2018,Q3,Elderly
152329161,15232916,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,TABLET,,2018,Q3,Unresponsive to stimuli,,2018,Q3,1,I,,20180726.0,20180802,20180802,EXP,,CA-FRESENIUS KABI-FK201808314,FRESENIUS KABI,,73.0,YR,,M,Y,107.0,KG,20180802.0,,OT,CA,CA,2018,Q3,Elderly
152542921,15254292,1,PS,CANAGLIFLOZIN 300mg,CANAGLIFLOZIN,1,Oral,,,,N,D,,,,300.0,MG,,QD,2018,Q3,Diabetic ketoacidosis,,2018,Q3,1,I,20180627.0,,20180717,20180717,DIR,,,FDA-CTU,,48.0,YR,,F,N,50.0,KG,20180707.0,N,PH,US,US,2018,Q3,Adult
152546254,15254625,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK, UNKNOWN FREQ.",,,,,,,,,,,,2018,Q3,Erythema multiforme,,2018,Q3,4,F,201806.0,20180911.0,20180808,20180919,EXP,,JP-PFIZER INC-2018316003,PFIZER,,79.0,YR,,M,Y,,,20180919.0,,MD,JP,JP,2018,Q3,Elderly
152546254,15254625,9,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK, UNKNOWN FREQ.",,,,,,,,,,,,2018,Q3,Oedema,,2018,Q3,4,F,201806.0,20180911.0,20180808,20180919,EXP,,JP-PFIZER INC-2018316003,PFIZER,,79.0,YR,,M,Y,,,20180919.0,,MD,JP,JP,2018,Q3,Elderly
152566931,15256693,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,28.0,DF,TABLET,,2018,Q3,Intentional overdose,,2018,Q3,1,I,,20180730.0,20180808,20180808,EXP,,GB-TEVA-2018-GB-936674,TEVA,,29.0,YR,,F,Y,,,20180808.0,,MD,GB,GB,2018,Q3,Young Adult
152566931,15256693,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,,,,,28.0,DF,TABLET,,2018,Q3,Ovarian cancer,,2018,Q3,1,I,,20180730.0,20180808,20180808,EXP,,GB-TEVA-2018-GB-936674,TEVA,,29.0,YR,,F,Y,,,20180808.0,,MD,GB,GB,2018,Q3,Young Adult
152566931,15256693,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,100.0,MG,TABLET,,2018,Q3,Intentional overdose,,2018,Q3,1,I,,20180730.0,20180808,20180808,EXP,,GB-TEVA-2018-GB-936674,TEVA,,29.0,YR,,F,Y,,,20180808.0,,MD,GB,GB,2018,Q3,Young Adult
152566931,15256693,9,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,U,,,,,100.0,MG,TABLET,,2018,Q3,Ovarian cancer,,2018,Q3,1,I,,20180730.0,20180808,20180808,EXP,,GB-TEVA-2018-GB-936674,TEVA,,29.0,YR,,F,Y,,,20180808.0,,MD,GB,GB,2018,Q3,Young Adult
152616491,15261649,2,C,canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q3,Urinary tract infection,,2018,Q3,1,I,20180713.0,,20180719,20180719,DIR,,,FDA-CTU,,58.0,YR,,F,N,91.0,KG,20180719.0,N,PH,US,US,2018,Q3,Adult
152653251,15265325,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,Y,N,,,204042.0,,,TABLET,,2018,Q3,Metabolic acidosis,,2018,Q3,1,I,,20180807.0,20180810,20180810,EXP,,GB-JNJFOC-20180810492,JANSSEN,"PANG J, MALIK R, HO S, SAHA S, HUSSAIN N. SODIUM GLUCOSE CO?TRANSPORTER 2 (SGLT2) INHIBITOR: HOW WELL DO WE KNOW THE SIDE EFFECT PROFILE IN ITU? SHOULD CURRENT PERI?OPERATIVE DIABETES GUIDELINE BE CHALLENGED?. JOURNAL OF THE INTENSIVE CARE SOCIETY 2018?19 (2 SUPPLEMENT 1):122.",42.0,YR,A,F,Y,,,20180810.0,,MD,GB,GB,2018,Q3,Adult
152906853,15290685,5,C,VOKANAMET [CANAGLIFLOZIN;METFORMIN HYDROCHLORIDE],,2,,UNK,,,,,,,,,,,,2018,Q3,Haemothorax,,2018,Q3,3,F,20180729.0,20180831.0,20180817,20180905,EXP,,ES-PFIZER INC-2018326599,PFIZER,,63.0,YR,,M,Y,,,20180905.0,,OT,ES,ES,2018,Q3,Adult
153004651,15300465,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,,,,,2018,Q3,Euglycaemic diabetic ketoacidosis,,2018,Q3,1,I,20180603.0,,20180808,20180808,DIR,,,FDA-CTU,,61.0,YR,,F,N,102.0,KG,20180808.0,N,PH,US,US,2018,Q3,Adult
153004651,15300465,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,,,,,2018,Q3,Fatigue,,2018,Q3,1,I,20180603.0,,20180808,20180808,DIR,,,FDA-CTU,,61.0,YR,,F,N,102.0,KG,20180808.0,N,PH,US,US,2018,Q3,Adult
153229151,15322915,1,PS,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q3,Acidosis,,2018,Q3,1,I,20180821.0,,20180822,20180822,DIR,,,FDA-CTU,,50.0,YR,,F,N,128.0,KG,20180822.0,N,MD,US,US,2018,Q3,Adult
153229151,15322915,1,PS,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q3,Renal failure,,2018,Q3,1,I,20180821.0,,20180822,20180822,DIR,,,FDA-CTU,,50.0,YR,,F,N,128.0,KG,20180822.0,N,MD,US,US,2018,Q3,Adult
153254131,15325413,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2018,Q3,Diabetic ketoacidosis,,2018,Q3,1,I,20180820.0,,20180822,20180822,DIR,,,FDA-CTU,,71.0,YR,,M,N,76.0,KG,20180822.0,N,PH,US,US,2018,Q3,Elderly
153586101,15358610,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,U,,,204042.0,,,TABLET,,2018,Q3,Diabetic ketoacidosis,,2018,Q3,1,I,,20180829.0,20180906,20180906,EXP,,US-JNJFOC-20180900316,JANSSEN,"BREAUX BM, DIPP SL. EUGLYCEMIC DIABETIC KETOACIDOSIS?NEWER CLASS OF MEDICATION CAN LEAD TO RARE PRESENTATION OF AN OLD FOE. DIABETES 2018?67 (SUPPLEMENT 1):A604.",31.0,YR,A,M,Y,,,20180906.0,,MD,US,US,2018,Q3,Young Adult
153649302,15364930,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q3,Gastrointestinal disorder,,2018,Q3,2,F,,20180907.0,20180910,20180918,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-081636,BRISTOL MYERS SQUIBB,,31.0,YR,,M,Y,,,20180918.0,,OT,US,US,2018,Q3,Young Adult
153649302,15364930,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q3,Gastrooesophageal reflux disease,,2018,Q3,2,F,,20180907.0,20180910,20180918,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-081636,BRISTOL MYERS SQUIBB,,31.0,YR,,M,Y,,,20180918.0,,OT,US,US,2018,Q3,Young Adult
153649302,15364930,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,,,,,,,,,2018,Q3,Vomiting,,2018,Q3,2,F,,20180907.0,20180910,20180918,PER,,US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-081636,BRISTOL MYERS SQUIBB,,31.0,YR,,M,Y,,,20180918.0,,OT,US,US,2018,Q3,Young Adult
153711231,15371123,2,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q3,Blood alkaline phosphatase increased,,2018,Q3,1,I,20180517.0,,20180905,20180905,DIR,,,FDA-CTU,,62.0,YR,,F,N,50.8,KG,20180905.0,N,PH,US,US,2018,Q3,Adult
153711231,15371123,2,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q3,Therapy cessation,,2018,Q3,1,I,20180517.0,,20180905,20180905,DIR,,,FDA-CTU,,62.0,YR,,F,N,50.8,KG,20180905.0,N,PH,US,US,2018,Q3,Adult
153711231,15371123,2,C,Canagliflozin,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q3,Therapy change,,2018,Q3,1,I,20180517.0,,20180905,20180905,DIR,,,FDA-CTU,,62.0,YR,,F,N,50.8,KG,20180905.0,N,PH,US,US,2018,Q3,Adult
153761681,15376168,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, QD PREFERABLY BEFORE BREAKFAST",,,D,, UNKNOWN,,,300.0,MG,,QD,2018,Q3,Constipation,,2018,Q3,1,I,,20180910.0,20180912,20180912,EXP,GB-MHRA-MIDB-64B279B2-8181-411B-A153-70B5E2234649,GB-MYLANLABS-2018M1066954,MYLAN,,56.0,YR,,M,Y,,,20180912.0,,PH,GB,GB,2018,Q3,Adult
153761681,15376168,6,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"300 MG, QD PREFERABLY BEFORE BREAKFAST",,,D,, UNKNOWN,,,300.0,MG,,QD,2018,Q3,Epistaxis,,2018,Q3,1,I,,20180910.0,20180912,20180912,EXP,GB-MHRA-MIDB-64B279B2-8181-411B-A153-70B5E2234649,GB-MYLANLABS-2018M1066954,MYLAN,,56.0,YR,,M,Y,,,20180912.0,,PH,GB,GB,2018,Q3,Adult
153864161,15386416,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,U,,,,,,,,,2018,Q3,Facial paralysis,,2018,Q3,1,I,20180306.0,20180906.0,20180914,20180914,EXP,GB-MHRA-EYC 00184459,GB-SA-2018SA252344,SANOFI AVENTIS,,52.0,YR,A,F,Y,105.0,KG,20180914.0,,PH,GB,GB,2018,Q3,Adult
153930921,15393092,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 DF, BID",,,,,,,,1.0,DF,,BID,2018,Q3,Headache,,2018,Q3,1,I,,20180905.0,20180917,20180917,EXP,,ES-ELI_LILLY_AND_COMPANY-ES201809002462,ELI LILLY AND CO,,60.0,YR,,F,Y,,,20180917.0,,CN,ES,ES,2018,Q3,Adult
153930921,15393092,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 DF, BID",,,,,,,,1.0,DF,,BID,2018,Q3,Hyperglycaemia,,2018,Q3,1,I,,20180905.0,20180917,20180917,EXP,,ES-ELI_LILLY_AND_COMPANY-ES201809002462,ELI LILLY AND CO,,60.0,YR,,F,Y,,,20180917.0,,CN,ES,ES,2018,Q3,Adult
153930921,15393092,5,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"1 DF, BID",,,,,,,,1.0,DF,,BID,2018,Q3,Hypoglycaemia,,2018,Q3,1,I,,20180905.0,20180917,20180917,EXP,,ES-ELI_LILLY_AND_COMPANY-ES201809002462,ELI LILLY AND CO,,60.0,YR,,F,Y,,,20180917.0,,CN,ES,ES,2018,Q3,Adult
153969501,15396950,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,IN THE MORNING,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q3,Chills,,2018,Q3,1,I,,20180912.0,20180918,20180918,EXP,GB-MHRA-EYC 00184723,GB-JNJFOC-20180913907,JANSSEN,,63.0,YR,A,M,Y,,,20180918.0,,PH,GB,GB,2018,Q3,Adult
153969501,15396950,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,IN THE MORNING,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q3,Genitourinary tract infection,,2018,Q3,1,I,,20180912.0,20180918,20180918,EXP,GB-MHRA-EYC 00184723,GB-JNJFOC-20180913907,JANSSEN,,63.0,YR,A,M,Y,,,20180918.0,,PH,GB,GB,2018,Q3,Adult
153969501,15396950,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,IN THE MORNING,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q3,Pyrexia,,2018,Q3,1,I,,20180912.0,20180918,20180918,EXP,GB-MHRA-EYC 00184723,GB-JNJFOC-20180913907,JANSSEN,,63.0,YR,A,M,Y,,,20180918.0,,PH,GB,GB,2018,Q3,Adult
153972182,15397218,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,QD,2018,Q3,Hyperglycaemia,,2018,Q3,2,F,,20180921.0,20180918,20180926,EXP,,CA-TEVA-2018-CA-954513,TEVA,"DIZON S, KEELY EJ, MALCOLM J, ARNAOUT A. INSIGHTS INTO THE RECOGNITION AND MANAGEMENT OF SGLT2?INHIBITOR?ASSOCIATED KETOACIDOSIS: IT^S NOT JUST EUGLYCEMIC DIABETIC KETOACIDOSIS. CAN?J?DIAB 2017?41(5):499?503.",74.0,YR,,M,Y,,,20180926.0,,MD,CA,CA,2018,Q3,Elderly
153972182,15397218,2,SS,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,U,,,,,100.0,MG,,QD,2018,Q3,Ketoacidosis,,2018,Q3,2,F,,20180921.0,20180918,20180926,EXP,,CA-TEVA-2018-CA-954513,TEVA,"DIZON S, KEELY EJ, MALCOLM J, ARNAOUT A. INSIGHTS INTO THE RECOGNITION AND MANAGEMENT OF SGLT2?INHIBITOR?ASSOCIATED KETOACIDOSIS: IT^S NOT JUST EUGLYCEMIC DIABETIC KETOACIDOSIS. CAN?J?DIAB 2017?41(5):499?503.",74.0,YR,,M,Y,,,20180926.0,,MD,CA,CA,2018,Q3,Elderly
154063211,15406321,1,PS,canagliflozin,CANAGLIFLOZIN,1,Oral,,,,D,D,,,,300.0,MG,,QD,2018,Q3,Euglycaemic diabetic ketoacidosis,,2018,Q3,1,I,20180918.0,,20180918,20180918,DIR,,,FDA-CTU,,52.0,YR,,F,N,77.4,KG,20180918.0,N,PH,US,US,2018,Q3,Adult
154133651,15413365,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,QD,2018,Q3,Skin ulcer,,2018,Q3,1,I,20170810.0,20180913.0,20180921,20180921,EXP,ES-AEMPS-396570,ES-JNJFOC-20180919131,JANSSEN,,80.0,YR,E,M,Y,,,20180921.0,,PH,ES,ES,2018,Q3,Elderly
154298871,15429887,8,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MG, DAILY",,,,,,,,300.0,MG,,,2018,Q3,Acute kidney injury,,2018,Q3,1,I,,20180917.0,20180926,20180926,EXP,,US-APOTEX-2018AP021116,APOTEX,"TAYLOR SR, MOODY MT. ACUTE KIDNEY INJURY OCCURRING IN A PATIENT INITIATED ON DULAGLUTIDE. DOI: 10.1177/8755122518782155. JOURNAL OF PHARMACY TECHNOLOGY. 2018?34 (5):231?232",63.0,YR,,F,Y,,,20180926.0,,PH,US,US,2018,Q3,Adult
154317521,15431752,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q3,Abdominal pain,,2018,Q3,1,I,20180705.0,20180920.0,20180926,20180926,EXP,,PL-ASTRAZENECA-2018SF20468,ASTRAZENECA,,59.0,YR,,M,Y,127.0,KG,20180926.0,,MD,PL,PL,2018,Q3,Adult
154317521,15431752,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q3,Pancreatitis acute,,2018,Q3,1,I,20180705.0,20180920.0,20180926,20180926,EXP,,PL-ASTRAZENECA-2018SF20468,ASTRAZENECA,,59.0,YR,,M,Y,127.0,KG,20180926.0,,MD,PL,PL,2018,Q3,Adult
128582692,12858269,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q4,Borderline personality disorder,,2018,Q4,2,F,20160312.0,20180925.0,20161018,20181003,EXP,,JP-JNJFOC-20161013100,JANSSEN,,39.0,YR,A,F,Y,86.0,KG,20181003.0,,OT,JP,JP,2018,Q4,Adult
128582692,12858269,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q4,Facial paralysis,,2018,Q4,2,F,20160312.0,20180925.0,20161018,20181003,EXP,,JP-JNJFOC-20161013100,JANSSEN,,39.0,YR,A,F,Y,86.0,KG,20181003.0,,OT,JP,JP,2018,Q4,Adult
130360217,13036021,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,,100.0,MG,TABLET,QD,2018,Q4,Blood ketone body increased,,2018,Q4,7,F,20160623.0,20180921.0,20161216,20181002,EXP,,JP-JNJFOC-20161213676,JANSSEN,,60.0,YR,A,M,Y,68.0,KG,20181002.0,,OT,JP,JP,2018,Q4,Adult
130360217,13036021,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,,100.0,MG,TABLET,QD,2018,Q4,Cholecystitis acute,,2018,Q4,7,F,20160623.0,20180921.0,20161216,20181002,EXP,,JP-JNJFOC-20161213676,JANSSEN,,60.0,YR,A,M,Y,68.0,KG,20181002.0,,OT,JP,JP,2018,Q4,Adult
130360217,13036021,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,,100.0,MG,TABLET,QD,2018,Q4,Crystal urine present,,2018,Q4,7,F,20160623.0,20180921.0,20161216,20181002,EXP,,JP-JNJFOC-20161213676,JANSSEN,,60.0,YR,A,M,Y,68.0,KG,20181002.0,,OT,JP,JP,2018,Q4,Adult
130360217,13036021,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,,100.0,MG,TABLET,QD,2018,Q4,Pancreatitis acute,,2018,Q4,7,F,20160623.0,20180921.0,20161216,20181002,EXP,,JP-JNJFOC-20161213676,JANSSEN,,60.0,YR,A,M,Y,68.0,KG,20181002.0,,OT,JP,JP,2018,Q4,Adult
130360217,13036021,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,,100.0,MG,TABLET,QD,2018,Q4,Urinary sediment present,,2018,Q4,7,F,20160623.0,20180921.0,20161216,20181002,EXP,,JP-JNJFOC-20161213676,JANSSEN,,60.0,YR,A,M,Y,68.0,KG,20181002.0,,OT,JP,JP,2018,Q4,Adult
130360217,13036021,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,,100.0,MG,TABLET,QD,2018,Q4,Urine ketone body present,,2018,Q4,7,F,20160623.0,20180921.0,20161216,20181002,EXP,,JP-JNJFOC-20161213676,JANSSEN,,60.0,YR,A,M,Y,68.0,KG,20181002.0,,OT,JP,JP,2018,Q4,Adult
130360217,13036021,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,,100.0,MG,TABLET,QD,2018,Q4,Urine phosphorus abnormal,,2018,Q4,7,F,20160623.0,20180921.0,20161216,20181002,EXP,,JP-JNJFOC-20161213676,JANSSEN,,60.0,YR,A,M,Y,68.0,KG,20181002.0,,OT,JP,JP,2018,Q4,Adult
130360217,13036021,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,,100.0,MG,TABLET,QD,2018,Q4,White blood cells urine,,2018,Q4,7,F,20160623.0,20180921.0,20161216,20181002,EXP,,JP-JNJFOC-20161213676,JANSSEN,,60.0,YR,A,M,Y,68.0,KG,20181002.0,,OT,JP,JP,2018,Q4,Adult
130360217,13036021,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q4,Blood ketone body increased,,2018,Q4,7,F,20160623.0,20180921.0,20161216,20181002,EXP,,JP-JNJFOC-20161213676,JANSSEN,,60.0,YR,A,M,Y,68.0,KG,20181002.0,,OT,JP,JP,2018,Q4,Adult
130360217,13036021,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q4,Cholecystitis acute,,2018,Q4,7,F,20160623.0,20180921.0,20161216,20181002,EXP,,JP-JNJFOC-20161213676,JANSSEN,,60.0,YR,A,M,Y,68.0,KG,20181002.0,,OT,JP,JP,2018,Q4,Adult
130360217,13036021,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q4,Crystal urine present,,2018,Q4,7,F,20160623.0,20180921.0,20161216,20181002,EXP,,JP-JNJFOC-20161213676,JANSSEN,,60.0,YR,A,M,Y,68.0,KG,20181002.0,,OT,JP,JP,2018,Q4,Adult
130360217,13036021,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q4,Pancreatitis acute,,2018,Q4,7,F,20160623.0,20180921.0,20161216,20181002,EXP,,JP-JNJFOC-20161213676,JANSSEN,,60.0,YR,A,M,Y,68.0,KG,20181002.0,,OT,JP,JP,2018,Q4,Adult
130360217,13036021,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q4,Urinary sediment present,,2018,Q4,7,F,20160623.0,20180921.0,20161216,20181002,EXP,,JP-JNJFOC-20161213676,JANSSEN,,60.0,YR,A,M,Y,68.0,KG,20181002.0,,OT,JP,JP,2018,Q4,Adult
130360217,13036021,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q4,Urine ketone body present,,2018,Q4,7,F,20160623.0,20180921.0,20161216,20181002,EXP,,JP-JNJFOC-20161213676,JANSSEN,,60.0,YR,A,M,Y,68.0,KG,20181002.0,,OT,JP,JP,2018,Q4,Adult
130360217,13036021,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q4,Urine phosphorus abnormal,,2018,Q4,7,F,20160623.0,20180921.0,20161216,20181002,EXP,,JP-JNJFOC-20161213676,JANSSEN,,60.0,YR,A,M,Y,68.0,KG,20181002.0,,OT,JP,JP,2018,Q4,Adult
130360217,13036021,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q4,White blood cells urine,,2018,Q4,7,F,20160623.0,20180921.0,20161216,20181002,EXP,,JP-JNJFOC-20161213676,JANSSEN,,60.0,YR,A,M,Y,68.0,KG,20181002.0,,OT,JP,JP,2018,Q4,Adult
132911882,13291188,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, UNK",,,U,,,,,100.0,MG,,,2018,Q4,Abdominal pain upper,,2018,Q4,2,F,,20181112.0,20170303,20181122,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-016092,BRISTOL MYERS SQUIBB,SUZUKI. A CASE OF HAEMOGLOBINOPATHY COMPLICATED WITH DIABETIC KETOACIDOSIS (DNK) DURING ADMINISTRATION OF SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITOR. PRESENTATION AT THE 54TH KANTO KOSHINETSU CHAPTER MEETING OF THE JAPAN DATABASE. 2017;85,60.0,YR,,M,Y,,,20181122.0,,MD,JP,JP,2018,Q4,Adult
132911882,13291188,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, UNK",,,U,,,,,100.0,MG,,,2018,Q4,Blood ketone body increased,,2018,Q4,2,F,,20181112.0,20170303,20181122,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-016092,BRISTOL MYERS SQUIBB,SUZUKI. A CASE OF HAEMOGLOBINOPATHY COMPLICATED WITH DIABETIC KETOACIDOSIS (DNK) DURING ADMINISTRATION OF SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITOR. PRESENTATION AT THE 54TH KANTO KOSHINETSU CHAPTER MEETING OF THE JAPAN DATABASE. 2017;85,60.0,YR,,M,Y,,,20181122.0,,MD,JP,JP,2018,Q4,Adult
132911882,13291188,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, UNK",,,U,,,,,100.0,MG,,,2018,Q4,Cholecystitis,,2018,Q4,2,F,,20181112.0,20170303,20181122,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-016092,BRISTOL MYERS SQUIBB,SUZUKI. A CASE OF HAEMOGLOBINOPATHY COMPLICATED WITH DIABETIC KETOACIDOSIS (DNK) DURING ADMINISTRATION OF SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITOR. PRESENTATION AT THE 54TH KANTO KOSHINETSU CHAPTER MEETING OF THE JAPAN DATABASE. 2017;85,60.0,YR,,M,Y,,,20181122.0,,MD,JP,JP,2018,Q4,Adult
132911882,13291188,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, UNK",,,U,,,,,100.0,MG,,,2018,Q4,Diabetic ketoacidosis,,2018,Q4,2,F,,20181112.0,20170303,20181122,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-016092,BRISTOL MYERS SQUIBB,SUZUKI. A CASE OF HAEMOGLOBINOPATHY COMPLICATED WITH DIABETIC KETOACIDOSIS (DNK) DURING ADMINISTRATION OF SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITOR. PRESENTATION AT THE 54TH KANTO KOSHINETSU CHAPTER MEETING OF THE JAPAN DATABASE. 2017;85,60.0,YR,,M,Y,,,20181122.0,,MD,JP,JP,2018,Q4,Adult
132911882,13291188,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, UNK",,,U,,,,,100.0,MG,,,2018,Q4,Vomiting,,2018,Q4,2,F,,20181112.0,20170303,20181122,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2017-016092,BRISTOL MYERS SQUIBB,SUZUKI. A CASE OF HAEMOGLOBINOPATHY COMPLICATED WITH DIABETIC KETOACIDOSIS (DNK) DURING ADMINISTRATION OF SODIUM-GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITOR. PRESENTATION AT THE 54TH KANTO KOSHINETSU CHAPTER MEETING OF THE JAPAN DATABASE. 2017;85,60.0,YR,,M,Y,,,20181122.0,,MD,JP,JP,2018,Q4,Adult
140337838,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q4,Acute kidney injury,,2018,Q4,8,F,,20180927.0,20171003,20181010,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20181010.0,,MD,AT,AT,2018,Q4,Elderly
140337838,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q4,Anion gap increased,,2018,Q4,8,F,,20180927.0,20171003,20181010,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20181010.0,,MD,AT,AT,2018,Q4,Elderly
140337838,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q4,Base excess decreased,,2018,Q4,8,F,,20180927.0,20171003,20181010,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20181010.0,,MD,AT,AT,2018,Q4,Elderly
140337838,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q4,Blood bicarbonate decreased,,2018,Q4,8,F,,20180927.0,20171003,20181010,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20181010.0,,MD,AT,AT,2018,Q4,Elderly
140337838,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q4,Blood lactic acid increased,,2018,Q4,8,F,,20180927.0,20171003,20181010,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20181010.0,,MD,AT,AT,2018,Q4,Elderly
140337838,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q4,Blood pH decreased,,2018,Q4,8,F,,20180927.0,20171003,20181010,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20181010.0,,MD,AT,AT,2018,Q4,Elderly
140337838,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q4,Body temperature decreased,,2018,Q4,8,F,,20180927.0,20171003,20181010,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20181010.0,,MD,AT,AT,2018,Q4,Elderly
140337838,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q4,Diabetic ketoacidosis,,2018,Q4,8,F,,20180927.0,20171003,20181010,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20181010.0,,MD,AT,AT,2018,Q4,Elderly
140337838,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q4,Hyperventilation,,2018,Q4,8,F,,20180927.0,20171003,20181010,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20181010.0,,MD,AT,AT,2018,Q4,Elderly
140337838,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q4,Hypotension,,2018,Q4,8,F,,20180927.0,20171003,20181010,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20181010.0,,MD,AT,AT,2018,Q4,Elderly
140337838,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q4,Ketoacidosis,,2018,Q4,8,F,,20180927.0,20171003,20181010,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20181010.0,,MD,AT,AT,2018,Q4,Elderly
140337838,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q4,Lactic acidosis,,2018,Q4,8,F,,20180927.0,20171003,20181010,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20181010.0,,MD,AT,AT,2018,Q4,Elderly
140337838,14033783,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,U,U,,,,,,,,2018,Q4,PCO2 decreased,,2018,Q4,8,F,,20180927.0,20171003,20181010,EXP,,AT-AUROBINDO-AUR-APL-2017-40976,AUROBINDO,,71.0,YR,,M,Y,,,20181010.0,,MD,AT,AT,2018,Q4,Elderly
143218104,14321810,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,LAST DOSE: 04/02/17 20:00,,,,,,,,300.0,MG,TABLET,QD,2018,Q4,Lower gastrointestinal haemorrhage,,2018,Q4,4,F,20170403.0,20181023.0,20171224,20181030,PER,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2017-BI-068336",BOEHRINGER INGELHEIM,,68.0,YR,,F,Y,100.3,KG,20181030.0,,CN,US,US,2018,Q4,Elderly
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Asthenia,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Bladder stenosis,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Blood glucose increased,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Chills,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Deafness unilateral,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Diabetes mellitus,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Dizziness,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Dry throat,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Erythema,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Exostosis,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Fatigue,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Gait disturbance,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Genitourinary operation,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Headache,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Hot flush,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Hypersomnia,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Hypoacusis,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Hypophagia,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Injection site hypersensitivity,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Limb mass,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Muscle spasms,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Myalgia,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Nasal dryness,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Nausea,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Pain,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Pain in extremity,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Penile pain,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Plantar fasciitis,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Pruritus,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Radical prostatectomy,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Rash erythematous,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Skin plaque,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Thrombosis in device,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
145150485,14515048,11,C,CANAGLIFLOZINE,CANAGLIFLOZIN,1,Unknown,,,,,,,,,100.0,MG,,QD,2018,Q4,Urinary incontinence,,2018,Q4,5,F,201711.0,20181013.0,20180209,20181019,EXP,,CA-ABBVIE-18S-028-2248446-00,ABBVIE,,57.0,YR,,M,Y,99.5,KG,20181018.0,,MD,CA,CA,2018,Q4,Adult
147902576,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2018,Q4,Acne,,2018,Q4,6,F,2011.0,20181126.0,20180423,20181206,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20181206.0,,CN,US,US,2018,Q4,Adult
147902576,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2018,Q4,Diarrhoea,,2018,Q4,6,F,2011.0,20181126.0,20180423,20181206,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20181206.0,,CN,US,US,2018,Q4,Adult
147902576,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2018,Q4,Fall,,2018,Q4,6,F,2011.0,20181126.0,20180423,20181206,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20181206.0,,CN,US,US,2018,Q4,Adult
147902576,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2018,Q4,Fatigue,,2018,Q4,6,F,2011.0,20181126.0,20180423,20181206,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20181206.0,,CN,US,US,2018,Q4,Adult
147902576,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2018,Q4,Gingivitis,,2018,Q4,6,F,2011.0,20181126.0,20180423,20181206,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20181206.0,,CN,US,US,2018,Q4,Adult
147902576,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2018,Q4,Limb injury,,2018,Q4,6,F,2011.0,20181126.0,20180423,20181206,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20181206.0,,CN,US,US,2018,Q4,Adult
147902576,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2018,Q4,Nephrolithiasis,,2018,Q4,6,F,2011.0,20181126.0,20180423,20181206,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20181206.0,,CN,US,US,2018,Q4,Adult
147902576,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2018,Q4,Off label use,,2018,Q4,6,F,2011.0,20181126.0,20180423,20181206,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20181206.0,,CN,US,US,2018,Q4,Adult
147902576,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2018,Q4,Root canal infection,,2018,Q4,6,F,2011.0,20181126.0,20180423,20181206,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20181206.0,,CN,US,US,2018,Q4,Adult
147902576,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2018,Q4,Sepsis,,2018,Q4,6,F,2011.0,20181126.0,20180423,20181206,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20181206.0,,CN,US,US,2018,Q4,Adult
147902576,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2018,Q4,Tooth abscess,,2018,Q4,6,F,2011.0,20181126.0,20180423,20181206,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20181206.0,,CN,US,US,2018,Q4,Adult
147902576,14790257,2,C,Canagliflozin,CANAGLIFLOZIN,1,,UNK,,,U,U,,,,,,,,2018,Q4,Tooth infection,,2018,Q4,6,F,2011.0,20181126.0,20180423,20181206,EXP,,US-UCBSA-2017003871,UCB,,63.0,YR,,M,Y,,,20181206.0,,CN,US,US,2018,Q4,Adult
148501732,14850173,58,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q4,Acute kidney injury,,2018,Q4,2,F,20160503.0,20181107.0,20180505,20181115,EXP,,US-ASTRAZENECA-2018SE57758,ASTRAZENECA,,27840.0,DY,,F,Y,77.1,KG,20181115.0,,,US,US,2018,Q4,Elderly
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Adverse drug reaction,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Arthralgia,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Arthritis,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Blood creatinine decreased,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Blood uric acid decreased,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Drug effect decreased,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Drug effect incomplete,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Drug ineffective,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Gastrointestinal haemorrhage,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Glycosylated haemoglobin increased,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Haemoglobin decreased,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Hepatic cirrhosis,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Hepatosplenomegaly,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Hypertrophy,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Inflammatory marker increased,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Joint effusion,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Joint swelling,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Liver disorder,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Low density lipoprotein increased,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Nausea,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Non-alcoholic fatty liver,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Pain in extremity,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Psoriasis,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Psoriatic arthropathy,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Red blood cell sedimentation rate increased,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Rheumatoid arthritis,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Type 2 diabetes mellitus,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
148727572,14872757,13,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"300 MG, UNK",,,,,,,,300.0,MG,TABLET,,2018,Q4,Varices oesophageal,,2018,Q4,2,F,2007.0,20181203.0,20180510,20181212,EXP,,CA-AMGEN-CANSP2018061765,AMGEN,,47.0,YR,A,F,Y,,,20181212.0,,OT,CA,CA,2018,Q4,Adult
149958512,14995851,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q4,Hepatic function abnormal,,2018,Q4,2,F,20170116.0,20181003.0,20180611,20181015,EXP,,JP-JNJFOC-20170924905,JANSSEN,,75.0,YR,E,M,Y,62.0,KG,20181015.0,,OT,JP,JP,2018,Q4,Elderly
149958512,14995851,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q4,Silent myocardial infarction,,2018,Q4,2,F,20170116.0,20181003.0,20180611,20181015,EXP,,JP-JNJFOC-20170924905,JANSSEN,,75.0,YR,E,M,Y,62.0,KG,20181015.0,,OT,JP,JP,2018,Q4,Elderly
151206724,15120672,8,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",,,U,,,,,100.0,MG,,QD,2018,Q4,Facial paralysis,,2018,Q4,4,F,20180306.0,20181001.0,20180709,20181005,EXP,,GB-SA-2018SA180520,SANOFI AVENTIS,,52.0,YR,A,F,Y,105.0,KG,20181005.0,,PH,GB,GB,2018,Q4,Adult
152695682,15269568,4,SS,CANAGLIFLOZIN HYDRATE,CANAGLIFLOZIN,1,Oral,DOSAGE IS UNCERTAIN.,,,D,,,,,,,TABLET,,2018,Q4,Blood glucose decreased,,2018,Q4,2,F,,20180810.0,20180813,20180817,EXP,,JP-ROCHE-2168572,ROCHE,"SUEYOSHI K, KISHITANI Y A FEMALE PATIENT WITH TYPE 2 DIABETES MELLITUS WHO TOOK HIGH-DOSE CANAGLIFLOZIN FOR SUICIDE ATTEMPT [ABSTRACT NUMBER II-P-49]. JOURNAL OF THE JAPAN DIABETES SOCIETY 2018 APR 25;61(S1):S299-.",41.0,YR,,F,Y,,,20180817.0,,MD,JP,JP,2018,Q4,Adult
152695682,15269568,4,SS,CANAGLIFLOZIN HYDRATE,CANAGLIFLOZIN,1,Oral,DOSAGE IS UNCERTAIN.,,,D,,,,,,,TABLET,,2018,Q4,Intentional overdose,,2018,Q4,2,F,,20180810.0,20180813,20180817,EXP,,JP-ROCHE-2168572,ROCHE,"SUEYOSHI K, KISHITANI Y A FEMALE PATIENT WITH TYPE 2 DIABETES MELLITUS WHO TOOK HIGH-DOSE CANAGLIFLOZIN FOR SUICIDE ATTEMPT [ABSTRACT NUMBER II-P-49]. JOURNAL OF THE JAPAN DIABETES SOCIETY 2018 APR 25;61(S1):S299-.",41.0,YR,,F,Y,,,20180817.0,,MD,JP,JP,2018,Q4,Adult
152695682,15269568,4,SS,CANAGLIFLOZIN HYDRATE,CANAGLIFLOZIN,1,Oral,DOSAGE IS UNCERTAIN.,,,D,,,,,,,TABLET,,2018,Q4,Suicide attempt,,2018,Q4,2,F,,20180810.0,20180813,20180817,EXP,,JP-ROCHE-2168572,ROCHE,"SUEYOSHI K, KISHITANI Y A FEMALE PATIENT WITH TYPE 2 DIABETES MELLITUS WHO TOOK HIGH-DOSE CANAGLIFLOZIN FOR SUICIDE ATTEMPT [ABSTRACT NUMBER II-P-49]. JOURNAL OF THE JAPAN DIABETES SOCIETY 2018 APR 25;61(S1):S299-.",41.0,YR,,F,Y,,,20180817.0,,MD,JP,JP,2018,Q4,Adult
153135763,15313576,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, ONCE A DAY",,,U,U,,,,300.0,MG,,QD,2018,Q4,Drug ineffective,,2018,Q4,3,F,,20181009.0,20180824,20181023,EXP,,GB-AUROBINDO-AUR-APL-2018-042397,AUROBINDO,"HOLT C, ET AL.. FLUCLOXACILLIN/PARACETAMOL HIGH ANION GAP METABOLIC ACIDOSIS: CASE REPORT. REACTIONS WEEKLY. 2018;1715:101",65.0,YR,,M,Y,,,20181023.0,,OT,GB,GB,2018,Q4,Elderly
153135763,15313576,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, ONCE A DAY",,,U,U,,,,300.0,MG,,QD,2018,Q4,Drug interaction,,2018,Q4,3,F,,20181009.0,20180824,20181023,EXP,,GB-AUROBINDO-AUR-APL-2018-042397,AUROBINDO,"HOLT C, ET AL.. FLUCLOXACILLIN/PARACETAMOL HIGH ANION GAP METABOLIC ACIDOSIS: CASE REPORT. REACTIONS WEEKLY. 2018;1715:101",65.0,YR,,M,Y,,,20181023.0,,OT,GB,GB,2018,Q4,Elderly
153135763,15313576,11,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"300 MILLIGRAM, ONCE A DAY",,,U,U,,,,300.0,MG,,QD,2018,Q4,Metabolic acidosis,,2018,Q4,3,F,,20181009.0,20180824,20181023,EXP,,GB-AUROBINDO-AUR-APL-2018-042397,AUROBINDO,"HOLT C, ET AL.. FLUCLOXACILLIN/PARACETAMOL HIGH ANION GAP METABOLIC ACIDOSIS: CASE REPORT. REACTIONS WEEKLY. 2018;1715:101",65.0,YR,,M,Y,,,20181023.0,,OT,GB,GB,2018,Q4,Elderly
153339492,15333949,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,QD,2018,Q4,Dehydration,,2018,Q4,2,F,20180724.0,20181011.0,20180830,20181015,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-043237",BOEHRINGER INGELHEIM,,80.0,YR,,M,Y,72.57,KG,20181015.0,,CN,US,US,2018,Q4,Elderly
153339492,15333949,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,QD,2018,Q4,Fatigue,,2018,Q4,2,F,20180724.0,20181011.0,20180830,20181015,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-043237",BOEHRINGER INGELHEIM,,80.0,YR,,M,Y,72.57,KG,20181015.0,,CN,US,US,2018,Q4,Elderly
153339492,15333949,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,QD,2018,Q4,Myocardial infarction,,2018,Q4,2,F,20180724.0,20181011.0,20180830,20181015,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-043237",BOEHRINGER INGELHEIM,,80.0,YR,,M,Y,72.57,KG,20181015.0,,CN,US,US,2018,Q4,Elderly
153339492,15333949,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,QD,2018,Q4,Pneumonia,,2018,Q4,2,F,20180724.0,20181011.0,20180830,20181015,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-043237",BOEHRINGER INGELHEIM,,80.0,YR,,M,Y,72.57,KG,20181015.0,,CN,US,US,2018,Q4,Elderly
153339492,15333949,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,QD,2018,Q4,Renal failure,,2018,Q4,2,F,20180724.0,20181011.0,20180830,20181015,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-043237",BOEHRINGER INGELHEIM,,80.0,YR,,M,Y,72.57,KG,20181015.0,,CN,US,US,2018,Q4,Elderly
153339492,15333949,2,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,,,,,300.0,MG,TABLET,QD,2018,Q4,Weight decreased,,2018,Q4,2,F,20180724.0,20181011.0,20180830,20181015,EXP,,"US-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2018-BI-043237",BOEHRINGER INGELHEIM,,80.0,YR,,M,Y,72.57,KG,20181015.0,,CN,US,US,2018,Q4,Elderly
154638861,15463886,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, UNKNOWN,,204042.0,100.0,MG,TABLET,,2018,Q4,Back pain,,2018,Q4,1,I,20180710.0,20181002.0,20181004,20181004,EXP,GB-MHRA-EYC 00185847,GB-JNJFOC-20181004342,JANSSEN,,61.0,YR,A,M,Y,77.0,KG,20181004.0,,OT,GB,GB,2018,Q4,Adult
154638861,15463886,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, UNKNOWN,,204042.0,100.0,MG,TABLET,,2018,Q4,Headache,,2018,Q4,1,I,20180710.0,20181002.0,20181004,20181004,EXP,GB-MHRA-EYC 00185847,GB-JNJFOC-20181004342,JANSSEN,,61.0,YR,A,M,Y,77.0,KG,20181004.0,,OT,GB,GB,2018,Q4,Adult
154638861,15463886,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, UNKNOWN,,204042.0,100.0,MG,TABLET,,2018,Q4,Liver abscess,,2018,Q4,1,I,20180710.0,20181002.0,20181004,20181004,EXP,GB-MHRA-EYC 00185847,GB-JNJFOC-20181004342,JANSSEN,,61.0,YR,A,M,Y,77.0,KG,20181004.0,,OT,GB,GB,2018,Q4,Adult
154638861,15463886,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, UNKNOWN,,204042.0,100.0,MG,TABLET,,2018,Q4,Malaise,,2018,Q4,1,I,20180710.0,20181002.0,20181004,20181004,EXP,GB-MHRA-EYC 00185847,GB-JNJFOC-20181004342,JANSSEN,,61.0,YR,A,M,Y,77.0,KG,20181004.0,,OT,GB,GB,2018,Q4,Adult
154638861,15463886,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N, UNKNOWN,,204042.0,100.0,MG,TABLET,,2018,Q4,Oropharyngeal pain,,2018,Q4,1,I,20180710.0,20181002.0,20181004,20181004,EXP,GB-MHRA-EYC 00185847,GB-JNJFOC-20181004342,JANSSEN,,61.0,YR,A,M,Y,77.0,KG,20181004.0,,OT,GB,GB,2018,Q4,Adult
154703311,15470331,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"UNK UNK, UNK",,,U,,,,,,,,,2018,Q4,Bone disorder,,2018,Q4,1,I,,20180927.0,20181005,20181005,EXP,,US-SA-2018SA272349,SANOFI AVENTIS,,64.0,YR,A,M,Y,,,20181005.0,,CN,US,US,2018,Q4,Adult
154703311,15470331,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"UNK UNK, UNK",,,U,,,,,,,,,2018,Q4,Cardiac failure congestive,,2018,Q4,1,I,,20180927.0,20181005,20181005,EXP,,US-SA-2018SA272349,SANOFI AVENTIS,,64.0,YR,A,M,Y,,,20181005.0,,CN,US,US,2018,Q4,Adult
154703311,15470331,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,"UNK UNK, UNK",,,U,,,,,,,,,2018,Q4,Renal impairment,,2018,Q4,1,I,,20180927.0,20181005,20181005,EXP,,US-SA-2018SA272349,SANOFI AVENTIS,,64.0,YR,A,M,Y,,,20181005.0,,CN,US,US,2018,Q4,Adult
154932731,15493273,1,PS,Canagliflozin,CANAGLIFLOZIN,1,,,,,Y,D,,20191031.0,,300.0,MG,,,2018,Q4,Diabetic ketoacidosis,,2018,Q4,1,I,20181003.0,,20181004,20181004,DIR,,,FDA-CTU,,57.0,YR,,F,N,56.2,KG,20181004.0,N,PH,US,US,2018,Q4,Adult
154932731,15493273,1,PS,Canagliflozin,CANAGLIFLOZIN,1,,,,,Y,D,,20191031.0,,300.0,MG,,,2018,Q4,Pollakiuria,,2018,Q4,1,I,20181003.0,,20181004,20181004,DIR,,,FDA-CTU,,57.0,YR,,F,N,56.2,KG,20181004.0,N,PH,US,US,2018,Q4,Adult
154932731,15493273,1,PS,Canagliflozin,CANAGLIFLOZIN,1,,,,,Y,D,,20191031.0,,300.0,MG,,,2018,Q4,Vomiting,,2018,Q4,1,I,20181003.0,,20181004,20181004,DIR,,,FDA-CTU,,57.0,YR,,F,N,56.2,KG,20181004.0,N,PH,US,US,2018,Q4,Adult
155147751,15514775,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q4,Migraine with aura,,2018,Q4,1,I,201708.0,20180427.0,20181016,20181016,EXP,,GB-AMGEN-GBRSP2018058978,AMGEN,,61.0,YR,A,F,Y,,,20181016.0,,MD,GB,GB,2018,Q4,Adult
155147751,15514775,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,,,,,,,,,,,,,,2018,Q4,Myalgia,,2018,Q4,1,I,201708.0,20180427.0,20181016,20181016,EXP,,GB-AMGEN-GBRSP2018058978,AMGEN,,61.0,YR,A,F,Y,,,20181016.0,,MD,GB,GB,2018,Q4,Adult
155265431,15526543,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,,,TABLET,,2018,Q4,Urinary retention,,2018,Q4,1,I,20180801.0,20181010.0,20181018,20181018,EXP,,PL-JNJFOC-20181016504,JANSSEN,,74.0,YR,E,M,Y,,,20181018.0,,MD,PL,PL,2018,Q4,Elderly
155265431,15526543,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,U,U,,,204042.0,,,TABLET,,2018,Q4,Urinary tract infection,,2018,Q4,1,I,20180801.0,20181010.0,20181018,20181018,EXP,,PL-JNJFOC-20181016504,JANSSEN,,74.0,YR,E,M,Y,,,20181018.0,,MD,PL,PL,2018,Q4,Elderly
155265461,15526546,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,,2018,Q4,Diabetic ketoacidosis,,2018,Q4,1,I,20180925.0,20181016.0,20181018,20181018,EXP,GB-MHRA-ADR 24347852,GB-JNJFOC-20181026150,JANSSEN,,61.0,YR,A,M,Y,,,20181018.0,,OT,GB,GB,2018,Q4,Adult
155286191,15528619,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,N,,,204042.0,300.0,MG,TABLET,QD,2018,Q4,Nephropathy,,2018,Q4,1,I,,20181011.0,20181018,20181018,EXP,,US-JNJFOC-20181018748,JANSSEN,"KAUSHAL A, PHADKE GM, JOHNSON RJ, KUKLA A, ALEXANDER MP, HAO W, ET AL. OSMOTIC NEPHROSIS: SGLT2 INHIBITOR (SGLT2-I) LEAVES A FOOTPRINT BEHIND.",68.0,YR,E,M,Y,,,20181018.0,,OT,US,US,2018,Q4,Elderly
155331502,15533150,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,,N,,,204042.0,10.0,MG,TABLET,QD,2018,Q4,Foot amputation,,2018,Q4,2,F,,20181105.0,20181019,20181113,EXP,GB-MHRA-EYC 00186741,GB-JNJFOC-20181024630,JANSSEN,,75.0,YR,E,M,Y,98.0,KG,20181113.0,,MD,GB,GB,2018,Q4,Elderly
155365251,15536525,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q4,Gangrene,,2018,Q4,1,I,20180328.0,20181016.0,20181022,20181022,EXP,ES-AEMPS-405553,ES-JNJFOC-20181024236,JANSSEN,,42.0,YR,A,M,Y,90.0,KG,20181022.0,,MD,ES,ES,2018,Q4,Adult
155365251,15536525,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q4,Toe amputation,,2018,Q4,1,I,20180328.0,20181016.0,20181022,20181022,EXP,ES-AEMPS-405553,ES-JNJFOC-20181024236,JANSSEN,,42.0,YR,A,M,Y,90.0,KG,20181022.0,,MD,ES,ES,2018,Q4,Adult
155369881,15536988,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, DAILY",2900.0,MG,U,,,,,100.0,MG,,QD,2018,Q4,Gangrene,,2018,Q4,1,I,20180328.0,20181012.0,20181022,20181022,EXP,ES-AEMPS-405553,ES-ELI_LILLY_AND_COMPANY-ES201810006775,ELI LILLY AND CO,,42.0,YR,,M,Y,90.0,KG,20181022.0,,CN,ES,ES,2018,Q4,Adult
155379002,15537900,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, DAILY",7500.0,MG,U,U, UNKNOWN,,,100.0,MG,,,2018,Q4,Nausea,,2018,Q4,2,F,20180929.0,20181106.0,20181022,20181113,EXP,GB-MHRA-INP71B24AE9-FD66-41BF-B026-6479E6956A69,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-096989,BRISTOL MYERS SQUIBB,,81.0,YR,,F,Y,90.0,KG,20181113.0,,MD,GB,GB,2018,Q4,Elderly
155379002,15537900,4,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MG, DAILY",7500.0,MG,U,U, UNKNOWN,,,100.0,MG,,,2018,Q4,Vomiting,,2018,Q4,2,F,20180929.0,20181106.0,20181022,20181113,EXP,GB-MHRA-INP71B24AE9-FD66-41BF-B026-6479E6956A69,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-096989,BRISTOL MYERS SQUIBB,,81.0,YR,,F,Y,90.0,KG,20181113.0,,MD,GB,GB,2018,Q4,Elderly
155471031,15547103,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,N,D,,,,100.0,MG,,QD,2018,Q4,Abdominal wall infection,,2018,Q4,1,I,20181018.0,,20181024,20181024,DIR,,,FDA-CTU,,43.0,YR,,F,N,99.0,KG,20181024.0,N,,US,US,2018,Q4,Adult
155471031,15547103,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,N,D,,,,100.0,MG,,QD,2018,Q4,Localised infection,,2018,Q4,1,I,20181018.0,,20181024,20181024,DIR,,,FDA-CTU,,43.0,YR,,F,N,99.0,KG,20181024.0,N,,US,US,2018,Q4,Adult
155471031,15547103,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,N,D,,,,100.0,MG,,QD,2018,Q4,Necrotising fasciitis,,2018,Q4,1,I,20181018.0,,20181024,20181024,DIR,,,FDA-CTU,,43.0,YR,,F,N,99.0,KG,20181024.0,N,,US,US,2018,Q4,Adult
155471031,15547103,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,N,D,,,,100.0,MG,,QD,2018,Q4,Vulvitis,,2018,Q4,1,I,20181018.0,,20181024,20181024,DIR,,,FDA-CTU,,43.0,YR,,F,N,99.0,KG,20181024.0,N,,US,US,2018,Q4,Adult
155517021,15551702,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,Y,U,,,,,,,,2018,Q4,Pancreatitis acute,,2018,Q4,1,I,,20181011.0,20181025,20181025,EXP,,"US-IMPAX LABORATORIES, INC-2018-IPXL-03434",IMPAX,"DAFALLA M, GANTA V, HAGAHMED N, ODONKOR W, NUNLEE-BLAND G. CANAGLIFLOZIN AND SITAGLIPTIN INDUCED ACUTE PANCREATITIS. ENDOCR PRACT. 2018;24(SUPPL 1):30",54.0,YR,,F,Y,,,20181024.0,,OT,US,US,2018,Q4,Adult
155517111,15551711,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2018,Q4,Euglycaemic diabetic ketoacidosis,,2018,Q4,1,I,,20181011.0,20181025,20181025,EXP,,"US-IMPAX LABORATORIES, INC-2018-IPXL-03420",IMPAX,"BOLLIMUNTA P, NAHA S, PANGINIKKOD S, JOHN S. THE MISLEADING BLOOD GLUCOSE LEVEL-AVOID DIAGNOSTIC DELAYS. ENDOCR REV. 2018;39(2 SUPPL 1)",57.0,YR,,M,Y,,,20181024.0,,OT,US,US,2018,Q4,Adult
155517111,15551711,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,U,U,,,,,,,,2018,Q4,Intestinal adenocarcinoma,,2018,Q4,1,I,,20181011.0,20181025,20181025,EXP,,"US-IMPAX LABORATORIES, INC-2018-IPXL-03420",IMPAX,"BOLLIMUNTA P, NAHA S, PANGINIKKOD S, JOHN S. THE MISLEADING BLOOD GLUCOSE LEVEL-AVOID DIAGNOSTIC DELAYS. ENDOCR REV. 2018;39(2 SUPPL 1)",57.0,YR,,M,Y,,,20181024.0,,OT,US,US,2018,Q4,Adult
155558941,15555894,1,PS,canagliflozin,CANAGLIFLOZIN,1,,,,,Y,Y,,,,,,,,2018,Q4,Hypoaesthesia,,2018,Q4,1,I,20181021.0,,20181026,20181026,DIR,,,FDA-CTU,,56.0,YR,,M,N,,,20181026.0,N,PH,AL,AL,2018,Q4,Adult
155558941,15555894,1,PS,canagliflozin,CANAGLIFLOZIN,1,,,,,Y,Y,,,,,,,,2018,Q4,Paraesthesia,,2018,Q4,1,I,20181021.0,,20181026,20181026,DIR,,,FDA-CTU,,56.0,YR,,M,N,,,20181026.0,N,PH,AL,AL,2018,Q4,Adult
155925241,15592524,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,,2018,Q4,Diabetic ketoacidosis,,2018,Q4,1,I,20180926.0,20181102.0,20181106,20181106,EXP,GB-MHRA-EYC 00188064,GB-JNJFOC-20181102918,JANSSEN,,71.0,YR,E,M,Y,64.25,KG,20181106.0,,MD,GB,GB,2018,Q4,Elderly
155999271,15599927,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MILLIGRAM, ONCE A DAY",1600.0,MG,D,, UNK,,,100.0,MG,,QD,2018,Q4,Hepatitis,,2018,Q4,1,I,20180823.0,20181026.0,20181108,20181108,EXP,,ES-AUROBINDO-AUR-APL-2018-053781,AUROBINDO,,75.0,YR,,F,Y,,,20181109.0,,MD,ES,ES,2018,Q4,Elderly
156038161,15603816,4,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,UNK,,,Y,,,,,,,TABLET,,2018,Q4,Diabetic ketoacidosis,,2018,Q4,1,I,,20181106.0,20181109,20181109,EXP,,JP-009507513-1811JPN000634J,MERCK,"OMI T, OKABE R, MATSUOKA Y, SUMITANI K, YAMADA M, SANKE T.. O-110, A CASE OF DKA ONSET WHILE ON ORAL SGLT2 INHIBITOR RESULTING IN INSULIN-DEPENDENT STATUS. THE 55TH KINKI REGIONAL MEETING OF THE JAPAN DIABETES SOCIETY. 131",48.0,YR,,F,Y,,,20181109.0,,MD,JP,JP,2018,Q4,Adult
156075461,15607546,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, 1X/DAY",1700.0,MG,D,,,,,100.0,MG,,QD,2018,Q4,Hepatitis,,2018,Q4,1,I,20180823.0,20181106.0,20181112,20181112,EXP,ES-AEMPS-412098,ES-PFIZER INC-2018459436,PFIZER,,75.0,YR,,F,Y,,,20181112.0,,MD,ES,ES,2018,Q4,Elderly
156169281,15616928,1,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,Y,,,,100.0,MG,TABLET,QD,2018,Q4,Polycythaemia vera,Polycythaemia vera,2018,Q4,1,I,,20181106.0,20181114,20181114,EXP,,IN-JNJFOC-20181107364,JANSSEN,"DAS L, BHANSALI A, WALIA R. UNMASKING AND AGGRAVATION OF POLYCYTHEMIA VERA BY CANAGLIFLOZIN. DIABETIC MEDICINE NOV-2018;35/11:1613-1616.",51.0,YR,A,M,Y,,,20181114.0,,OT,IN,IN,2018,Q4,Adult
156169281,15616928,2,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,,,,,Y,,,204042.0,,,TABLET,,2018,Q4,Polycythaemia vera,Polycythaemia vera,2018,Q4,1,I,,20181106.0,20181114,20181114,EXP,,IN-JNJFOC-20181107364,JANSSEN,"DAS L, BHANSALI A, WALIA R. UNMASKING AND AGGRAVATION OF POLYCYTHEMIA VERA BY CANAGLIFLOZIN. DIABETIC MEDICINE NOV-2018;35/11:1613-1616.",51.0,YR,A,M,Y,,,20181114.0,,OT,IN,IN,2018,Q4,Adult
156170941,15617094,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,,2018,Q4,Diabetic ketoacidosis,,2018,Q4,1,I,20181018.0,20181107.0,20181114,20181114,EXP,GB-MHRA-EYC 00188423,GB-JNJFOC-20181109299,JANSSEN,,57.0,YR,A,M,Y,110.0,KG,20181114.0,,PH,GB,GB,2018,Q4,Adult
156172871,15617287,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2018,Q4,Impaired healing,,2018,Q4,1,I,20181113.0,,20181114,20181114,DIR,,,FDA-CTU,,52.0,YR,,F,N,158.7,KG,20181114.0,N,PH,US,US,2018,Q4,Adult
156172871,15617287,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2018,Q4,Intellectual disability,,2018,Q4,1,I,20181113.0,,20181114,20181114,DIR,,,FDA-CTU,,52.0,YR,,F,N,158.7,KG,20181114.0,N,PH,US,US,2018,Q4,Adult
156172871,15617287,1,PS,Canagliflozin,CANAGLIFLOZIN,1,Oral,,,,Y,D,,,,300.0,MG,,QD,2018,Q4,Necrotising soft tissue infection,,2018,Q4,1,I,20181113.0,,20181114,20181114,DIR,,,FDA-CTU,,52.0,YR,,F,N,158.7,KG,20181114.0,N,PH,US,US,2018,Q4,Adult
156270491,15627049,3,SS,CANAGLIFLOZINA (8703A),CANAGLIFLOZIN,1,Oral,100 MILLIGRAM DAILY;,,,,, UNKNOWN,,,100.0,MG,,,2018,Q4,Hepatitis,,2018,Q4,1,I,20180823.0,20181109.0,20181116,20181116,EXP,ES-AEMPS-412098,ES-TEVA-2018-ES-975311,TEVA,,75.0,YR,,F,Y,,,20181116.0,,MD,ES,ES,2018,Q4,Elderly
156310671,15631067,3,C,INVOKANA [CANAGLIFLOZIN],,2,,"UNK, UNKNOWN",,,,,,,,,,,,2018,Q4,Accidental underdose,,2018,Q4,1,I,20181104.0,20181107.0,20181119,20181119,PER,,US-ELI_LILLY_AND_COMPANY-US201811003938,ELI LILLY AND CO,,53.0,YR,,F,Y,,,20181119.0,,CN,US,US,2018,Q4,Adult
156442531,15644253,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2018,Q4,Abdominal pain,,2018,Q4,1,I,,20181112.0,20181121,20181121,EXP,,JP-009507513-1811JPN007515,MERCK,"OHMI T, ET AL.. A CASE OF DIABETIC KETOACIDOSIS (DKA) PROGRESSED TO INSULIN-DEPENDENT STATE DURING TREATMENT WITH SGLT2 INHIBITORS. THE 55TH KINKI REGIONAL MEETING OF THE JAPAN DIABETES SOCIETY. 2018;O-110",48.0,YR,,F,Y,,,20181121.0,,OT,JP,JP,2018,Q4,Adult
156442531,15644253,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2018,Q4,Diabetic ketoacidosis,,2018,Q4,1,I,,20181112.0,20181121,20181121,EXP,,JP-009507513-1811JPN007515,MERCK,"OHMI T, ET AL.. A CASE OF DIABETIC KETOACIDOSIS (DKA) PROGRESSED TO INSULIN-DEPENDENT STATE DURING TREATMENT WITH SGLT2 INHIBITORS. THE 55TH KINKI REGIONAL MEETING OF THE JAPAN DIABETES SOCIETY. 2018;O-110",48.0,YR,,F,Y,,,20181121.0,,OT,JP,JP,2018,Q4,Adult
156442531,15644253,2,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,UNK,,,Y,,,,,,,,,2018,Q4,Nausea,,2018,Q4,1,I,,20181112.0,20181121,20181121,EXP,,JP-009507513-1811JPN007515,MERCK,"OHMI T, ET AL.. A CASE OF DIABETIC KETOACIDOSIS (DKA) PROGRESSED TO INSULIN-DEPENDENT STATE DURING TREATMENT WITH SGLT2 INHIBITORS. THE 55TH KINKI REGIONAL MEETING OF THE JAPAN DIABETES SOCIETY. 2018;O-110",48.0,YR,,F,Y,,,20181121.0,,OT,JP,JP,2018,Q4,Adult
156487651,15648765,2,C,CANAGLIFLOZIN HEMIHYDRATE,CANAGLIFLOZIN,1,Oral,"100 MG, UNK",,,,,,,,100.0,MG,,,2018,Q4,Ketosis,,2018,Q4,1,I,,20181112.0,20181122,20181122,EXP,,JP-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-108317,BRISTOL MYERS SQUIBB,TAKAYAMA. A CASE OF KETOSIS PROBABLY INDUCED BY SGLT2 INHIBITOR. THE JAPANESE SOCIETY OF INTERNAL MEDICINE. 2018;34-4,46.0,YR,,M,Y,,,20181122.0,,OT,JP,JP,2018,Q4,Adult
156548561,15654856,3,C,INVOKANA [CANAGLIFLOZIN],,2,,"UNK, DAILY",,,,,,,,,,,QD,2018,Q4,Drug ineffective,,2018,Q4,1,I,20181119.0,20181119.0,20181126,20181126,PER,,US-ELI_LILLY_AND_COMPANY-US201811009891,ELI LILLY AND CO,,48.0,YR,,M,Y,,,20181126.0,,CN,US,US,2018,Q4,Adult
156548561,15654856,3,C,INVOKANA [CANAGLIFLOZIN],,2,,"UNK, DAILY",,,,,,,,,,,QD,2018,Q4,Product dose omission,,2018,Q4,1,I,20181119.0,20181119.0,20181126,20181126,PER,,US-ELI_LILLY_AND_COMPANY-US201811009891,ELI LILLY AND CO,,48.0,YR,,M,Y,,,20181126.0,,CN,US,US,2018,Q4,Adult
156562851,15656285,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,,2018,Q4,Diabetic ketoacidosis,,2018,Q4,1,I,20181031.0,20181116.0,20181126,20181126,EXP,GB-MHRA-WEBRADR-20181101095617,GB-JNJFOC-20181124883,JANSSEN,,63.0,YR,A,M,Y,,,20181121.0,,PH,GB,GB,2018,Q4,Adult
156741261,15674126,8,C,INVOKANA [CANAGLIFLOZIN],,2,,"300 MG, EACH MORNING",,,,,,,,300.0,MG,,QD,2018,Q4,Accidental underdose,,2018,Q4,1,I,20181126.0,20181126.0,20181130,20181130,PER,,US-ELI_LILLY_AND_COMPANY-US201811013102,ELI LILLY AND CO,,59.0,YR,,M,Y,,,20181129.0,,CN,US,US,2018,Q4,Adult
156741261,15674126,8,C,INVOKANA [CANAGLIFLOZIN],,2,,"300 MG, EACH MORNING",,,,,,,,300.0,MG,,QD,2018,Q4,Blood glucose decreased,,2018,Q4,1,I,20181126.0,20181126.0,20181130,20181130,PER,,US-ELI_LILLY_AND_COMPANY-US201811013102,ELI LILLY AND CO,,59.0,YR,,M,Y,,,20181129.0,,CN,US,US,2018,Q4,Adult
156741261,15674126,8,C,INVOKANA [CANAGLIFLOZIN],,2,,"300 MG, EACH MORNING",,,,,,,,300.0,MG,,QD,2018,Q4,Blood glucose increased,,2018,Q4,1,I,20181126.0,20181126.0,20181130,20181130,PER,,US-ELI_LILLY_AND_COMPANY-US201811013102,ELI LILLY AND CO,,59.0,YR,,M,Y,,,20181129.0,,CN,US,US,2018,Q4,Adult
156845111,15684511,1,PS,CANAGLIFLOZIN 300MG,CANAGLIFLOZIN,1,Oral,,,,,D,,,,300.0,MG,,QD,2018,Q4,Diabetic ketoacidosis,,2018,Q4,1,I,20180611.0,,20181121,20181121,DIR,,,FDA-CTU,,58.0,YR,,F,N,68.0,KG,20180711.0,N,PH,US,US,2018,Q4,Adult
156845111,15684511,1,PS,CANAGLIFLOZIN 300MG,CANAGLIFLOZIN,1,Oral,,,,,D,,,,300.0,MG,,QD,2018,Q4,Dyspnoea,,2018,Q4,1,I,20180611.0,,20181121,20181121,DIR,,,FDA-CTU,,58.0,YR,,F,N,68.0,KG,20180711.0,N,PH,US,US,2018,Q4,Adult
156845111,15684511,1,PS,CANAGLIFLOZIN 300MG,CANAGLIFLOZIN,1,Oral,,,,,D,,,,300.0,MG,,QD,2018,Q4,Hyperhidrosis,,2018,Q4,1,I,20180611.0,,20181121,20181121,DIR,,,FDA-CTU,,58.0,YR,,F,N,68.0,KG,20180711.0,N,PH,US,US,2018,Q4,Adult
156845111,15684511,1,PS,CANAGLIFLOZIN 300MG,CANAGLIFLOZIN,1,Oral,,,,,D,,,,300.0,MG,,QD,2018,Q4,Nausea,,2018,Q4,1,I,20180611.0,,20181121,20181121,DIR,,,FDA-CTU,,58.0,YR,,F,N,68.0,KG,20180711.0,N,PH,US,US,2018,Q4,Adult
156845111,15684511,1,PS,CANAGLIFLOZIN 300MG,CANAGLIFLOZIN,1,Oral,,,,,D,,,,300.0,MG,,QD,2018,Q4,Pain,,2018,Q4,1,I,20180611.0,,20181121,20181121,DIR,,,FDA-CTU,,58.0,YR,,F,N,68.0,KG,20180711.0,N,PH,US,US,2018,Q4,Adult
156845111,15684511,1,PS,CANAGLIFLOZIN 300MG,CANAGLIFLOZIN,1,Oral,,,,,D,,,,300.0,MG,,QD,2018,Q4,Vomiting,,2018,Q4,1,I,20180611.0,,20181121,20181121,DIR,,,FDA-CTU,,58.0,YR,,F,N,68.0,KG,20180711.0,N,PH,US,US,2018,Q4,Adult
156866161,15686616,7,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"UNK UNK, UNKNOWN",,,,,,,,,,,,2018,Q4,Sudden death,,2018,Q4,1,I,20181105.0,20181109.0,20181204,20181204,EXP,,JP-ALLERGAN-1853161US,ALLERGAN,,54.0,YR,,M,Y,65.9,KG,20181204.0,,MD,JP,JP,2018,Q4,Adult
157104411,15710441,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,200.0,MG,TABLET,,2018,Q4,Diabetic ketoacidosis,,2018,Q4,1,I,20181120.0,20181210.0,20181211,20181211,EXP,GB-MHRA-EYC 00190253,GB-JNJFOC-20181211270,JANSSEN,,41.0,YR,A,M,Y,,,20181211.0,,OT,GB,GB,2018,Q4,Adult
157104411,15710441,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,200.0,MG,TABLET,,2018,Q4,Incorrect dose administered,,2018,Q4,1,I,20181120.0,20181210.0,20181211,20181211,EXP,GB-MHRA-EYC 00190253,GB-JNJFOC-20181211270,JANSSEN,,41.0,YR,A,M,Y,,,20181211.0,,OT,GB,GB,2018,Q4,Adult
157104411,15710441,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,200.0,MG,TABLET,,2018,Q4,Off label use,,2018,Q4,1,I,20181120.0,20181210.0,20181211,20181211,EXP,GB-MHRA-EYC 00190253,GB-JNJFOC-20181211270,JANSSEN,,41.0,YR,A,M,Y,,,20181211.0,,OT,GB,GB,2018,Q4,Adult
157189721,15718972,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,300.0,MG,TABLET,,2018,Q4,Ketoacidosis,,2018,Q4,1,I,20181120.0,20181210.0,20181213,20181213,EXP,GB-MHRA-EYC 00190443,GB-JNJFOC-20181211842,JANSSEN,,62.0,YR,A,F,Y,,,20181213.0,,MD,GB,GB,2018,Q4,Adult
157226561,15722656,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Rectal,,,,Y,N,,,204042.0,200.0,MG,TABLET,,2018,Q4,Diabetic ketoacidosis,,2018,Q4,1,I,20181119.0,20181210.0,20181214,20181214,EXP,GB-MHRA-EYC 00190349,GB-JNJFOC-20181211234,JANSSEN,,41.0,YR,A,M,Y,,,20181214.0,,PH,GB,GB,2018,Q4,Adult
157226561,15722656,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Rectal,,,,Y,N,,,204042.0,200.0,MG,TABLET,,2018,Q4,Incorrect dose administered,,2018,Q4,1,I,20181119.0,20181210.0,20181214,20181214,EXP,GB-MHRA-EYC 00190349,GB-JNJFOC-20181211234,JANSSEN,,41.0,YR,A,M,Y,,,20181214.0,,PH,GB,GB,2018,Q4,Adult
157226561,15722656,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Rectal,,,,Y,N,,,204042.0,200.0,MG,TABLET,,2018,Q4,Incorrect route of product administration,,2018,Q4,1,I,20181119.0,20181210.0,20181214,20181214,EXP,GB-MHRA-EYC 00190349,GB-JNJFOC-20181211234,JANSSEN,,41.0,YR,A,M,Y,,,20181214.0,,PH,GB,GB,2018,Q4,Adult
157226561,15722656,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Rectal,,,,Y,N,,,204042.0,200.0,MG,TABLET,,2018,Q4,Off label use,,2018,Q4,1,I,20181119.0,20181210.0,20181214,20181214,EXP,GB-MHRA-EYC 00190349,GB-JNJFOC-20181211234,JANSSEN,,41.0,YR,A,M,Y,,,20181214.0,,PH,GB,GB,2018,Q4,Adult
157226571,15722657,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,,2018,Q4,Abdominal pain,,2018,Q4,1,I,20181118.0,20181210.0,20181214,20181214,EXP,GB-MHRA-EYC 00190224,GB-JNJFOC-20181213807,JANSSEN,,62.0,YR,A,F,Y,,,20181214.0,,MD,GB,GB,2018,Q4,Adult
157226571,15722657,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,,2018,Q4,Euglycaemic diabetic ketoacidosis,,2018,Q4,1,I,20181118.0,20181210.0,20181214,20181214,EXP,GB-MHRA-EYC 00190224,GB-JNJFOC-20181213807,JANSSEN,,62.0,YR,A,F,Y,,,20181214.0,,MD,GB,GB,2018,Q4,Adult
157226571,15722657,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,,2018,Q4,Vomiting,,2018,Q4,1,I,20181118.0,20181210.0,20181214,20181214,EXP,GB-MHRA-EYC 00190224,GB-JNJFOC-20181213807,JANSSEN,,62.0,YR,A,F,Y,,,20181214.0,,MD,GB,GB,2018,Q4,Adult
157530661,15753066,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, DAILY",,,Y,,,,,100.0,MG,,QD,2018,Q4,Pituitary tumour benign,,2018,Q4,1,I,,20181207.0,20181221,20181221,EXP,,"JP-IMPAX LABORATORIES, LLC-2018-IPXL-04237",IMPAX,,47.0,YR,,F,Y,87.5,KG,20181222.0,,MD,JP,JP,2018,Q4,Adult
157530661,15753066,3,C,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Unknown,"100 MILLIGRAM, DAILY",,,Y,,,,,100.0,MG,,QD,2018,Q4,Pituitary-dependent Cushing's syndrome,,2018,Q4,1,I,,20181207.0,20181221,20181221,EXP,,"JP-IMPAX LABORATORIES, LLC-2018-IPXL-04237",IMPAX,,47.0,YR,,F,Y,87.5,KG,20181222.0,,MD,JP,JP,2018,Q4,Adult
157546321,15754632,2,C,Canagliflozin,CANAGLIFLOZIN,1,Unknown,,,,D,, UNK,,,,,,,2018,Q4,Gastrointestinal disorder,,2018,Q4,1,I,,20180903.0,20181224,20181224,PER,,US-LAURUS LABS LIMITED-201800188,LAURUS LABS LIMITED,,31.0,YR,,M,Y,,,20181217.0,,OT,US,US,2018,Q4,Young Adult
157548371,15754837,3,SS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,"100 MG, QD",1700.0,MG,D,,,,,100.0,MG,,,2018,Q4,Hepatitis,,2018,Q4,1,I,20180823.0,20181211.0,20181224,20181224,EXP,ES-AEMPS-412098,ES-APOTEX-2018AP027989,APOTEX,,75.0,YR,,F,Y,,,20181224.0,,CN,ES,ES,2018,Q4,Elderly
157558351,15755835,1,PS,CANAGLIFLOZIN,CANAGLIFLOZIN,1,Oral,,,,Y,N,,,204042.0,100.0,MG,TABLET,QD,2018,Q4,Ketoacidosis,,2018,Q4,1,I,,20181214.0,20181224,20181224,EXP,,JP-JNJFOC-20181229759,JANSSEN,,8.0,DEC,E,F,Y,,,20181224.0,,MD,JP,JP,2018,Q4,Child
